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ABSTRACT 
 
The Receptor Tyrosine Kinase (RTK) Met influences behaviour of several 
cancers by controlling growth, survival and metastasis. Recently, 
compartmentalisation of signals generated by RTKs, due to their 
endocytosis / trafficking, has emerged as a major determinant of various 
cell functions. The aim of my project was to study oncogenic Met signalling 
in relation to endosomal trafficking and to determine the consequences of 
such spatial changes on tumour cell growth and migration in vitro and in 
vivo.  
The model studied was NIH3T3 cells stably transfected with Wild type (Wt) 
Met or with three distinct mutants reported in human cancers. I found that 
two activating mutations in the kinase domain are highly tumorigenic in 
vivo. Using functional assays and tumour growth experiments, I 
demonstrated that one mutant is highly sensitive to Met specific tyrosine 
kinase inhibitors (TKI) while another is resistant. Such results suggested 
that therapeutical approaches to these mutants should be different. 
Furthermore, I demonstrated a direct link between endocytosis and 
tumorigenicity, suggesting a major role for Met endosomal signalling in 
cancer progression. Using confocal microscopy and quantitative 
biochemical assays, I demonstrated that Met mutants displayed an 
increased endocytosis and recycling and a decreased degradation profile. 
This led to an accumulation of phosphorylated Met on endosomes that 
induced activation of the GTPase Rac1, loss of stress fibres and increased 
cell migration. Blocking endocytosis by pharmacological and genetic 
 4 
means inhibited mutants’ anchorage independent growth and, strikingly, 
tumorigenesis and experimental metastasis. Interestingly, the mutant 
resistant to TKI inhibition was sensitive to endocytosis inhibition. Taken 
together, these results suggest that Met localisation constitutes a major 
determinant in neoplastic development, while Met activation alone is 
insufficient to effect this change.  
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INTRODUCTION 
 
 
Receptor tyrosine kinases (RTKs) form a large family of enzymes, more 
than fifty, that control fundamental cellular processes including the cell 
cycle, proliferation/differentiation, cell migration, survival and cellular 
metabolism1. As these receptors catalyse the transfer of a phosphate to 
tyrosine residues on their substrates, using Adenosine Tri-Phosphate 
(ATP) as a phosphate donor, they are identified as protein tyrosine 
kinases2. RTKs are cell surface receptors for the majority of growth 
factors.  
RTKs share structural characteristics and can be subdivided schematically 
into five functional domains: an extracellular ligand binding region usually 
glycosylated, a single transmembrane segment, a juxtamembrane domain, 
a catalytic domain and a C-terminal tail3. Twenty RTK subfamilies have 
been identified on the basis of their extra-cellular domains. Most of them 
are formed with a single polypeptide chain, as is the case for the EGF 
receptor (Epidermal Growth Factor), which belongs to the largest 
subfamily of RTKs. However, the insulin receptor and Met subfamilies are 
composed of a dimer consisting of two polypeptide chains (Fig. 1).  
RTKs are activated by their dimerisation. Ligand binding induces this 
dimeric state that leads to autophosphorylation of the receptor that, in turn, 
results in trans-autophosphorylation of tyrosines located in their C-terminal 
tail. The phosphorylation of these tyrosines permits the recruitment and 
then the activation of a wide variety of signalling molecules1.  
 18 
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The Met family includes only three members: RON (Receptor d’“Origine 
Nantaise”)4, the avian oncogene Sea5 and, the prototype of the family, 
Met. A family of related proteins serve as ligands for these receptors. 
 
1. The Met Receptor Tyrosine Kinase 
Met originally was identified in 1984 by Cooper et al 6 as an activated 
oncogene corresponding to a fusion protein, “TPR/Met”, resulting from 
chromosomal translocation in a human osteogenic sarcoma (HOS) cell 
line treated with the chemical carcinogen N-Methyl-N-nitro-N-
nitrosoguanidine6. Met’s name derived from this chemical treatment. The 
Met proto-oncogene, located on the long arm of chromosome 7 (q11.2-
q21.1)7, was involved in a translocation that placed the TPR locus 
(Translocated Promoter Region) on chromosome 1 just upstream of a 
portion of the Met gene. TPR/Met was shown to be constitutively active8. A 
couple of years after its discovery, Met was found to belong to the family 
of RTKs9 but its ligand still was unknown.  
The Met gene spans more than 120 kb in length and consists of 21 exons 
separated by 20 introns10. Met was first found expressed as a 9.0-kb RNA 
in epithelial cells8,9,11. At least three Met mRNA variants, generated by 
alternative splicing, have been reported. The most abundant form of Met, 
present in a large variety of tissue and cell lines, differs from the first 
published11 by the absence of 54 bp predicted to encode 18 amino 
acids12. Lee and Yamada also reported a Met variant, termed Metsm for 
small, that presents with a deletion of 47 amino acids in the 
juxtamembrane domain13.  
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Based on sequence similarity and structural characteristics, the Met family 
can be classified as a new subfamily within the RTK family. Indeed, Met is 
a disulphide-linked heterodimer, which results from cleavage by furin of a 
170 KDa glycosylated precursor. This mature Met, with an apparent 
molecular weight of 190 kDa, comprises an N-terminal ? chain (45kDa) 
located outside the membrane and a C-terminal ? chain that contains an 
extracellular part, a single membrane spanning segment and a 
cytoplasmic part (145kDa) (Fig. 2). The ? chain and the first 212 amino 
acids of the ? chain are responsible for ligand binding and these two Met 
regions are both homologous to the sema-domain (domain identified in the 
semaphorin protein). The remainder of the Met ? chain ectodomain 
contains a PSI domain - also found in the plexins, semaphorins and 
integrins, hence its name, including 4 disulphide bonds followed by 4 IPT 
domains related to immunoglobulin-like domains named after their 
presence in plexins and transcription factors14,15 (Fig. 2). The intracellular 
region of Met includes three domains: (1) juxta-membrane, (2) tyrosine 
kinase and (3) a C-terminal region that contains an unique multifunctional-
docking site, essential for the recruitment of adaptors and several 
transducers15 (Fig. 2).  
 21 
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2. Met ligand: Hepatocyte Growth Factor 
Two soluble factors were discovered independently in 1987: a motility 
factor, called Scatter Factor, (SF)16, which induced the scattering and the 
motility of epithelial cells through a paracrine mode since its production 
and release were found to be limited to mouse and human fibroblast cells; 
and a mitogenic factor, first purified from rat platelets, named Hepatocyte 
Growth Factor (HGF)17 since it was a potent mitogen for rat hepatocytes. It 
was only a couple of years later, after the cloning of the human HGF18, 
that it became apparent that these two factors were the same molecule 
and were established as the natural Met ligand19-22.  
HGF/SF is a large multidomain protein, similar to plasminogen. It consists 
of six domains:  amino-terminal hairpin loop (N), four kringle domains, K1-
K4, (80 amino-acids defined by three conserved disulphide bridges), and a 
Serine Proteinase Homology (SPH) domain with no enzymatic activity14,15 
(Fig. 3). HGF/SF is synthesised and secreted as a single chain precursor 
(pro-HGF) of 92 kDa missing biological activity until it is proteolytically 
cleaved in the extracellular environment into a two-chain, active 
heterodimer23. The conversion of pro-HGF to the mature form is done by 
several extracellular serine proteases, which cleave the bond between 
Arg494 and Val495. They include the urokinase plasminogen activator 
(uPA), tissue-type plasminogen activator and coagulation factors X, XI and 
XII23,24. This cleavage process generates a factor composed of an ?-chain 
of 69 kDa and a ?-chain of 34 kDa, linked by disulphide bonds. 
 23 
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This unique Met ligand binds also to heparan-sulphate proteoglycans with 
high affinity. However this interaction is not essential for receptor 
activation. HGF is homologous to Macrophage Stimulating Protein (MSP), 
which is the ligand of the highly Met homologous, RON receptor. 
 
3. Met/HGF signalling 
3.1. Met activation 
Met is activated through binding of HGF/SF. How HGF and Met interact is 
still not well understood. HGF is a bivalent molecule that contains 2 Met 
binding sites with distinct receptor affinities. The low-affinity binding site, 
located in the ? chain of HGF and accessible only when the HGF is active, 
interacts with the Sema domain of Met. The high affinity site was only 
identified recently25. It was found in the ? chain of HGF and binds with   
the IPT domains 3 and 4 of Met independently of the activation status of 
HGF25.  
Using cryo-electron microscopy and small-angle-x-ray scattering, Gherardi 
et al 26 have proposed a model for the active HGF-Met complex, in which a 
2:2 ligand-receptor complex is stabilised through dimerisation of the ‘N’ 
and ‘K1’ domains of HGF (see Fig. 3). 
HGF binding induces Met dimerisation. This step results in the stabilisation 
of the receptor in an active conformation that leads to its trans-
autophosphorylation on a doublet of tyrosines (Y1234-Y1235) located in the 
kinase domain, followed by the phosphorylation on two other tyrosines 
(Y1349-Y1356) in its C-terminal part. These two tyrosine residues, with their 
surrounding amino-acids, constitute a unique C-terminal multisubstrate-
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docking site, well conserved among Met family members. This short 
sequence (Y1349VHVNATY1356VNV) alone is responsible for mediating high 
affinity interactions with a wide range of transducers and is responsible for 
the concomitant activation of several signalling pathways27. This multi-
docking site is specific for Met, as most RTKs have several tyrosines 
distributed along the intracellular domain and each tyrosine binds specific 
signalling molecules.   
 
3.2. Kinase activity of Met is tightly regulated 
In parallel to the activation of signalling pathways, Met activation also 
leads to negative feed-back in order to modulate, and eventually switch 
off, its activity.  
One negative regulation is the result of the phosphorylation of the 
Serine985 located in the juxtamembrane domain5,28,29. Once 
phosphorylated, Serine985 causes Met inhibition by reducing tyrosine 
phosphorylation. This Serine985 is embedded in a sequence for 
phosphorylation by Protein Kinase-C  (PKC) and by Calcium ion (Ca2+)-
dependent kinases. These kinases become active when the intracellular 
Ca2+ concentration is increased. Met activates PhosphoLipase-C? (PLC?) 
leading to the generation of diacyl-glycerol, a powerful activator of PKC. 
PKC then generates inositol-3-phosphate, which increases the intracellular 
concentration of Ca2+ 28,29. This Ser985 is found at a position similar to that 
of the regulatory Threonine654 of EGFR30. 
Another negative regulation operates via the phosphorylation of the 
Tyrosine1003 within the juxtamembrane domain. The E3 ubiquitin ligase c-
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Cbl binds to phosphorylated Tyrosine1003 and induces Met down 
regulation. This mechanism will be examined in more detail later (see 
section 4. “Met trafficking”). 
 
3.3. Met signalling  
When the multidocking site, or “supersite”, becomes phosphorylated, Met 
interacts with multiple adaptors and signal transducers. 
  
3.3.1. Met adaptors  
The two major Met adaptors are Grb2 (Growth-factor-receptor-Bound 
protein 2) and Gab1 (Grb2-Associated Binder 1). Among other RTKs, 
Gab1 has particular relationships with Met. Indeed, Gab1 contains a 
specific binding site of thirteen amino-acids, called the “Met binding site”, 
that mediates direct interaction with Met31. Such strong interaction 
mediates prolonged Gab1 phosphorylation upon HGF/SF binding 
compared with other RTKs. Moreover, this direct interaction is possible on 
both tyrosines present in the docking site, Y1349 and Y1356 32 (but mostly 
Y1349). Moreover, Gab1 can bind Met indirectly via its interaction with 
another Met adaptor, Grb233,34, meaning that two molecules of Gab1 can 
interact, directly and indirectly, with the same Met dimer. Unlike Gab1, 
Grb2 can only bind Met on one tyrosine, the Y1356 35.  
 
3.3.2. Main signalling partners  
Several signalling partners can bind Met directly on tyrosines in the 
docking site and/or, indirectly via binding to phosphorylated Gab1 or Grb2. 
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Most of them contain an SH2 domain (Src-homology-2) or have a 
PhosphoTyrosine-Binding (PTB) domain, allowing recognition and binding 
to tyrosine-phosphorylated sequences36 (Fig. 4). These interacting 
proteins15 include PhosphatidylInositol 3-Kinase (PI3-K), SH2-containing 
protein tyrosine Phosphatase 2 (Shp2), PhosphoLipase C (PLC), Crk37, 
Src, SH2-domain-containing (Shc), SH2-domain-containing Inositol-5-
Phosphatase (Ship1), the small GTPase Ras and the transcription factor 
Stat338. Met activation, through the complex Grb2/Sos (Son Of 
Sevenless), leads to the activation of the Mitogen-Activated Protein Kinase 
(MAPK) signalling pathway. Sos is a Guanine Exchange Factor (GEF) that 
promotes the shift of Ras protein from the inactive form (GDP-bound) to 
the active form (GTP-form)39. Ras, once activated, can then trigger the 
activation of the Raf/MAPK cascade. In addition, Ras can, as well, 
stimulate PI-3K that in turn via production of the lipid phosphatidylinositol 
(3,4,5) triphosphate (PIP3), will elicit GEF activation40.  
 
3.3.3. The Rho GTPase Rac1 and cell migration  
The Rho GTPase Rac1 was shown to be activated by Met41,42 for the 
control of cell migration. HGF through activating Met, induces the motility 
and the scattering of several types of cells including MDCK cells43. In 
these cells, Rac was shown to be activated by Met and to be necessary to 
promote actin reorganisation and subsequent cell scattering44,45.  
 28 
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Rac1 is a member of the Rho Guanosine TriPhosphatases (GTPases), 
within the Ras superfamily of small GTPases (21kDa), which constitutes a 
family of 30 members46,47. All these molecules cycle between two 
conformational states, inactivated GDP-bound and active GTP-bound.  
The switch between these two states is highly regulated. There are three 
different types of molecules that control their activation status47,48.  
One set of molecule called GEFs (Guanine nucleotide Exchange Factor) 
increased their activity49. They promote GDP dissociation and then the 
binding to GTP. Conversely, two other set of molecules, GAPs (GTPase 
Activating Proteins) and GDIs (Guanine nucleotide Dissociation Inhibitor), 
participate in the inactivation of the Rho GTPases. GAPs enhance the 
intrinsic GTPase activity of the Rho GTPases and then promote the 
hydrolysis of the GTP into GDP50. GDIs sequester the Rho GTPases in 
the cytoplasm by preventing their binding to the membranes51. Usually 
GDIs bind to the C-terminal prenyl groups of Rho GTPases when they are 
GDP-loaded. This lipid group allows the interaction of the Rho GTPases 
with the membrane, thus the binding of the GDI on the top of this group 
avoids interaction between the Rho GTPases and the membrane. GDIs 
prevent as well the binding between the Rho proteins and their effectors. 
Once activated, Rho proteins bind to their effectors and control many 
biological functions through the regulation of the actin cytoskeleton52,53 
including cell division, cell adhesion, cell polarity, vesicular trafficking54,55 
and cellular motility/migration56.   
The three most studied and best characterised Rho GTPases are Rac1, 
RhoA, and Cdc42. 
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Rac1, through promoting actin polymerisation, triggers the assembly of 
actin-rich surface protrusions at the plasma membrane, called 
lamellipodia57,58. Lamellipodia and membrane ruffle extension occurs at 
the front of migrating cells, where they contribute to push forward the 
leading edge of the membrane. This represents the first steps of an 
orientated migration. The three following step in migration are: formation of 
new adhesions, cell body contraction and tail detachment56,59. Rac 
proteins are also implicated in the formation and control of cell adhesions 
but the two final steps are more regulated by Rho proteins56.  
Conversely to Rac, RhoA leads to stress fibre formation that usually 
causes a decrease in cell motility44,47,60. 
Cdc42, also through promoting actin polymerisation, induces the formation 
of filipodia, which are actin-rich finger-like protrusions from the cell 
surface61.  
How does Met activate Rac and how does Met induce cell movement 
through Rac? The activation of Rho GTPases by RTKs appears to be 
mediated by GEFs, which can be activated directly or indirectly by the 
RTKs62. In MDCK cells, the Met-dependent Rac activation, lamellipodia 
formation and cell dissociation was shown to require the activity of         
PI3-K45, suggesting in this case an indirect activation between Met and the 
Rac-GEF. The PI3-K, which produces the lipid PIP3, was shown to be 
able to activate Rac upon HGF stimulation42. This may occur via the 
activation of a Rac-GEF, since PIP3 was shown to bind and activate 
several GEFs40,62,63. Once activated, Rac coordinates lamellipodium 
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extension at the leading edge of the cells to promote directional cell 
movement.  
Activated Rac is localised preferentially at the front of migrating cells64 and 
the classical model is that it gets activated at the plasma membrane59. 
Interestingly, a recent study reported that Rac activation may not only 
happen at the plasma membrane. Indeed, upon HGF stimulation (or Rab5 
expression), Rac1 was found to be present on endosomes and to be 
activated from there by a Rac-GEF, Tiam1, located or recruited in these 
compartments41,65. How can the Rac GTP-bound form reach the leading 
edge of the cells from the endosomal compartment? The GTPase Arf6, 
implicated in membrane trafficking, including recycling, was shown to be 
implicated in the transport, possibly along the microtubules, of vesicles-
containing activated Rac1 from the endosomes to the zone of the 
membrane ruffling65,66. These new findings are in favour of the “endosomal 
signalling” concept. 
 
3.3.4. A pathway for several functions and several pathways for one 
function 
Since HGF can trigger several cell responses, including proliferation, 
motility and morphogenesis (see section entitled “Biological Effects”), 
many studies have aimed to identify which individual downstream effectors 
of Met lead to specific cellular responses. For example, PI3-K was found 
to control cell survival upon HGF/Met activation67,68 and the MAPK 
pathway was found to be essential for the early step of cell migration69. 
However, Met signalling is actually more complex than initially thought and 
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different pathways are interconnected. Moreover, one pathway can trigger 
several functions while several pathways that act in synergy or compete 
usually are required to trigger one function. In addition, several signalling 
molecules are shared between different pathways. 
Therefore, an unresolved, but major, question is how signalling pathways 
of Met are spatially and temporally integrated in the cell to generate the 
appropriate cell functions? This is the concept of spatio-temporal signalling 
which underpins much of the work I have been doing. The emerging 
concept of endosomal signalling may constitute an element of response. 
Indeed, it has been discovered recently that Met endocytic trafficking plays 
a role in its signalling70,71. Based on these concepts it seems likely that 
receptor location, the signalling pathways, their intensity and their 
duration, all could be different in their activity according to their sub-
cellular distribution and therefore could influence cell function in different 
fashions.  
 
4. Met trafficking 
Initially, RTKs were thought to remain at the plasma membrane where 
they would make the link between the extracellular environment and the 
inside of the cell. EGFR was the first RTK described as being internalised 
after ligand binding and shown to be sorted to early and late endosomes72. 
Nowadays we know that this observation is true for all the RTKs73. 
Internalisation was first described as a desensitisation mechanism but now 
it also is emerging as a positive signalling regulator prior to 
desensitisation. 
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4.1. RTK endocytosis via the clathrin pathway 
Endocytosis can occur by four mechanisms: macropinocytosis, the 
caveolin-mediated pathway, the clathrin-mediated pathway and the 
clathrin-and caveolin-independent pathway74. As the major route for RTK 
endocytosis in most cells, and the best understood, is the clathrin-coated 
pathway and so far the only pathway described for Met endocytosis, I will 
focus on this pathway.  
 
4.1.1. Ubiquitination 
Ubiquitination plays a key role in RTK endosomal trafficking. Ubiquitin 
consists of 76 amino-acids that attach to Lysine (Lys) residues on target 
proteins. There are three different modes of ubiquitination: 
monoubiquitination (1 molecule of ubiquitin on 1 Lys residue), 
multiubiquitination (1 ubiquitin on several Lys residues) and 
polyubiquitination (several ubiquitin molecules on 1 Lys residue).  
Degradation of RTKs seems to be driven mainly by monoubiquitination75. 
Molecules of ubiquitin are added onto RTKs by an E3 ubiquitin- ligase, c-
Cbl, that binds phosphorylated receptors76. 
 
4.1.2. Clathrin-coated-vesicle formation (Fig. 5) 
RTKs can move laterally along the membrane. When the ligand-receptor 
interaction occurs, the complex accumulates in specific membrane regions 
called clathrin coated pits. Clathrin accumulates around the pits, drives its 
invagination and helps to stabilise the nascent vesicle. The clathrin-coated 
vesicle (CCV) is then formed and gets pinched off the membrane. 
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However, endocytosis is a complex mechanism still not fully understood. 
Despite extensive research, for more than two decades, the understanding 
of the molecular interactions leading to the recruitment of activated RTKs 
into coated pits and receptor internalisation is limited. Clathrin does not act 
alone and many clathrin endocytic adaptors and scaffold proteins are 
necessary to promote clathrin recruitment, polymerisation at the plasma 
membrane and formation of clathrin-coated vesicles as well as the 
subsequent trafficking77. 
• Endocytic adaptors are usually defined by the fact that they can bind: i) 
clathrin, ii) PhosphatidylInositol bisphosphate PIP2 enriched in the 
cytoplasmic leaflet of the plasma membrane and iii) sorting signals present 
on the receptor. They are grouped in two classes: the multimeric Adaptor 
Protein complex AP-2, and the monomeric adaptor proteins Clathrin-
Associated Sorting Protein (CLASP). AP180, Eps15, and epsin are the 
most important CLASPs for RTK internalisation77. 
The endocytic process is thought to be initiated by the recruitment of these 
endocytic adaptors at the plasma membrane where they bind PIP2. In 
addition, adaptors recognise and bind the receptor to sorting signals that 
are present in the cytosolic tail of the receptor. The sorting signals include, 
but are not limited to, phosphorylation and/or ubiquitination of the RTK. 
Then, adaptors recruit clathrin to the plasma membrane.  
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• Recruitment of scaffold proteins synchronises and organises all these 
interactions, such as those involving Esp15, that act within the forming 
vesicle structure.  
• The combined action of the clathrin coats and the curvature driving 
molecules such as epsin, amphiphysin and endophilin, allow membrane 
curving to form a vesicle.  
• c-Cbl, a molecule mostly known for its E3 ubiquitin ligase activity, has 
been shown to play a role in the curvature step through linking the 
receptor to endophilin via binding to the adaptor CIN85 (c-Cbl INteracting 
protein of 85kDa)78.  
• Modification of RTKs by ubiquitination initially was widely believed to be 
the mechanism responsible for endocytosis. Indeed ubiquitination is 
required for internalisation of several receptors, such as nerve growth 
factor or ?2-adrenergic receptor79. However, controversial data exist in the 
literature. EGFR mutants for ubiquitination (lysine mutants)80 or for direct 
binding to the ubiquitin ligase c-Cbl (Y1045F)81 can still be internalised. 
Moreover, it has been suggested that EGFR normally is internalised by 
clathrin-coated pits by using a tyrosine kinase-, Grb2-, and c-Cbl-
dependent mechanism. Even if an ubiquitination event is involved in this 
pathway, the ubiquitination of the receptor is not necessary for its 
internalisation. This suggest that ubiquitination of an unidentified protein 
by c-Cbl is required to mediate EGFR endocytosis. Moreover if kinase 
activity is partially inhibited, ubiquitination of the receptor can mediate its 
internalisation80. Thus, EGFR internalisation, and probably that of other 
RTKs, can be mediated by multiple mechanisms. Such robustness of this 
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step of RTKs trafficking and the redundancy of the internalisation 
mechanisms can explain why these mechanisms are so difficult to 
elucidate.  
• The last step is the scission of the new vesicles from the plasma 
membrane, with the help of late acting components such as the GTPase 
Dynamin74,77. 
 
4.1.3. Vesicle sorting  
After the pinching off from the plasma membrane, clathrin is removed and 
the newly formed vesicles will fuse with one another and with pre-existing 
early endosomes and, more precisely, with sorting endosomes. This 
fusion process mainly is regulated by the small GTPase Rab5, EEA1 
(Early Endosome Antigen 1) and SNAREs (Sensitive N-ethylmaleimide 
factor Attachment protein Receptor) proteins (Fig. 5). EEA1 contain a 
membrane lipid targeting domain, FYVE (Fab1/YOTB/Vac1/EEA1), that 
selectively recognises PhosphatidylInositol-3-Phosphate (PtdIns(3)P). 
PtdIns(3)P  has a specific endosomal localisation, which strongly suggests 
that FYVE-containing proteins have a role in vesicular trafficking82. 
Actually, early endosomes correspond to two distinct endosomal 
organelles: sorting endosomes and Endocytic Recycling Compartments 
(ERC). The role of sorting endosomes is to target the receptors to their 
correct destinations. Three destinations are possible: the plasma 
membrane, the ERC or the late endosome (Fig. 6). In sorting endosomes, 
since the pH is around 6, the ligand can dissociate from the receptor 
allowing the recycling of the receptor back to the plasma membrane, 
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where it will be free to be re-stimulated by the ligand83. From ERC, 
receptors are recycled back to the plasma membrane, a process regulated 
by the small GTPase Rab11, or are directed to the trans-Golgi network or 
to late endosomes/ MVB (MultiVesicular Body).  
 
4.1.4. RTK degradation and recycling 
When proteins are targeted to late endosomes, RTKs can be internalised 
into intralumenal vesicles of MVB. At this step the cytoplasmic tail of the 
receptor is no longer exposed, leading to the end of the signal and 
preventing the RTKs from recycling to the cell surface. MVB subsequently 
fuse with lysosomes and the receptor is then degraded. The first step in 
targeting a receptor to late endosomes often is the ubiquitination of its 
cytoplasmic domain.  
The ubiquitinated receptors are recognised by multiple proteins of the 
endocytic pathway that contain an Ubiquitin Interacting Motif (UIM). The 
first recruited, in regions of the endosomes containing a specialised 
bilayered clathrin coat, is Hrs (HGF-Regulated tyrosine kinase Substrate). 
This interaction might be important for retaining the receptor in maturing 
endosomes, leading to its delivery to late endosomes83. Hrs seems also to 
be implicated in receptor degradation by recruiting the ESCRT complex 
(Endosomal Sorting Complexes Required for Transport) that helps sort 
ubiquitinated receptors from early endosomes to lysosomes via MVB84.  
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Instead of being translocated into internal vesicles of the MVB, and thence 
being degraded, another fate for the RTK could be possible. Indeed, 
endosomal DeUBiquitinating proteases (DUBs) can deubiquitinate the 
RTKs, leading to the escape of the receptor from the MVB; the RTKs are 
no longer targeted to degradation and can be recycled back to the plasma 
membrane85. This was described recently for EGFR by the DUB called 
AMSH (Associate Molecule with the SH3 domain of STAM (Signal 
Transducing Adaptor Molecule))86.  
It seems that the balance between degradation and recycling could be 
determined by the pathway of RTK internalisation: clathrin-dependent or 
independent. Sigismund et al reported that the EGFR internalisation 
pathway varies upon the doses of EGF: a low dose would promote a 
clathrin dependent internalisation while a high dose would preferentially 
trigger non-clathrin dependent internalisation87. When it is endocytosed via 
clathrin-independent mechanisms, EGFR would predominantely be 
targeted to degradation. In contrast, when its internalisation is mediated 
mainly via a clathrin pathway, EGFR would rather be recycled back to the 
cell surface87. 
Traditionally, the goal of endocytosis was thought to be only the 
degradation of the receptor in order to switch off the signal, at least when 
recycling does not occur. Recently, it has become evident that receptor 
trafficking after internalisation participates considerably in modulating 
receptor signalling.  
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4.1.5. Role of endocytosis in signalling: “endosomal signalling” 
In the early 1990’s, studies started to demonstrate that RTKs remain 
active after their internalisation within the endosomes and thus could 
signal from intracellular compartments before their degradation. In 1994, 
EGFR was the first RTK to be found associated with signalling partners in 
early endosomes, suggesting a persisting signalling in this compartment88. 
Two years later, the Nerve Growth Factor (NGF) receptor was also found 
to be activated and bound to its ligand, in endocytic compartments; a 
discovery leading to the concept of “Endosomal Signalling”89. Since then, 
several studies, mainly done on EGFR, have confirmed this concept73,90,91. 
By Fluorescence Resonance Energy Transfert (FRET), interaction 
between EGFR and Grb2 was observed on endosomes, showing for the 
first time in a living cell, interaction on endosomes between an activated 
RTK and an adaptor molecule92.  
The detection of signalling proteins in the endosomal compartment raised 
the question as to whether signal transduction actually can occur from the 
endocytic membrane. Wang et al reported that endosomal localisation of 
EGFR93,94 and PDGFR95 is sufficient to activate signal transduction. 
PDGFR was shown to be associated with several proteins (Grb2, SHC 
and the p85 subunit of PI3-K) in the endosomes95 while the TGF-? 
receptor, a serine/threonine kinase receptor, was also found recruited on 
endosomes via the association with the compartment-specific adaptor 
protein, SARA (SMAD Anchor for Receptor Activation), a FYVE domain 
protein96. Further studies demonstrated the importance of endosomal 
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localisation in TGF-? signalling to generate specific signals from this 
compartment97.  
It was further suggested that trafficking of activated RTKs could therefore 
have an impact on their signalling. Studies aiming at interfering with 
receptor trafficking have been pioneered by Viera et al98. By 
overexpressing a dynamin dominant-negative construct in Hela cells, to 
impair EGFR internalisation, it was shown that some signalling molecules 
were hypophosphorylated (such as ERK) but others were 
hyperphosphorylated (such as PLC-?), showing evidence of the need for 
correct receptor trafficking in establishing specific signalling pathways. 
Endosomal signalling was also shown to be pathway selective for the 
insulin receptor99. But some proteins appear to be found activated in the 
endosome and at the plasma membrane. It is the case for Ras 
GTPase100,101. ERK has been found activated at the plasma membrane, in 
focal adhesion complexes or in endosomes101.  
Signalling from the endosome appears to require specific scaffolds that 
“anchor” the signalling complexes to the endosome in response to growth 
factor stimulation. Indeed, ERK was reported to be localised and activated 
on late endosomes through association with the scaffold protein MP1 
(MEK1-binding Partner), itself bound to the adaptor p14, attached to the 
cytoplasmic face of endosomes102,103. Recently, p18, a novel lipid raft 
adaptor anchored to late endosomes, was shown to directly bind the p14-
MP1 complex, thus assembling the p14-MP1-MEK-ERK complex on late 
endosomes104. Moreover, this endosomal localisation, thanks to the 
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association with MP1/P14, was necessary for full ERK activation upon 
EGF stimulation103.  
More recently, Akt and its substrate GSK-3? have been found recruited by 
the Rab5 effector Appl1 on newly identified endosomes bearing Rab5 and 
Appl proteins41, thus called “Appl endosomes”105. In addition, Appl1 was 
also required to recruit, directly or indirectly with its ligand the NGF, 
activated TrkA on endosomes, hence allowing ERK and AKT activation106. 
Different receptor locations could mean different activated pathways 
leading to different cellular responses107. Recent studies support the 
hypothesis that “endosomal signalling” is an important mechanism to 
control RTK-generated cell responses such as cell migration70,71,108,109 and 
cell survival41,94,95. Endosomal signalling was also shown to influence cell 
proliferation, although this could be both positively95,110, or negatively98. 
Further investigations are required for a better understanding of how these 
two diametrically opposed actions are evoked. One of the strongest pieces 
of evidence supporting the concept of “signalling endosomes” was 
probably made by Schenck el al41. They demonstrated, for the first time, 
the importance of “endosomal signalling” in vivo. They showed that 
specific signals were generated from the endosomal compartment, and 
moreover were required for AKT-dependent survival in zebrafish 
development41. 
Together, these findings have identified RTK endosomal signalling as 
requiring more than just ligand-receptor interactions at the cell surface. 
Signalling can occur at the plasma membrane and could be continued on 
endosomes thus modifying signal intensity, or signalling can require 
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endocytosis to generate endosome-specific signals, thus contributing to 
signal diversification and specificity111,112. How is it that endosomes could 
generate specific signals? Endosomal membranes are composed of 
particular lipids, only present on endosomes, such as PtdIns(3)P. This 
induces the recruitment of specific adaptor proteins, such as EEA1 or p18 
on late endosomes104. In addition, this lipid composition evolves during 
endosome maturation leading to the recruitment of other/new partners. For 
example, Appls are present on early stages of early endosomes and then 
will be replaced by proteins such as EEA1 as endosomal maturation 
occurs113.  
Moreover, the pH of endosomes is acidic and that can be required for the 
activity of diverse enzymes114. Endosomes define restricted compartments 
in which activated receptors and signals are in close juxtaposition and 
then act by providing protection against phosphatases115. 
Thus, the current concept is that endosomes represent a platform, which 
integrates signalling pathways temporally, and spatially to determine 
response specificity that has important biological and pathological 
consequences111,116,117.  
 
4.2. Met endocytosis / trafficking  
4.2.1. Met endocytosis 
Studies on Met endocytosis and trafficking have only started relatively 
recently. After ligand binding, and therefore activation, Met is internalised 
via a typical clathrin-mediated process118-120. Indeed Met endocytosis is 
impaired when clathrin-mediated endocytosis is blocked by dynamin 
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mutant expression70,118 or by overexpression of the COOH part of the 
endocytic adaptor, AP180119 or by knock-down of clathrin70. Met 
endocytosis is fast, the totality of Met present at the cell surface being 
internalised within a few minutes upon HGF stimulation119.  
So far, the mechanisms found to regulate Met endocytosis are similar to 
the ones described for EGFR (detailed above). They include c-Cbl-CIN85-
endophilin complex formation121 and c-Cbl indirect binding to Met via Grb2 
associated to c-Cbl ubiquitin ligase activity122. Indeed, when the indirect 
interaction of c-Cbl to Met via Grb2 is abrogated, the step of endocytosis is 
impaired. However, a c-Cbl mutant able to bind Grb2 but lacking its 
ubiquitin ligase activity failed to promote Met internalisation; thus, as for 
EGFR, the ubiquitin ligase activity of c-Cbl is required for Met 
endocytosis122. Accordingly a dual role for c-Cbl, as an ubiquitin ligase and 
as an endocytic adaptor, is involved in Met endocytosis. 
 
4.2.2. Met trafficking 
After internalisation, following 15 min of HGF stimulation, Met shows a 
good co-localisation with the early endosomal compartment marker, 
EEA1. This co-localisation is lost at later time points (120 min) as Met has 
trafficked from early endosomes to a perinuclear compartment118,119. This 
perinuclear compartment, in part, includes the Golgi119 and has also been 
reported to correspond to late endosomes118. This traffic is an active 
regulated process as it is microtubule-dependent and regulated by PKC 
activity119 (Fig. 7).  
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4.2.3. Met degradation 
Endocytosed Met upon HGF stimulation gets further degraded such that 
50% of the molecule is degraded after 120 minutes of stimulation 119.  
As it is for EGFR, the requirement of Met ubiquitination by c-Cbl for it to be 
degraded has clearly been established. The recruitment of c-Cbl to Met 
leads to its ubiquitination123 and c-Cbl can directly bind Met on its 
phosphorylated Tyr1003 123,124. Again like for EGFR81, when the direct 
interaction between Met and c-Cbl is impaired by mutation of the  Tyr1003, 
Met degradation is delayed (but the internalisation is intact)124. The 
Y1003F mutant fails to interact with Hrs, suggesting that Met needs to go 
in endosomes, to interact and phosphorylate Hrs, in order to be 
degraded124,125. 
The nature of the degradative pathway for Met remains controversial in the 
literature. After ligand binding, Met was reported to be 
polyubiquitinated118,126 but also multimono-ubiquitinated125. In addition, 
Met has been characterised as being degraded not only via the lysosomal 
pathway118,125, which represents a classical pathway for membrane 
receptors, but also via the proteasomal pathway119. Perhaps, several 
mechanisms are implicated in Met degradation and it is a question of the 
balance between the various pathways that changes depending on the cell 
environmental conditions. It also is possible that the proteasome pathway 
is only implicated indirectly (maybe the proteasomal degradation of a 
molecule is needed to allow the degradation of Met via the lysosome). In 
addition, lysosomal sorting of EGFR has been shown to be influenced by 
proteasome inhibition127. 
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Interestingly, Met degradation does not require the trafficking to the 
perinuclear location and could be generated from peripheral endosomal 
compartments119.  
Finally, a novel transmembrane protein, LRIG1 recently was identified and 
reported to induce Met degradation in a ligand-c-Cbl independent manner 
via the lysosome pathway128. 
Met degradation can be regulated by the chaperone protein HSP90 (Heat 
Shock Protein 90) activity. Webb et al developed a cell-based assay in 
MDCK cells in which HGF stimulation induced the high activation of 
plasmin protease activity129. Over 1000 compounds were tested and 
geldanamycin, an Hsp90 inhibitor, was identified as a potent inhibitor of 
plasmin activation129. These authors proved that HSP90 inhibitors 
hampered Met induced pathways. In addition this study, and others, 
demonstrated that geldanamycin treatment induced Met down regulation 
suggesting, at least in part, that HSP90 is involved in Met protection 
against degradation130,131.  
In contrast with EGFR, no recycling of Met, with or without ligand 
stimulation, has so far been described. 
 
4.2.4. Met endosomal signalling 
As for other RTKs, Kermorgant et al showed that Met undergoes an 
“Endosomal signalling”70,71,119. Endosomal Met was shown to be 
associated with a phosphotyrosine signal, indicating it is still active in 
these vesicular compartments70. In the same study, Kermorgant et al 
demonstrated that Met dependent ERK1/2 phosphorylation requires 
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endocytosis70. The sustained ERK1/2 phosphorylation was not due to a 
persistent signal from the plasma membrane but rather was due to 
endosomal signalling. It was concluded that the spatial control of Met 
signalling events might be critical in determining cellular responses70,132. 
Moreover, a recent paper from Kermorgant et al has confirmed the 
importance of Met endosomal signalling in Stat3 activation and nuclear 
translocation. In this study, it was reported that, not only is endocytosis 
required for Met dependent Stat3 activation but that Met trafficking to a 
perinuclear endosome was necessary to induce a robust Stat3 
phosphorylation and consequent nuclear accumulation of phosphorylated 
Stat371,133,134.  
 
5. Biological effects of Met/HGF 
HGF/SF is produced by tumour stroma and acts in a paracrine manner to 
stimulate epithelial cells that express Met. By the activation of multiple 
pathways Met triggers a wide range of biological activities, that comprise 
proliferation, protection from apoptosis, cell dissociation (scattering), 
motility, migration, cell polarisation and invasion of the surrounding 
matrix15,135. The coordination of all these biological responses under 
physiological conditions results in the establishment of the so-called 
“branching morphogenesis”15 or “invasive growth program”136,137 which 
takes place during embryonic development or when Met/HGF signalling is 
deregulated during tumour progression.  
 
 
 50 
5.1. Implications of Met/HGF signalling at development stages 
Knock out (KO) for Met or HGF/SF are both lethal and the mice die in 
utero, showing the crucial role of Met/HGF in development138,139. Two 
side-by-side papers, and another published the same year in Nature, in 
1995 showed that HGF/SF knock out and Met knock out mice respectively 
die between 13 and 16.5 days of embryogenesis (E13-E19.5) with a slight 
reduction in body size. The three groups found that the most marked 
phenotype was a strong reduction in the size of the liver139,140. A defect in 
placenta formation, with a reduced number of trophoblast cells, also was 
observed. This could explain the embryonic lethality suggesting it occured 
by a default in nutrient transport from the mother.  
A complete absence of muscle in the limbs, shoulders and diaphragm was 
observed, due to an absence of migrative myogenic progenitors. In 
contrast, the muscles that do not originate from migrative precursors, such 
as axial muscles, were normal. Indeed, HGF/SF is expressed in a 
sequential manner that drives Met progenitor muscle cells to their final 
destination to constitute new muscles138. This observation established the 
important role of Met/HGF signalling in control of migration during 
embryogenesis. Both Met and HGF/SF are expressed in the developing 
nervous system. A similar role for Met/HGF signalling could be attributed 
in neuronal development and, more precisely, in the development of the 
projection of spinal motor axons to target muscle cells141. In fact, 
explanted mouse limb bud mesenchyme attracts axons from motor 
neurons in a collagen matrix142. As they are for the muscle development, 
HGF/SF and Met are expressed in patterns that are consistent with a 
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chemoattractant guidance role: Met is expressed by motor neurons and 
HGF/SF by the limb bud mesenchyme142. HGF/Met interactions were also 
shown to be implicated in human embryonic gut development; a dynamic 
expression and localisation pattern of HGF and Met that followed the 
morphogenesis of the gut, according to time of development, was 
identified143. 
 
5.2. Implications of Met/HGF signalling into post-natal life 
Met/HGF interactions also play a major role throughout adult life. Indeed, 
the expression of both Met and HGF/SF was found to be increased after 
various injuries144,145. Increased HGF expression levels could be a 
defensive reaction of the injured organ in order to protect or heal itself.  
After hepatectomy in the rat, a huge increase in HGF/SF plasma levels 
was detected, leading hepatocytes to synthesise DNA and thus 
proliferate144. This result confirmed older studies conferring upon HGF a 
mitogenic capacity for hepatocytes17. In a rat model of 
ischaemia/reperfusion injury, plasma HGF levels and Met mRNA levels in 
the ischaemic myocardium were found to be increased considerably145. 
HGF has also been shown to be cardioprotective in vivo145.  
In 2007, the group of Walter Birchmeier demonstrated that Met signalling 
is necessary in skin wound healing146. They generated conditional mice, 
where Met was knocked out only in keratinocytes, and found that such 
animals were unable to induce in vivo skin wound healing and that no 
compensatory systems appeared to exist.  
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HGF/SF is also known as an angiogenic factor. In vitro studies showed 
that HGF can act directly on endothelial cells, shown to express Met, by 
inducing their proliferation and their migration/motility147,148. A study 
conducted on rabbit corneas showed that HGF promotes formation of new 
capillaries without inducing an inflammatory reaction147.  
All these data prove that Met/HGF interactions play a key role in several 
postnatal processes and these actions are necessary for maintaining 
homeostasis. Deregulation of these normal interactions could lead to 
human malignancies.  
 
6. Met/HGF and cancer 
A large amount of evidence suggests that RTKs are implicated in the 
development of human cancers either through receptor gain of function 
mutations or through ligand/receptor overexpression. Indeed, half of the 
members of the RTK family have been associated with human 
malignancies2. Met is one of them. Historically, as described in the section 
“The Met receptor tyrosine kinase”, Met was identified as a proto-
oncogene corresponding to a fusion protein “TPR/Met” in a cell line treated 
with a chemical carcinogen. In 1991, this translocation was reported to 
occur spontaneously in gastric carcinomas, suggesting a role for 
oncogenic Met in cancer progression149. Met is also able to induce cell 
transformation when it is transfected into fibroblasts (that do not express 
endogenous Met)150. These cells are able to grow in an anchorage 
independent manner (soft agar assay), to generate a tumour when grafted 
into mouse models150, and to generate metastases151. The cells originating 
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from the parental tumour explants have an enhanced tumorigenic potential 
correlating with an increase in total Met expression151. In conclusion, in 
mesenchymal cells, Met signalling by itself appears to promote 
tumorigenesis.  
Additionally in vitro studies showed that HGF/Met signalling could enhance 
the migration and the invasiveness of many cancer cell lines. Invasion 
through Matrigel was shown to be facilitated by the stimulation, by HGF, of 
the production/activity of several Metalloproteinases (MMP), including 
MMP-1 and -2152. An autocrine loop was described in a gastric cancer cell 
line that promotes migration, suggesting the possible involvement of 
HGF/Met autocrine signalling in the progression of stomach cancer153.  
Moreover, Met/HGF signalling has been reported to be deregulated in a 
large variety of human cancers14,154. Met-dependent signalling could, for 
example, be increased through overexpression of the receptor due to 
gene amplification, enhanced transcription or post-transcriptional 
modifications155, by ligand binding (autocrine and paracrine) or because of 
activating mutations156. In addition, Met could be activated in an aberrant 
way by other cell surface receptors, such as CD44, integrin or other RTKs 
as has been shown to occur for EGFR or RON154,157,158. 
 
6.1. Met/HGF overexpression 
Met and/or HGF/SF have been found to be expressed or overexpressed in 
several human carcinomas and in other types of cancers, and also in their 
metastases14,15. Moreover, their levels of (over)expression could serve as 
indicators of prognosis.  
 54 
• Met overexpression has been linked to tumour progression of several 
cancers, including breast, colon, liver and kidney159-161. For example, 
based on micro-array analysis, Met overexpression in hepatocellular 
carcinomas has been associated with expression of a pattern of Met 
regulated genes which composed the signature of an aggressive cancer 
which carried an increased probability of death162.  
Met gene amplification, leading to overexpression, was reported in several 
human cancers14 including 8% of oesophageal carcinomas163, 23 % of 
gastric carcinomas164, metastases of oesophageal carcinomas in the 
lymph node163 and of colorectal carcinomas in the liver165. More recently, a 
quantitative PCR study reported that more than 78% of HNSCC tested 
had a higher Met gene copy number as compared to normal tissue166.  
Finally, trisomy of chromosome 7, the chromosome bearing Met, was 
identified in 95% of sporadic Papillary Renal Carcinomas (PRC) and in 
100% of Hereditary Papillary Renal Carcinomas (HPRC)167-169. 
• HGF/SF has also been found to be overexpressed in tumours of the 
breast with a correlation with poor prognosis170. In this study, these 
investigators established that the intra-tumoral quantity of HGF correlated 
with the disease free interval and the patient’s survival. A high amount of 
HGF was linked with a shorter disease free time and with a reduction in 
overall survival170.  
 
 
 
 
 55 
6.2. Identification of Met mutations and experimental evidence of 
their role in tumorigenesis 
A possible direct link between Met and cancer was the identification, in 
1997 by Schmidt et al, of Met mutations in HPRC and sporadic PRC168. 
Nine missense mutations were found in the tyrosine kinase region of Met 
(exon 17,18,19) including five germline and four somatic mutations. 
Germline mutations were detected in 4/7 HPRC tested families and 
somatic mutations in 3/60 patients with sporadic HPRC. At this time 
nothing had proved that these mutations lead directly to tumorigenesis but 
this was suggested. Six of these identified mutations correspond to a 
change in amino-acid class, implying an impact on protein function. 
Commonly, these tumours present a trisomy of chromosome 7, as 
mentioned above, and further studies showed that it was particularly the 
chromosome with the mutated allele of Met that was duplicated, 
suggesting its involvement in tumorigenesis171. Moreover, these mutations 
are located in codons homologous to codons that are the target of 
disease-producing mutations in other receptor tyrosine kinases, such as 
RET and Kit172,173.  
In order to know whether these mutations could play a role in cancer 
development/progression, Jeffers et al introduced them in mouse Met 
cDNA and transfected constructs containing such altered cDNA into 
NIH3T3 fibroblast cells156. They demonstrated that these cells were more 
transformed in vitro than cells expressing Wild type (Wt) Met and this 
occurred without the need for HGF binding. Indeed, they had lost contact 
inhibition and acquired the capacity to form foci. Interestingly, the mutated 
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receptor exhibited an increased level of tyrosine phosphorylation when 
compared to Wt Met. Moreover, these cells were more tumorigenic than 
Wt Met expressing cells when grafted into nude mice156 and induced 
metastasis in vivo174. Similar results were obtained with NIH3T3 
expressing a chimeric Met composed of the extracellular domain of NGF 
fused with the intracellular domain of Met with or without the different 
mutations. Conclusions from these studies were that mutationally 
activated Met forms reside in a partially activated state (without ligand 
binding) that can be enhanced further through ligand stimulation and that 
these biochemical changes might play a crucial role in HPRC.  
Since 1997, these missense Met mutations, and others, have been 
identified in several human cancers (Fig. 8, Table 1). They are localised 
either in the tyrosine kinase domain166,167,175-178, the juxtamembrane 
region166,179-182, or in the semaphorin domain166,179,183,184. In 2006, a 
somatic intronic mutation, leading to the deletion of exon 14, which 
encodes for the juxtamembrane domain, was identified in non-small cell 
lung cancer185. 
 
6.3. Mechanisms of Met activating mutations in cell transformation 
6.3.1. Met activation 
The question now is to understand how these oncogenic Met mutations 
confer upon the cell a transforming potential. So far, investigations have 
been mainly performed on the mutations found in the kinase domain.  
Computational studies reported that the M1268T and D1246N mutations 
would contribute to the stabilisation of Met in an active conformation186.  
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The tyrosines identified to be essential in Met/HGF signalling27,187, Y1349 
and Y1356, are indispensable to the mutants for inducing transforming 
ability188-190. Indeed, when these tyrosines were converted into 
phenylalanines, such that no more coupling with transducers was 
possible, no cell transformation occurred191.  
This work suggested that the constitutive coupling of the Met mutants to 
downstream partners is necessary to promote cell transformation.  
The activation of Wt Met by HGF requires the sequential phosphorylation 
of the two major tyrosines, 1234 and 1235, in the kinase domain. An 
intriguing result obtained by Chiara et al was that tyrosine 1234 was not 
phosphorylated in the Met mutants tested, showing a decrease in the 
kinase activation threshold189.  
 
6.3.2. Downstream signalling 
Several studies aimed to identify the signalling partners of the oncogenic 
Met forms174,188,192.  
The MAPK pathway seems to be involved, as an increased level of MAPK 
phosphorylation was found in NIH3T3 cells expressing the mutated 
receptor compared to cells expressing the Wt Met174. However, a different 
cell model, derived from NIH3T3 cells expressing the M1268T mutation 
and able to grow in suspension, did not display a constitutive MAPK 
phosphorylation193.  
Unlike for TPR-Met, the binding of Grb2 appears unnecessary to promote 
transformation by the Met forms with activating mutations188. However, 
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Grb2, as well as the p85 subunit of PI3-K, and Gab1 were found to be 
bound constitutively to Met mutants191.  
The tumorigenic potential of M1268T, one of the most studied mutants, 
appears to be driven by c-Src. This protein phosphorylates Paxillin and 
Focal Adhesion Kinase (FAK), two proteins important for cytoskeleton 
rearrangements193, and such changes often are associated with 
transformation.  
Changes in substrate specificity have also been reported for the M1268T 
Met mutation186,191. In fact, the mutation changes the sequence into a 
sequence characteristic of cytosolic tyrosine kinases, thus allowing the 
binding of c-Abl tyrosine kinase substrates. 
 
The identification of partners or mechanisms of these different oncogenic 
Met mutants is impossible to generalise about since they might vary 
between each mutation190,192.  
These differences in signalling translate into changes or variations in 
biological functions, such as proliferation versus apoptosis protection and 
the stimulation of invasion192. Thus, the M1268T and D1248H Met 
mutations would signal more through the Ras signalling pathway, leading 
to important transforming potential as seen in the focus formation assay, 
whereas the Y1248C Met mutant would interact more readily with PI3-K, 
thus protecting cells against apoptosis.  
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7. RTK mutations and cancer 
As for Met, other RTKs present mutations that have been shown to 
contribute to the growth and metastasis of human cancers194,195. Some of 
these mutations confer drug resistance or, in an opposite fashion, greater 
sensitivity to inhibitors in expressing cells (see Discussion-Part I).   
EGFR  
In 2004, somatic mutations were identified in the EGFR in 10% of patients 
with Non-Small Cell Lung Cancer (NSCLC)196. The hotspots of mutations 
have been found to be located in the tyrosine kinase domain. They 
correspond to point mutations, small in frame deletions or insertions. 
Kit and Ret 
Among the RTK family, Met, Kit and Ret present a highly conserved 
tyrosine kinase region. Mutations identified in one of them led to the 
discovery of the same mutation, at the corresponding amino-acid position, 
in the others. Indeed, the two Met mutations (M1268T and D1246N), 
affecting conserved residues, were found previously in tumorigenic forms 
of the Ret and Kit receptors respectively172,173. The Ret M918T mutation 
was identified in multiple endocrine neoplasia type 2B and this mutation 
has been shown to be responsible for most of the cases of this tumour173. 
The Kit D816Y/V has been found in human mastocytosis172,197. As noted 
for Met and EGFR mutations, the Kit D814Y mutant and Ret R918T 
mutant, are highly phosphorylated198,199. In both of them, a change in 
substrate specificity was also observed199,200.  
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FLT-3  
The RTK Fms-Like Tyrosine kinase 3 (FLT-3), has been found mutated in 
the juxtamembrane201 in a large proportion of acute myeloid leukaemias203 
FGFR3 
Mutation of the Fibroblast Growth Factor 3 (FGFR3) in the kinase 
domain202 was reported in a variety of skeletal disorders204.  
 
All these mutations are “gain of function” events, increasing the activation 
of the receptors, leading to an increased activity of their downstream 
pathways.  
 
Since the initiation of my project, few recently published studies have 
revealed trafficking perturbations of such mutants, leading to an impaired 
down-regulation, or to an incorrect maturation, which both could play a 
substantial role in the gain of function of these mutations (though this has 
not yet been reported for Met mutations). 
 
7.1 Mutations and trafficking modifications 
7.1.1. Impaired down-regulation: EGFR  
Two of the EGFR mutations found in NSCLC, L858R and L816Q, were 
shown to lead to modifications in EGFR trafficking. The mutants escape 
ligand-induced down-regulation and are associated constitutively with 
chaperone protein HSP90 and the ubiquitin ligase c-Cbl205. By treating the 
cell with an HSP90 inhibitor, this degradation was restored suggesting that 
HSP90 maintains the stability of EGFR in an active conformation.  
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Another mutant, EGFRvIII, which lacks a part of the extra-cellular domain, 
presents defects in internalisation and degradation206. The impaired down-
regulation was attributed to an inefficient ubiquitination due to the 
hypophosphorylation of the Y1045 c-Cbl binding site, and thus an altered 
association with c-Cbl206. Although c-Cbl was shown still to bind to the 
EGFR mutant via Grb2, this was inefficient in terms of leading to proper 
ubiquitination. However, although these EGFR mutants can still be 
internalised they are not sorted correctly as they recycle back to the 
plasma membrane206,207.  
 
7.1.2. Incorrect maturation leading to intracellular accumulation 
Kit: accumulation in the Golgi 
An immature form of a Kit mutant, the D814V was found localised in the 
Golgi, from where it is able to signal, and this was sufficient to promote 
tumorigenesis, both in vitro and in vivo208. The same mutant had no 
transforming properties when localised in the Endoplasmic Reticulum 
(ER)208.  
Ret, FLT-3 and FGFR3: accumulation in the ER 
Following inefficient maturation, precursor forms of Ret, FLT-3 and FGFR3 
mutants were detected in the ER where they induced downstream 
signalling209, 202,201. This was for example reported for the FLT-3 ITD 
mutant, which, as a consequence, had a reduced expression at the cell 
surface. Its artificial targeting to different cellular localisations was found to 
mediate differential signalling, leading to differences in cell growth210.  
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There are some possible explanations as to why these RTK mutants are 
improperly targeted to the plasma membrane. Their high state of 
phosphorylation seems to be one of the reasons since overexpression of 
protein tyrosine phosphatases or kinase inactivation restored maturation 
and surface localisation of the FGFR3 and FLT-3 mutants201,202,211. 
Glycosylation of RTKs seems also to be involved in their defect of 
trafficking to the cell surface. Thus, the FLT-3 mutant, when modified in 
order to eliminate the majority of its glycosylation sites, was addressed 
normally to the plasma membrane210. 
 
So far, no study aiming at investigating the trafficking and the subcellular 
localisation of Met mutants located in the kinase domain has been 
conducted and thus I undertook to perform such an evaluation.  
 
8. Targeting Met in Cancer 
As described above, Met was shown to be oncogenic through different 
processes that, ultimately, lead to quantitative and/or qualitative 
modifications of its signalling154,212 while deregulated Met signalling was 
found to be implicated in a wide range of cancer types15,154. Met can 
impact on all the different steps of tumour progression, from initial tumour 
development to the underpinning of cancer spread; the process termed 
metastasis213. Furthermore, Met recently was reported to contribute to 
tumour resistance to treatments targeted toward other RTKs, such as 
EGFR inhibitors gefitinib214 or erlotinib215 in lung cancers and the anti-
EGFR monoclonal antibody trastuzumab (herceptin) in breast cancers216. 
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Based on all of these observations, it is not surprising that Met recently 
became a target of choice for the development of new anti-cancer 
treatments217. The interest of the pharmaceutical companies in the 
possibilities of using Met as a therapeutic target is growing very rapidly. 
Before 2003 no small molecules specifically targeting Met were available. 
Nowadays, many have been tested in preclinical studies and currently 
some already are in clinical trials (phase I, II and/or III)218,219.  
 
8.1. Main approaches (Fig. 9) 
Three main strategies have been developed to hamper Met activation: 1) 
antagonism of ligand/receptor interaction, 2) inhibition of the tyrosine 
kinase catalytic activity and 3) interference with the recruitment of 
downstream signalling molecules.  
 
8.1.1. Antagonism of ligand/receptor interaction 
To prevent interaction between Met and its ligand, several types of 
molecules have been engineered, including competitors and neutralising 
or blocking monoclonal antibodies (Table 2).  
 
• Competitors 
The competitors developed either are antagonists or decoys of either Met 
or HGF. 
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HGF competitors 
Among the HGF antagonists generated, the molecule NK4 is the most 
studied and one of the more promising for modulating Met signalling. NK4 
is a molecular analogue of HGF. It corresponds to a truncated form of 
HGF consisting of only the entire ? chain. NK4 binds to Met but does not 
induce its activation. In diverse murine tumour models, NK4 efficiently 
blocked tumour growth (by 60%)220 as well as tumour dissemination221 and 
the development of lung metastases222. Interestingly, independently from 
its HGF antagonist action, NK4 also has displayed anti-angiogenic 
properties220 and these might enhance any HGF inhibiting therapeutic 
activity. 
 
Met competitors 
A Met competitor, or “decoy Met”, has shown good results in several 
preclinical experiments223. Decoy Met corresponds to the whole of the Met 
extracellular region, thus it is devoid of any enzymatic activity since this is 
located in the intracellular domain. The decoy Met can interact with both 
HGF and Met to prevent ligand binding and receptor dimerisation 
respectively. Introduced by lentiviral technology, the decoy Met inhibited 
both tumour growth and metastasis without any substantial side effects 223. 
Moreover, when combined with radiotherapy, decoy Met induced 
substantial tumour regression in established growths223. It is interesting to 
note that the same experiments, conducted in parallel with NK4223, gave 
similar results but with a better efficacy, in terms of tumour growth and 
metastasis inhibition, with the decoy Met.  
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• Neutralising and blocking antibodies 
In parallel approaches, both neutralising and blocking monoclonal 
antibodies against HGF or Met have been developed.  
 
HGF antibodies 
Amgen has developed several fully human monoclonal antibodies (IgG2) 
against HGF224. Among them, AMG102 demonstrated good anti-tumour 
activity against HGF/Met dependent human tumour xenografts and, 
moreover, was shown to enhance the activity of conventional 
chemotherapeutic agents225. AMG102 currently is being evaluated in 
Phase II trials against advanced glioblastomas and renal cell carcinomas 
and a forthcoming clinical trial will assess its efficacy in association with an 
anti-EGFR antibody, panitumumab, against metastatic colorectal cancers 
(http://www.clinicalstrials.gov). 
 
Met antibodies 
The first generated anti-Met antibodies were inefficient at inhibiting Met 
activity because they had intrinsic agonist activity and thus induced Met 
dimerisation and activation14,226.  
Then, Genentech developed the OA-5D5 (MetMab) reagent, a “one 
armed” anti-Met antibody that was highly efficient in preventing HGF 
binding. Thus, OA-5D5 is able to inhibit HGF dependent phosphorylation 
of Met in in vitro assays and to block glioma growth in an orthotopic in vivo 
model227. 
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In addition, promising results have been obtained in preclinical studies 
with protocols that combined OA-5D5 with anti-VEGF antibodies and/or 
with EGFR inhibitors, with the best anti-tumour activity being obtained 
when the triple combination was utilised228. OA-5D5 at this time is in 
Phase I evaluation in combination with an anti-VEGFR antibody 
(bevacizumab) in patients with advanced or metastatic solid tumours 
(http://www.clinicalstrials.gov). 
 
8.1.2. Inhibition of the tyrosine kinase catalytic activity  
Another approach that has been considered consists of the direct 
inhibition of the kinase activity of the receptor using small molecule 
inhibitors. This first was attempted with broad spectrum inhibitors but 
gradually inhibitors with a higher specificity for Met have been developed 
and tested (Table 3).  
 
• ATP competitive molecules 
Early work in the 90’s started with the K252a compound (Cephalon) a 
staurosporine analogue229. Even if this Tyrosine Kinase Inhibitor (TKI) was 
not Met specific, it was found to be very efficient in the inhibition of the Wt 
form of the receptor following interaction with HGF, and even more potent 
at inhibiting the constitutive enzymatic activity of the M1268T Met 
mutant230. These promising results, associated with the accumulation of 
data linking Met and cancer, have encouraged the pharmaceutical industry 
to develop Met-specific TKIs.  
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Development of SU-11274 and PHA-665752 
In 2003, 2 molecules specifically targeting Met, both defined by an indolin-
2-core structure were designed. SU-11274 was developed by Sugen, now 
Pfizer231,232 and then PHA-665752 was produced by Pfizer233 (Fig. 10). 
These molecules share the indolinone motif substituted at the position-5 of 
the indolinone core with 3-chlorobenzylsulphonide groups for SU-11274 or 
with 3,5-dimethypyrole groups for PHA-66575214 (Fig. 10). SU-11274 and 
PHA-665752, are both competitive ATP inhibitors that exhibit activity 
against Met, with an Ic50, obtained in in vitro kinase assays, of 20nM231 
and 9nM233, respectively. They both exhibited 50-fold selectivity for Met as 
compared with the majority of other tested kinases, with the exception of 
VEGFR for SU-11274 and RON for PHA-665752. Met and Ron belong to 
the same RTK family and show a high percentage of homology in their 
intracellular region4. This might be the reason why PHA-665752 can inhibit 
either Met or Ron activity. Interestingly in cellular assays, PHA-665752 
displayed at least a 10-fold greater potency than SU-11274 (Table 3). 
 
Preclinical studies with SU-11274 and PHA-665752 
Some important preclinical studies have been performed using these 
drugs, thus allowing evaluation of the advantages and the limits of the 
actions of these two compounds. 
Both drugs exhibited encouraging results against different cancer cell 
models in vitro. Indeed, both molecules inhibited Met phosphorylation 
efficiently, affecting, as a consequence, all the downstream signalling 
events. Although evaluation of SU-11274 has been limited to very few in 
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vivo studies it has been shown to induce significant cytoreduction in 
tumours developed from lung cancer cell xenografts215. In several studies 
PHA-665752 was shown to reduce, very efficiently, and even to stop 
completely, the growth of several cancer cell lines182,234,235. PHA-665752 
seemed particularly effective against xenografts where the injected cells 
were harbouring a Met amplification164.  
Interestingly, PHA-665752 has been shown to be effective not only in 
HGF-dependent tumours but also in HGF-independent tumour models 
such as a gastric carcinoma xenograft model, in which Met is activated 
constitutively233,236. 
Such promising results, combined with the success being obtained in the 
clinic with imatinib (a multitargeted TKI from Novartis) in the treatment of 
chronic myeloid leukaemia237, prompted pharmaceutical companies to 
develop Met specific drugs that could be used in human cancers. 
Unfortunately neither SU-11274 nor PHA-665752 are water-soluble which 
tends to limit their possible use.  
 
Development of PF-2341066 
In 2007, based on the co-crystal structure of PHA-665752 and the Met 
kinase domain, Pfizer designed the compound PF-2341066. This new, 
orally available 2 amino-3- benzyloxy-5-arylpyridine compound (Fig. 10) is 
a highly selective and potent ATP-competitive inhibitor of Met. It exhibited 
more than 100-fold selectivity for the Met enzyme compared with other 
evaluated kinases. Thus it is much more selective than the two other 
previously developed drugs, SU-11274 and PHA-665752238.  
 74 
 
 75 
In cellular assays, with an Ic50 of 11nM, PF-2341066 has demonstrated a 
better potency against Met activity as compared with PHA-665752 (Table 
3). It is important to note however that PF-2341066 is also a potent 
inhibitor of the Anaplastic Lymphoma Kinase (ALK)239, expressed only in 
neural, endothelial and perivascular entothelial cells in the brain. 
 
Preclinical studies with PF-2341066 
In different tumour models, whether HGF-dependent or not, PF-2341066 
inhibited tumour growth very efficiently240 or even totally (100% 
inhibition)238. Interestingly, PF-2341066 was shown also to have anti-
angiogenic properties166,238.  
 
Clinical studies with PF-2341066 
A Phase I study with healthy volunteers has just been completed with PF-
2341066 and several Phase I/II trials are now recruiting patients with 
advanced cancers (the origin is not provided) or with non-small cell lung 
cancers for evaluation. In addition, a Phase III study will start shortly but 
only against cancers with ALK identified alterations 
(http://www.clinicalstrials.gov).  
 
Development of PF-4217903 
Then, Pfizer developed a second more potent, and more selective, orally 
available small molecule inhibitor that targets Met, termed PF-4217903. In 
preclinical studies, this triazolopyrazine compound has been described to 
be exquisitively selective for Met, even more so than PF-2341066. Indeed, 
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it was determined to be more than 1000-fold selective for Met as 
compared to a panel of more than 200 kinases241. PF-4217903 was, until 
now, being evaluated in a Phase I trials but, for an unknown reason, this 
trial has just been suspended in mid-February 2010 
(http://www.clinicalstrials.gov). 
 
Other specific Met TKIs in clinical studies 
Three other different companies also have developed selective ATP-
competitive compounds, which can be administered per os (Table 3). 
These currently are in Phase I trials and are JNJ-38877605 from Johnson 
and Johnson, EMD1214063 from Merck-Serono242 and AMG208 from 
Amgen14,243. Except for the latter one, which was shown to inhibit         
Met-mediated signalling and functions both in vitro and in vivo243, there are 
no original publications available on these compounds. 
 
• Non-ATP competitive molecules 
Another class of Met tyrosine kinase inhibitor, a non-ATP-competitive 
agent, ARQ197, also showing high selectivity for Met244, is at this time 
being evaluated in Phase I and II trials against various tumours14,245. 
 
8.1.3. Interference with the recruitment of downstream signalling 
molecules 
A third strategy is emerging to block Met-dependent signalling. It relies on 
the prevention of the association of the receptor with its downstream 
partners. The adaptor Grb2 binds directly to Met and, through the 
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recruitment of a large panel of effectors, is thought to be accountable for 
the major part of the biological effects of the receptor27. Recently, 
compounds capable of penetrating the cells and binding to Grb2 with high 
affinity have been engineered246. These Grb2 antagonists efficiently 
blocked Grb2-dependent signalling in vitro and a prototype of this family of 
compounds was shown to block metastasis in murine model quite 
efficiently247. This type of molecule could, in the near future, be introduced 
into the clinic but it is not Met specific and because Grb2 is implicated in 
the signalling cascades of many types of receptors, some of which could 
well be beneficial, they have the potential to generate a lot of undesirable 
side effects. Preclinical studies and in vivo evaluations will have to be 
rigorous to rule out such possibilities. 
 
8.2. Limitations 
8.2.1. Ligand stimulated only 
Competitors and antibodies, with the exception of the decoy Met which by 
interfering with the Met dimerisation also inhibits HGF-independent Met 
activation, work by blocking the HGF / Met interaction.  
Therefore, these inhibitors likely will be efficient only against tumour cells 
in which Met activation is dependent on ligand binding227. This may 
represent a major potential limitation to the success of any such of these 
approaches since a proportion of Met-driven cancers express a 
constitutively activated Met that does not need interaction with HGF in 
order to be activated136. 
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8.2.2. Resistance due to mutations  
TKIs, by having the potential to block both HGF-dependent and HGF-
independent Met signalling, may offer the most comprehensive approach 
to achieving Met inhibition. However TKIs against other RTKs have been 
used in the clinic and, unfortunately, many of the treated patients either 
exhibit inherited resistance or develop resistance to these drugs248,249. 
RTK mutations may account for this resistance and it seems plausible that 
Met specific TKIs are likely to face similar resistance mechanisms . 
 
• RTK mutations and drug resistance 
Activating mutations leading to primary resistance to TKI treatment have 
been identified in several RTKs. In lung cancer, mutations reported in 
exon 20 of EGFR or HER2 have been shown to confer resistance to 
gefitinib and erlotinib inhibition250,251. Thus, even if these insertion 
mutations represent a small percentage (5%) of all the known EGFR 
mutations248, they are, at least in part, responsible for the failure of these 
TKI treatments against lung cancers. The Kit D816V/Y mutation, 
corresponding to the Met activating mutation D1246N, also has been 
implicated in resistance to imatinib treatment in mast cell diseases197,252, 
indicating the likelihood that certain Met mutations will have significant 
impact upon the sensitivity of expressing cells to various inhibitors.  
In contrast to these mutations which confer resistance, mutations which 
render expressing cells highly sensitive to the drugs, called “sensitive 
mutations”, have been identified and have been shown to improve overall 
treatment response to TKIs253,254. However, patients harbouring these 
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sensitive mutations also eventually become resistant to the treatment 
regime237,255,256. One of the most frequent reasons for this acquired 
resistance is due to the development of a second mutation in the same 
RTK255,256. Indeed, in 50% of patients with non-small cell lung cancers 
bearing a sensitive mutation in EGFR, who develop resistance to EGFR-
targeting TKIs, the mutation T790M has been reported to occur255,257. The 
same corresponding mutation within the homologous codon of the Kit 
receptor has been identified in gastrointestinal stromal tumours (GIST), 
where this T610I Kit mutation was associated with acquired resistance to 
imatinib treatment258. 
 
• Met mutations and drug resistance 
Resistance, either primary or acquired after TKI treatment, is therefore 
likely to be a major problem in single-agent therapy and it seems most 
likely that similar problems will occur with Met TKIs259. For example, Met 
mutations and/or RTK pathway redundancies may cause inherited 
resistance to Met TKIs260,261. Indeed, even if SU-11274 and PHA-665752 
were found to be very efficient against cells expressing the oncogenic, and 
constitutively active TPR-Met231,262, which is a product of a genetic 
rearrangement, other Met mutants identified in human cancers, particularly 
in HPRC, have displayed differential inhibition sensitivities to SU-11274261 
and to PF-2341066239. For example the highly activated M1268T Met 
mutant was reported to be sensitive, while other mutations also located in 
the tyrosine kinase domain (L1213V and Y1248H) were resistant, to 
inhibition239,261. However, not all the mutations identified in cancers have 
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yet been tested (D1246N for example) and so far, no studies using PHA-
665752 have been conducted on cells bearing Met mutations found in 
HPRC.  
Among the five highly specific Met TKIs currently being tested in clinical 
trials, only the two designed by Pfizer, (PF-2341066 and PF-4217903), 
have previously been evaluated in preclinical studies against cells 
expressing different Met mutants. Moreover, as for SU-11274, the two 
TKIs from Pfizer were only evaluated on a restricted panel of Met 
mutants238,241 and it seems possible that certain patients might be treated 
with a drug which will be totally inefficient if they bear tumours which have 
Met mutations not previously assessed for TKI sensitivity. 
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AIM OF THE PROJECT 
 
 
Diverse Met mutations have been identified in hereditary papillary renal 
carcinoma (HPRC) as well as in other carcinomas. Although they are 
distributed throughout the gene, there is a preferential hot spot within the 
region encoding for the kinase domain. Met mutations are present at a low 
frequency in most cancer types except in PRC in which 13% of tumour 
samples harbouring activating Met mutations have been recorded167. My 
thesis has focused on three mutations located in the kinase domain: 
D1246N(g), M1268T(s) and Y1248C(g).  
These mutations were shown to induce constitutive Met phosphorylation 
and malignant transformation of NIH3T3 cells263 (Table 1). Interestingly, 
mice bearing these different mutations exhibit unique tumour profiles, 
some of which are metastatic263-265. While D1246Nmu/mu and Y1248Cmu/+ 
animals developed a high frequency of sarcomas, M1268Tmu/+ mice were 
characterised by an abnormal frequency of carcinomas but did not 
develop any sarcomas. These differences in tumour profiles suggested 
that the activating mutations affect more than just phosphorylation levels 
of Met. It was proposed that structural changes induced by the mutations 
could differentially alter the ability of Met to recruit accessory proteins into 
an active signalling complex, leading to possible distinct signalling 
pathways263.   
Understanding the mechanisms of these mutations in cell transformation is 
essential to the identification and development of successful therapeutics. 
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Although Met has now been identified as a target of choice to block the 
growth of several cancers, and although several drugs have already been 
generated to block its activity, many barriers still need to be removed in 
order to optimise Met-targeted anti-tumour therapies. For example, 
preclinical and clinical studies using RTK specific inhibitors for cancer 
treatment have demonstrated the problem of innate or acquired 
resistance. RTK mutations have been shown to account for a substantial 
part of this drug resistance. Moreover, it is impossible to predict the 
efficacy of a drug on a particular Met mutant based on the data obtained 
on another one. Therefore, in the first part of my thesis, I compared the 
sensitivity of Met mutants D1246N and M1268T to Met-specific TKIs, in 
vitro and in vivo. 
 
In a second part, I concentrated my efforts on the identification of the 
mechanisms by which these mutants confer a transforming capacity to the 
cells. Keeping in mind that the activating mutations may affect more than 
just phosphorylation levels of Met, and since the endocytic trafficking of 
RTKs has emerged to critically modulate their signalling, I hypothesised 
that where the mutants signal in the cell might affect signalling and cellular 
outcome. I therefore investigated whether the endocytic trafficking of these 
mutated receptors could play a predominant role in their transforming 
ability.   
 83 
MATERIALS AND METHODS 
 
 
1. Cell culture  
Mouse fibroblast NIH3T3 cells, stably transfected with a construct 
encoding for Wt murine Met or for a mutated form of the receptor, were 
kindly provided by Prof. Vande Woude156. The three mutants, M1268T (s), 
D1246N (g) and Y1248C (g), are labelled according to their amino acid 
location change, and germ-line (g) vs. somatic (s) status. Cells were 
cultured at 37°C, 8% CO2 in complete medium (DMEM, PAA) 
supplemented with 10% Donor Calf Serum (DCS, Gibco) and were 
subcultured twice a week. 
Cells were seeded in 35- or 100-mm plates for biochemical experiments, 
or on coverslips for immunocytochemistry. When starvation was required, 
cells were plated 48 h before the experiment. 24 h after plating or after 
starvation, cells were stimulated with 50 ng/mL of recombinant human 
HGF (R&D) for the indicated period of time. When indicated, cells were 
preincubated with the appropriate drugs for 30 min in complete medium 
and were then stimulated with HGF. When HGF stimulation was not 
required, drug treatments were done for 90 min unless otherwise 
specified. Drugs were maintained within complete medium until the end of 
the experiment.  
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2. Reagents 
2.1. Antibodies for immunofluorescence 
Anti-EEA1 (rabbit IgG) and anti-mouse Met antibodies (B2, mouse IgG1) 
were used at a dilution of 1/100 and were purchased from Santa Cruz 
Technologies. Anti-GST (1/250, rabbit IgG), anti-PiP3 (1/200, mouse IgM) 
and anti-mouse Met (1/100, goat IgG) were bought from Abcam, Echelon 
and R&D or Sigma respectively. Antibodies specific for Rab11 (1/100, 
mouse IgG1), pan phosphotyrosine (1/100, 4G10, mouse IgG2b) and Rac1 
(1/250, mouse IgG2b) were purchased from Upstate. 
Alexa-488 labelled donkey anti-goat or anti-mouse IgG (1/500, Molecular 
Probes), Cy3-coupled donkey anti-rabbit or anti-mouse IgG (1/1000, 
Jackson Immunoresearch) and Cy5-coupled donkey anti-rabbit or anti-
mouse (1/1000, Jackson Immunoresearch) were used as secondary 
antibodies. 
 
2.2. Antibodies for Western Blotting 
Anti-phosphorylated ERK (1/1000, rabbit IgG), anti-phosphorylated Met 
(Y1234-Y1235, 1/1000, rabbit IgG) and anti-PARP (1/1000, rabbit IgG) 
antibodies were purchased from Cell Signalling. Antibodies specific for 
Grb2 (1/1000, rabbit IgG), HSC-70 (1/2000, mouse IgG2a) and Met (B2, 
1/200, mouse IgG1) were bought from Santa Cruz Technologies. The 
antibody specific for the phosphorylated Y1349 of Met was generated by 
Drs Kermorgant & Parker in collaboration with the CR-UK Antibody 
Service from the London Research Institute, or purchased from Cell 
Signalling (1/1000, rabbit IgG). Mouse IgG1 specific for clathrin heavy 
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chain (CHC), and HSP90 were provided by BD and used at a dilution of 
1/1000. HSP 90 beta (1/1000, mouse IgG1) and ubiquitin (1/1000, FK2, 
mouse IgG1) were purchased from BIOMOL International. Finally, 
antibodies recognising HSP90 alpha (1/1000, mouse IgG1), Rac1 (1/1000, 
mouse IgG1), tubulin (1/2000, mouse IgG1) were purchased from Abcam, 
Cytoskeleton and Sigma respectively.  
HRP-coupled anti-mouse and anti-rabbit IgG secondary antibodies were 
purchased from Amersham and used at a dilution of 1/1000 except for 
detection of mouse anti-HSC-70 and tubulin where they were used at 
1/2000. 
 
2.3. Antibodies for Flow cytometry 
The following antibodies were used for flow cytometry analysis: anti-heavy 
chain of clathrin (1/100, mouse IgG1) was purchased from BD and anti-
mouse Met (1/50, goat IgG) from R&D. 
Alexa-488 labelled donkey anti-goat IgG (1/250, Molecular Probes), PE-
conjugated donkey anti-rat IgG (1/1250, Jackson Immunoresearch) and 
APC-coupled donkey anti-mouse IgG (1/250, Jackson Immunoresearch) 
were used as secondary reagents. 
 
2.4. Growth factors, inhibitors and drugs 
HGF was used at 50 ng/mL, unless otherwise specified. Alexa-546-
labelled Phalloidin and Cy3-coupled transferrin were used at a final 
dilution of 1/250 and 1/500 respectively, and were purchased from 
Molecular Probes. Cycloheximide (50 ug/mL) and dynasore (80 μM) were 
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bought from Sigma. Rac1 inhibitor (NSC23766, 100 μM) and SU-11274 (2 
μM) were purchased from Calbiochem. PHA-665752 (100 nM) and PF-
2341066 (200 nM) were kindly provided by Dr. Christensen (Pfizer, La 
Jolla). 
 
2.5. Plasmids 
The plasmid pEGFP-dynamin2-K44A was a gift from Prof. De Camilli 
(Yale University). The plasmids pEF-Grb2 myc, pEF-Grb2 89A myc (SH2 
mutant) and pEF-Grb2 49L/203R myc (SH3 double mutant) were given by 
Prof. Downward (Cancer Research UK, London Research Institute). The 
plasmid pcDNA-Ub-His was a gift from Dr. Basu (Institute of Cancer). 
 
2.6. RNAi, short hairpin RNA 
siRNA or shRNA were used to knock-down the expression of different 
targets as indicated in the table below. 
 
Target Type N° Sequence Supplier 
shRNA 1 
CCGGGCGAACATCAATAGATGCTTACTCG
AGTAAGCATCTATTGATGTTCGCTTTTTG 
Sigma 
1 CAACUUAGCUGGUGCUGAA 
CHC 
siRNA 
2 UAGAGGAGCUUAUCAACUA 
Dharmacon 
1 GGACGAAGCTTGATCTTAG 
2 AGACGGAGCTGTTGGTAAA 
Rac1 siRNA 
3 GATCGGTGCTGTCAAATAC 
Dharmacon 
(pool) 
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4 GCAAAGTGGTATCCTGAAG 
 
1 UGAAUGAGCUGGUAGAUUA 
Grb2 siRNA 
2 CAACAUCCGUGUCCAGGAA 
Dharmacon 
1 CAUCAACACUUUCUAUUCA 
2 GAAACAUUCGCAGUUCAUA 
3 UGACUGAGCCUAUUGACGA 
Hsp90? siRNA 
4 GAUAUGAGAGCCUGACGGA 
Dharmacon 
(si Genome 
Smart Pool) 
1 GAGCUUAACUAACGAUUGG 
2 GGAAUUAAUCCCUGAGUAU 
3 GAACCAAUGGGUCGUGGAA 
Hsp90? siRNA 
4 CAUCGGACGCUCUGGAUAA 
Dharmacon 
(si Genome 
Smart Pool) 
 
 
3. Cell Transfection  
NIH3T3 cells were transfected using a liposome-based strategy 
(LipofectamineTM 2000 combined with the Plus reagentTM, both from 
Invitrogen). However, when a high percentage of transfection was required 
(for functional assays) or when this approach was not suitable for the cells, 
the Amaxa? Nuclefector? technology was used. This electroporation-
based strategy was also used for siRNA transfections.  
 
3.1. Transfection using LipofectamineTM 2000 and Plus reagentTM 
NIH3T3 cells were plated in 24-well plates in order to reach 60 to 70% 
confluency by 24 h later; the time of transfection. For each transfection 
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sample, 0.4 μg of DNA was diluted with 25 μL of Opti-MEM? (Invitrogen) 
and 4 μL of PlusTM reagent to enhance transfection efficiency. This mix 
was incubated at room temperature for 15 min. In parallel, 1μL of 
Lipofectamine 2000TM was diluted in 25 μL of Opti-MEM?. The pre-
complexed DNA and diluted Lipofectamine 2000TM were then combined 
incubated for 15 min and added to the cells. 3 h later, the transfection 
mixture was removed and replaced with complete medium. 
 
3.3. Transfection with Amaxa? Nucleofector? technology 
Transfection of NIH3T3 cells with Amaxa? Nucleofector? technology was 
performed following the manufacturer’s instructions (Lonza). The kit and 
program of nucleofection used were “R” and “U30” respectively. Cells 
transfected with DNA were harvested the following day and cells 
transfected with siRNA were harvested 3 days later. 
When NIH3T3 cells were transfected with the pEGFP-dynamin2-K44A, the 
transfection efficiency obtained was low, less than 50% of the cells were 
expressing the dynamin2-K44A-GFP. Before using these cells for 
functional assays, a pure population of cells expressing the dynamin2-
K44A-GFP was required. Therefore, a sorting procedure was performed 
48h after nucleofection based on GFP expression on a high speed MoFlo 
cell sorter (Beckman Coulter, Fort Collins CO). Then the cells were plated, 
and used the following day for the Transwell chemotactic migration 
assays.  
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3.4. Lentiviral transduction 
To generate stable long-term gene silencing in NIH3T3 cells, the 
MISSIONTM TRC shRNA Lentiviral Particles kit from Sigma was used. As 
a selection through puromycin was required, a titration was performed to 
determine the minimum concentration of puromycin (here 2 μg/mL) that 
caused complete NIH3T3 cell death after 3-5 days. Then, 3000 cells were 
plated in each well of a flat-bottom 96-well plate, to ensure that they were 
no more than 70% confluent upon transduction. The following day, the 
medium was changed and lentiviral particles were added at a multiplicity of 
infection of 15. At day 3, the viral particles were removed and, one day 
later, the medium was replaced with fresh medium containing puromycin. 
Medium was replaced every 2 days until the positive identification of 
resistant cells. Western blot experiments were then performed to evaluate 
the knock-down efficiency.  
 
4. Western Blotting 
4.1. Cell lysis 
Cells were grown to 70% confluence and, after the required 
treatment/stimulation, washed with Phosphate Buffered Saline (PBS, CR-
UK Media Services) and incubated for 10 min with RIPA lysis buffer 
(Upstate) supplemented with 1 mM sodium orthovanadate  (Sigma), 1 mM 
sodium fluoride (Sigma) and with a 1/100 dilution of protease inhibitor 
cocktail (Calbiochem). Cells were harvested and centrifuged at 13000g for 
10 min at 4°C. The protein concentration of the supernatant was 
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determined using the Bio-Rad Dc Protein Assay Kit according to 
manufacturer’s instructions (Bio-Rad Laboratories). 
 
4.2. Western blot analysis 
For each sample, an equal amount of total cellular proteins (10-50 μg, 
depending on experiments) was diluted in sample buffer (Invitrogen) and 
resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Samples were loaded onto precast gels (4-12% Bis-Tris 
Gel, Invitrogen), under reducing conditions and run at 150 V for 90 min. 
After transfer of the proteins to Hybond nitrocellulose membranes 
(Schleider & Schuell), the non-specific binding sites were blocked with Tris 
Buffer Saline (TBS, CR-UK Media Services), 3% BSA, 0.1% Tween 
(Sigma) for 30 min, and incubated overnight at 4°C with the appropriate 
primary antibody, diluted in TBS, 3% BSA and 0.1% Tween. Blots were 
washed three times with TBS 0.1% Tween and incubated for an hour at 
room temperature with appropriate HRP-conjugated secondary antibody. 
Membranes were then washed three times with TBS 0.1% Tween and 
incubated with ECL reagents (Amersham Biosciences) for 1 min. 
Chemiluminescence was detected by exposure to chemiluminescence film 
(Amersham Biosciences). Quantifications were done by densitometry 
analysis.  
 
4.3. Densitometry 
Densitometry was performed using Image J software. Band densities were 
normalised to HSC-70 and/or tubulin levels (detected on the same 
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membrane), to obtain a semi-quantitative measurements of the total 
amount of protein, or were normalised to total protein levels for semi-
quantitative measurement of protein phosphorylation status. 
 
5. Immunoprecipitation 
5.1. Standard protocol 
2.5 x 106 cells were plated on 15 cm plates. The next day, cells were lysed 
with 900 μL of lysis buffer (25mM HEPES at pH=7.4, 100 mM NaCl, 5 mM 
MgCl2, 1 mM EGTA, 10% glycerol, 1.25% CHAPS) (Sigma), protease 
inhibitor cocktail I and phosphatase inhibitor cocktail II (Calbiochem). 
Lysates were then centrifuged at 12000g for 10 min, and the soluble 
fraction subjected to immunoprecipitation with 5 μg of appropriate antibody 
and 70 μL of agarose-coupled anti-mouse or anti-rabbit IgG antibodies 
(Invitrogen). After overnight incubation at 4°C, beads were washed 3 times 
with lysis buffer. The bound fraction was then solubilised in 30 μL of 
sample buffer (4X). For each experiment, immunoprecipitations with beads 
only and an isotype-matched control IgG were performed as negative 
controls.  
Both (co-)immunoprecipitated protein/s and a fraction of the total lysate 
were subjected to SDS-PAGE and Western-blot analysis. 
 
5.2. Protein A Sepharose-antibody coupling 
The IgG heavy and light chains of antibodies used for immunoprecipitation 
protocols could be detected in Western blot assay and correspond to 2 
bands with a size of 50 and 25 kDa respectively. The protein Grb2 has a 
 92 
size of 24 kDa, the same as the IgG light chain. Thus its detection in 
Western blot after (co-)immunoprecipitation is impossible as it will be 
confounded with the IgG light chain. To resolve this issue, anti-Grb2 and 
anti-Met (B2) antibodies were then covalently coupled to Protein-A 
Sepharose? (Invitrogen).  
The concentration of salts from the coupling/washing buffer was adapted 
to the isotype of the antibody. For rabbit IgG and mouse IgG2a, 0.2 M 
sodium borate (pH 9.0) was used while mouse IgG1 required a buffer with 
a higher concentration of salts: 3 M NaCl, 50 mM sodium borate, pH 9.0. 
Protein-A Sepharose? beads were washed with the appropriate buffer and 
incubated for 1 h at room temperature with the required antibody at a final 
concentration of 1 μg per μL of beads (10 μg of antibody were used for 
each immunoprecipitation). The beads were then washed 4 times and 
finally were resuspended in the appropriate buffer containing 20 mM of 
cross-linker (dimethylpimelimidate (DMP)). After 30 min of incubation on a 
rotator at room temperature, the reaction was stopped by washing the 
beads twice with 0.2 M ethanolamine (pH 8.0). To remove any antibody 
that was non-covalently bound, DMP-coupled protein-A Sepharose? beads 
were washed with 0.1M glycine (pH 3.0). Eventually the beads were 
washed twice and stored at 4°C in a required volume of PBS                    
(20 μL = 10 μg of antibody). 
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6. Ubiquitination assay 
The level of Met ubiquitination was quantified by 2 different methods. 
 
6.1. Boiling SDS-lysis method 
This technique was performed as described266.  2.5 x 106 cells were plated 
on 15 cm plates. The next day, cells were lysed in boiling lysis buffer (2% 
SDS, 1 mM EDTA, 50 mM NaF, protease and phosphatase inhibitor 
cocktail preheated at 110°C). The lysates were incubated for 10 min at 
110°C before being cooled down and diluted 4 times in dilution buffer 
(2.5% Triton X-100, 12.5 mM Tris pH 7.5, 187.5 mM NaCl, protease and 
phosphatase inhibitor cocktails). The lysates were then subjected to Met 
immunoprecipitation. Western blots for Met and ubiquitin were performed 
on the immunoprecipitates and on a fraction of the total lysates. 
 
6.2 Nickel-NTA-agarose purification 
This method was performed as described267. 106 cells were transfected 
with a construct encoding a His-tagged form of ubiquitin using the Amaxa? 
Nucleofector? technology. The level of transfection was checked the next 
day by immunofluorescence with an anti-His antibody prior to performing 
the assay. Transfected cells were lysed in denaturating lysis buffer (6 M 
guanidinium-HCl / 0.1 M Na2HPO4 / NaH2PO4, pH 8 / 10 mM imidazole). 
The lysates were sonicated 2 times for 15 seconds, then mixed with 50 μL 
of Nickel-NTA-Agarose (Qiagen) for 3 h at room temperature. The beads 
were washed twice in lysis buffer then twice in lysis buffer diluted with the 
following dilution buffer, 25 mM with Tris-HCl (pH 6.8)/ 20 mM imidazole 
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and finally twice only with the dilution buffer. Purified proteins were eluted 
by boiling the beads in SDS-PAGE sample buffer (4X). Western blots for 
Met and ubiquitin were performed on the His-ubiquitin purified complex 
and on a fraction of total lysates. To have a better separation between the 
different forms of ubiquitinated Met, samples were loaded onto precast 
gels, 3-8% Tris-Acetate Gels (Invitrogen), that provide better separation 
than 4-12% Bis-Tris gels, of large molecular weight proteins.  
 
7. Immunofluorescence 
Cells were plated in 24-well plates (3.105 per well) onto acetic acid 
washed and poly-L-Lysine coated glass coverslips (0.01%, Sigma) or onto 
Poly-L-Lysine precoated coverslips from BD (BD BioCoat™ Poly-L-
Lysine). After appropriate treatments, cells were fixed for 10 min in PBS 
containing 4% paraformaldehyde (Sigma) and washed once in PBS before 
treatment with 50mM ammonium chloride. Cells were then blocked and 
permeabilised in PBS containing 3% bovine serum albumin (BSA, Sigma) 
and 0.1% Triton X-100 (Sigma), and incubated with indicated primary 
antibodies diluted in PBS containing 3% BSA for 30 min. After 3 washes in 
PBS, cells were incubated for 30 min with the secondary antibody in PBS 
with 3% BSA, then washed twice in PBS and once in distilled water and 
mounted with DAPI antifade medium (Invitrogen).  
When the anti-PIP3 antibody was used, PBS was replaced by TBS and 
the permeabilisation step was done with 0.5% saponin (Sigma). 
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7.1. Confocal microscopy analysis 
Confocal microscopy was performed using a confocal laser-scanning 
microscope (LSM510, Carl Zeiss Inc.) equipped with a 63x/1.4 Plan-
Apochromat oil immersion objective. Alexa-488 was excited with the 488-
nm line of an argon laser, Cy3, Alexa-546 and Alexa-555 were excited 
with a 543-nm HeNe laser and Cy5 was excited with a 633-nm HeNe 
laser. Each image represents a single section of 0.7 μm of thickness. 
Scale bar: 10 μM. 
 
7.2. Transferrin uptake 
Cells were incubated for 20 min with Cy3-coupled Transferrin (20 ?g/mL, 
Molecular Probes) in complete medium. 
 
7.3. Labelling of HGF with Alexa-555 
25 μg HGF were labelled using Alexa Fluor® 555 Microscale Protein 
Labelling Kit according to the manufacturer’s instructions (Molecular 
Probes). 
 
7.4. HGF-Alexa-555 uptake 
Cells were incubated for the indicated time with HGF-Alexa-555             
(50 ng/mL) in complete medium.  
 
7.5. Colocalisation measurements and statistical analysis 
Picture fields were chosen randomly based on DAPI staining.  Colocalisations 
were determined using the colocalisation platform from the MetaMorph 
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software and were expressed as percentage of Met or HGF within the indicated 
compartments. Seven pictures for each cell type were taken per experiment. 
The counting of cells with disorganised actin, or Rac1 at sites of membrane 
protrusion, were performed on at least 100 cells in each experiment. 
Data sets from 3 independent experiments were analysed for significance using 
Student’s t test. p< 0.05 was considered statistically significant. 
 
8. Biochemical quantification of Met distribution  
Biotinylation surface removal  
A modified version of the method described by Gampel et al.268 was 
established to measure the relative proportion of Met at the cell surface 
and in intracellular pools. All steps were performed at 4°C to prevent the 
occurrence of any trafficking events. Cells were washed twice in ice-cold 
PBS and incubated for 10 min with rocking with PBS containing 
0.15mg/mL NHS-SS-biotin (Pierce), a water-soluble membrane-
impermeant biotinylation reagent. The excess of reagent was quenched by 
washing once with a specific buffer (25 mM Tris, pH8; 137 mM NaCl; 5 
mM KCl; 2.3 mM CaCl2; 0.5 mM MgCl2; and 1 mM Na2HPO4) and three 
times with ice-cold PBS. Cells were then solubilised in RIPA lysis buffer 
(Upstate) and the lysates were centrifuged at 13000 g for 10 min. A 
fraction of the supernatant, corresponding to the total amount of Met in the 
cell, was collected. Streptavidin-agarose beads (Upstate) were added to 
the remaining supernatant (100 ?L packed beads per 500 ?L lysate) and 
left to tumble on a rotating wheel at 4°C for two hours. Beads were 
collected by centrifugation (7000 g, 1 min) and supernatant was collected; 
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this fraction constitutes the internal pool of Met. The beads were then 
washed 3 times in ice-cold lysis buffer and proteins were extracted from 
the beads by heating at 95°C with SDS-PAGE sample buffer (Invitrogen); 
this represents the surface pool of Met. Equivalent volumes were resolved 
by SDS-PAGE and analysed by Western blotting with an anti-Met 
antibody. 
 
9. Met internalisation and recycling assay 
9.1. Biochemical quantification of Met internalisation: Biotinylation 
internalisation assay 
To measure Met internalisation, cells were transferred on ice and washed 
twice with ice-cold PBS. The cell surface was labelled at 4°C with 0.2 
mg/mL NHS-SS-biotin in PBS for 45 min. Labelled cells were then washed 
twice in ice-cold PBS and transferred immediately in prewarmed (37°C) 
cell culture medium, with or without HGF (50 ng/mL), to allow 
internalisation. At indicated time-points, the medium was aspirated off and 
the dishes were rapidly transferred on ice and washed twice with ice-cold 
PBS. Biotin was removed from proteins remaining at the cell surface by 
reduction with Sodium 2-mercaptoethanesulphonate (MesNa, Pierce). 
Briefly, a solution of 180 mM of MesNa in 50 mM Tris, 100 mM NaCl was 
adjusted to pH 8.6 and added to the cells. Reduction was allowed to 
proceed for 15 min on ice at 4°C with gentle rocking. MesNa was 
quenched by addition of 180mM Iodoacetamide (IAA, Sigma) for 10 min. 
Cells were then lysed and scraped. Lysates were passed 3 times through 
a 27-gauge needle and clarified by centrifugation (13000 g, 10 min). The 
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following steps are similar to those described in the previous biochemical 
quantification. Streptavidin-agarose beads (Upstate), diluted in lysis buffer, 
were added to the pellet and left to tumble on a rotating wheel at 4°C for 
two hours. Beads were then collected by centrifugation (7000g, 1min, 
4°C), washed 3 times in lysis buffer at 4°C, dissociated from the proteins 
by heating at 95°C in SDS-PAGE sample buffer and analysed by Western 
blotting with an anti Met antibody. Densitometries were carried out.  
In each internalisation, or recycling, assay, two controls were performed: i) 
to measure the total amount of Met at the cell surface, biotinylated cells 
were lysed without biotin reduction; ii) to verify the efficiency of biotin 
removal from the cell surface, biotin reduction and MesNa quenching were 
performed on cells that remained on ice (time 0) throughout the 
experiment to avoid any internalisation.  
The percentage of internalised Met was calculated as follow:  
Internalised Met = [(Met level after incubation at 37°C) – (Met level at time 
0)] / (total surface Met) x 100. 
 
9.2. Biotinylation recycling assay 
To measure the proportion of internalised Met (see 9.1) that recycles back, 
the biotin present at the cell surface after the first incubation at 37°C was 
removed by reduction with MesNa (see above), and the internalised 
fraction was chased from the cells by placing them a second time at 37°C 
for 15 min. Cells were then returned to ice and biotin was removed from 
recycled proteins by a second step of reduction. Unreacted MesNa was 
quenched with IAA for 10 min and cells were lysed and processed as for 
 99 
measurements of receptor internalisation.  
Equivalent volumes were analysed in a Met Western blot and 
densitometries performed. The percentage of recycled Met was calculated 
from the following formula: recycled receptor = 100 – [(Met level after 15 
min of re-incubation at 37°C) – (Met level at time 0) / (Met level after first 
incubation at 37°C) – (Met level at time 0) x 100]. 
 
10. Biochemical quantification of Met degradation 
10.1. Total Met degradation 
Cells were pre-treated with cycloheximide (50 ?g/mL, Sigma) for 10 min 
before HGF stimulation in order to block protein synthesis, thus allowing 
me to follow the degradation of the mature Met form only. After stimulation 
with HGF for the indicated time point, the cells were washed in PBS and 
lysed. Protein concentrations were measured (Bio-Rad Protein Assay) and 
equivalent quantities of protein were resolved by SDS-PAGE and 
analysed by Western blotting with an anti Met antibody and with an anti 
HSC-70.   
 
10.2. Biotinylation degradation assay 
Cells were washed in PBS and incubated with 0.2 mg/mL biotin in PBS for 
45 min with rocking. Labelled cells were washed twice in ice-cold PBS and 
transferred immediately to prewarmed cell culture medium at 37°C, with or 
without HGF (50ng/mL) to allow internalisation. At indicated time-points, 
the medium was aspirated off and the dishes were rapidly transferred onto 
ice and washed with ice-cold PBS. Cells were lysed and scraped. Lysates 
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were passed 3 times through a 27-gauge needle and clarified by 
centrifugation at 13000 g for 10 min. Protein concentrations were 
measured, equivalent quantities of protein were resolved by SDS-PAGE 
and analysed by Western blotting with an anti Met antibody. 
 
11. Rac1 activation assay 
Levels of Rac1-GTP (activated Rac1) were measured using the Rac1 
activation assay Biochem KitTM (Cytoskeleton). This assay is based on the 
fact that many Rho family effectors, such as PAK (p21 activated kinase), 
have a specific region that interacts specifically with activated Rac1 (or 
Cdc42); so interacting specifically with Rac1 bound to GTP. The region of 
PAK is called CRIB (Cdc42/Rac Interactive Binding region) or PBD (p21 
Binding Domain). Thanks to this feature and to its fusion with GST, the 
PAK-PBD protein supplied in the kit allows the pull-down of Rac1-GTP (or 
Cdc42-GTP) with glutathione affinity beads. 
2.5x106 cells were plated in 15cm plates. The following day, culture dishes 
were washed once with ice-cold PBS and cells were lysed with 1mL of 
lysis buffer supplemented with protease inhibitors (both provided in the 
kit). From now, all the steps were performed at 4°C. The lysate was 
clarified by centrifugation, a small fraction being kept for total protein and 
total Rac1 quantification. The remaining lysate was snap frozen in liquid 
nitrogen. 500 μg of total proteins were then mixed with 20 μg of PAK-PBD 
beads and incubated on a rotator for 1 h at 4°C. After centrifugation, the 
PAK-PBD beads were washed once with a buffer provided in the kit and 
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the pellet resuspended in 20 μL of sample buffer (4X). The quantity of 
activated Rac1 was analysed by Western blotting with anti-Rac1 antibody.  
In each assay, two controls were performed: i) a positive control of the 
pull-down in which a saturating amount of GTP?S was added to the cell 
lysate. This GTP?S, which is non-hydrolysable, interacts with Rac1, thus 
allowing GTP-bound Rac1 pull-down with the PAK-PBD beads. ii) a 
negative control in which GDP will be added to the cell lysate that will be 
loaded with Rac1 leading to no Rac1 pull-down. 
 
12. Cell morphology assay 
Cells were seeded in 6-well plates in complete medium and grown for 24 
hours in order to reach 60% confluence. Then, cells were treated with 
DMSO or 0.2 μM of PF-2341066, or 0.1μM of PHA-665752, or 2 μM of 
SU-11274. After 16 hours of incubation, changes in morphology were 
observed by microscopy and random pictures were taken. 
 
13. Transwell chemotactic migration assay 
24 hours before the assay, NIH3T3 cells were serum deprived with E4 
supplemented with 1% DCS. 
The underside of the Transwell (Corning, 8 ?m pore size) was coated with 
fibronectin (Sigma) for 30 min at room temperature. The excess of 
fibronectin was removed and the inserts left for 1 hour to dry. Cells were 
then split, washed in serum free medium and resuspended in serum free 
medium supplemented with 0.1% BSA. The concentration was adjusted to 
105 cells per mL, and 200 ?L of this suspension (2x104 cells) was 
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disposed into the upper part of the well in the presence of indicated drugs 
or DMSO. To create a gradient of chemoattractants, the lower part of the 
well was filled in with 600 ?L of cell culture medium (E4 + 10% DSC). 
After 90 min of culture (37°C, 8% CO2), the medium was removed and the 
cells that did not go through the membrane were removed using a cotton 
bud. The inserts were fixed in 4% paraformaldehyde for 10 min and 
washed in PBS. Cell nuclei were then stained with Haematoxylin (Sigma) 
for 5 min. The membranes were cut and mounted with aqueous medium 
(Aquatex, VWR). 
To quantify the number of cells that migrated (i.e. the cells present on the 
underside of the membrane at the end of the assay), 10 fields per porous 
membrane were chosen randomly and counted (x20 lens, Zeiss Axiophot 
microscope). When at least 3 independent experiments were done, data 
sets were analysed for significance using Student’s t test. 
 
14. Survival assay (protection against anoïkis) 
Cells were grown up to 70% confluence, washed with PBS and 
trypsinised. They were then washed in serum free medium and counted. 
5x105 cells were resuspended in 1 mL of serum free medium, in the 
presence of drugs or DMSO, and incubated in a 15mL tube 
(Polypropylene, Falcon) at 37°C. After 24 h, 400 μL of cell suspension was 
taken and half of it was analysed by flow cytometry (FACSCALIBUR, BD) 
after staining with a live/dead discriminator reagent (Propidium Iodide (PI) 
or TOPRO?-3 (Invitrogen). The percentage of dead cells was determined 
by numbering those which had lost plasma membrane integrity and could 
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incorporate PI or TOPRO?-3. The other half of the cell suspension, was 
centrifuged, the cells were lysed and analysed by Western blotting with 
indicated antibodies. Data sets from 3 independent experiments were 
analysed for significance using Student’s t test. 
 
15. Soft Agar Assay 
500 cells in single cell suspension were mixed, on ice, in 5mL of medium 
with 0.3% agarose. After 20 min, 1 mL of medium with 10% serum was 
added and cells incubated at 37°C. Medium was changed every other day. 
Treatment started at day 5, with medium plus DMSO or dynasore (80 μM) 
changed daily. At day 9, the whole wells were pictured on a Zeiss, Stemi 
SV11 microscope and the total number of colonies counted. The total area 
of the colonies was determined with Image J software. 
 
16. In vivo tumorigenicity assays 
4-6 week-old-female athymic nude mice (CD1 Nu/Nu, Charles River UK) 
were used, in accord with United Kingdom Coordination Committee on 
Cancer Research guidelines and Home Office regulations.  
 
16.1. Tumour growth assay 
For the tumour growth assay, 5 x 105 cells were inoculated 
subcutaneously in the flank region of nude mice. The tumours were 
measured (width and length) with a caliper. Tumour volumes were 
calculated by using the formula:  length x width2 x (?/6). In some 
experiments, the entire skin surface over the tumours (when they reached 
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a volume of around 50 mm3) or where cells have been injected, was 
painted everyday with indicated reagents. When tumours reached the 
critical size of 1 cm in length in any directions, mice were killed humanely 
and tumours were resected, snap-frozed or fixed in formal saline. Protein 
lysates were generated from frozen samples and analysed by Western 
blotting. Fixed samples were paraffin embedded. Sections of 4 μM were 
processed for immunofluorescence.  
 
16.2. Lung colonisation assay 
For the experimental “metastasis” assay, cells expressing the indicated 
Met protein were resuspended in PBS at 5x106 /mL and 100 μL (5x105 
cells) were injected into the tail vein of the mice. 10 days later mice were 
killed and the lungs were removed, weighed and fixed in formal saline. 
The same area of each lung was cut and paraffin embedded. Sections of   
4 μM were processed and haematoxylin/eosin staining was performed 
before analysis on a Zeiss Axiophot microscope.  
 
17. Statistical analysis 
Two-tailed Student’s t test was performed, unpaired between the different 
cells, paired between different conditions for a given cell. Quantitative data 
of the indicated number of independent experiments are expressed as 
means ± SEM.  
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RESULTS - PART I  
 
 
Small Molecule Inhibitors Differentially Affect Distinct 
Oncogenic Met Mutants  
 
 
Since Wt and oncogenic forms of Met have been shown to play an 
important role in tumour progression and metastastic spread of many 
cancers15, a number of pharmaceutical companies have engineered small-
molecule inhibitors that target this receptor. Although these drugs have 
been reported to be specific for Met, a major question mark remains 
concerning their relative efficiencies against various tumorigenic forms of 
the receptor. Different mutations potentially can impact in different ways 
on the conformation, expression, stability, level of activation or subcellular 
localisation of a receptor, rendering each mutant differentially sensitive to 
a given drug. Therefore, results obtained with a particular molecule on a 
certain mutant would not necessarily predict results likely to be obtained 
on other mutants. Thus it seems important to me that each drug/mutant 
combination should be tested independently. Such an approach could 
allow the optimisation of anti-cancer therapies by matching a given 
mutation to what is likely to be its most efficient treatment.  
Here, I have studied and compared the sensitivity of two Met mutants, 
D1246N and M1268T, previously identified in human papillary renal 
carcinoma, to three pharmacological inhibitors, SU-11274, PHA-665752 
and PF-2341066, the latest of which currently is being tested in several 
Phase I clinical trials.  
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1. D1246N and M1268T Met mutants are highly phosphorylated and 
highly tumorigenic 
I used NIH3T3 cells (expressing very low levels of endogenous Met) stably 
transfected with Wt Met or with a specific mutant containing one of the 
following amino-acid changes: D1246N, M1268T or Y1248C. Mutants 
M1268T and Y1248C were expressed at levels comparable to the Wt 
while D1246N expression was elevated slightly (1.6 fold) (Fig. 1A). In the 
absence of exogenous HGF, tyrosines 1234-1235 in the kinase domain, 
and 1349 in the docking site, were highly phosphorylated in the D1246N 
and M1268T Met mutants relative to the Wt. These results were consistent 
with what was previously detected for total Met phosphorylation by co-
immunoprecipitation studies156, where D1246N and M1268T mutants had 
been shown to be the more highly phosphorylated156. The phosphorylation 
of the Y1248C Met mutant was also increased in relation to the Wt Met but 
not significantly. Normalisation on Met expression clearly excluded that 
these results were due to higher expression levels (Fig. 1B and 1D). The 
NIH3T3 fibroblasts used produce low amounts of HGF156 so that, under 
basal conditions, the three mutants clearly were phosphorylated 
spontaneously to a greater degree than Wt Met. Exogenous HGF 
significantly enhanced phosphorylation both of the Wt and of the mutants 
(Fig. 1B-D).  
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Fig.1. D1246N and M1268T Met mutants are highly phosphorylated 
and highly tumorigenic 
(A) Western blots for Met, phosphorylated Met (Y1234-35 and Y1349) and 
HSC-70 were performed on cells expressing Wt, D1246N, M1268T or 
Y1248C Met forms. Numbers represent fold increase of Met p-145 / HSC-
70 ratios (between mutants and the Wt) obtained from six independent 
experiments.  
(B) The graph shows phosphorylated Met-Y1349 / Met ratios identified by 
densitometries from Western blots (not shown) in the indicated cells non 
stimulated (no HGF) or stimulated with HGF (HGF) for 15 min. Data are 
represented in arbitrary units (from three independent experiments).  
#,*p<0.05, ## p<0.01. 
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Fig.1. D1246N and M1268T Met mutants are highly phosphorylated 
and highly tumorigenic 
(C) Western blots for Met and phosphorylated Met (Y1234-35) were 
performed on cells expressing Wt and M1268T Met forms. Cells were 
stimulated, or not, with HGF at 5, 50 and 200 ng/mL for 5, 10 and 20 min. 
(D) The graph represents phosphorylated Met-Y1234-35/Met ratios 
quantified by densitometries from Western blots (not shown) in the 
indicated cells non stimulated (no HGF) stimulated with HGF (50 ng/mL). 
Data are represented in arbitrary units (from three independent 
experiments).  
#,*p<0.05. 
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Fig.1. D1246N and M1268T Met mutants are highly phosphorylated 
and highly tumorigenic 
(E) Wt, D1246N, M1268T and Y1248C Met expressing cells (500,000 / 
100?l) were injected subcutaneously into nude mice (five per group). The 
graph plots tumour volumes (width2 x length x (? /6) against time post-
injection.  
(F) Western blots of lysates from resected tumour tissues for 
phosphorylated Met (Y1234-35 and Y1349), Met and HSC-70. 
(G) NIH3T3 cells, Wt and M1268T Met expressing cells were injected 
subcutaneously into nude mice (five per group). The graph plots tumour 
volumes (width2 x length x (? /6) against time post-injection.  
I acknowledge Prof. Ian Hart for injecting the cells and for training me for 
all the in vivo experiments.  
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To analyse the functional consequences of the hyperactivated status of 
the mutants, I tested their tumorigenicity in vivo by grafting each cell type 
subcutaneously into nude mice. While M1268T and D1246N Met mutants 
formed palpable tumours one week post-graft, Wt and Y1248C Met 
expressing cells generated detectable tumours around 17 days post-graft 
(Fig. 1E). Non-transfected NIH3T3 cells developed tumours at a rate 
similar to that of Wt and Y1248C expressing cells (Fig. 1G). All animals 
were killed when tumours reached a volume of 400-500 mm3 (days 10-15 
for MT1268T and D1246N; day 22 for Y1248C and Wt). D1246N and 
M1268T mutants remained highly phosphorylated in tumour tissue (Fig. 
1F). Taken together, these results established a strong correlation 
between the level of Met phosphorylation and tumorigenic potential. 
 
2. The three Met inhibitors tested inhibit the basal activation of the 
M1268T mutant efficiently but have little or no effect on D1246N 
In agreement with the literature156, my data showed that the three studied 
Met mutants are highly phosphorylated, and therefore highly activated, 
under basal conditions. There were, however, some differences among 
the three mutants in the levels of phosphorylation. Thus M1268T and 
D1246N were the most phosphorylated while Y1248C was the least 
phosphorylated. Interestingly, we also observed that only the M1268T and 
D1246N mutants were highly tumorigenic in vivo. Cells expressing either 
of these two forms of the receptor therefore were considered to constitute 
an ideal model with which to study the transforming mechanisms of Met 
activity and to analyse the relative potency of several Met-specific 
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Tyrosine Kinase Inhibitors (TKI). We tested three different compounds: 
PHA-665752233, SU-11274231 and PF-2341066238; the latter being the only 
one among the three, to be administered per os. These three drugs act by 
blocking ATP-binding to the kinase domain of Met, thereby inhibiting, as a 
consequence, its catalytic activity.  
Previously the efficiency of these three drugs in inhibiting Met activation 
has been tested in different cellular models. SU-11274 exhibited less 
potency than the two other TKIs, PHA-665752 and PF-2341066. It 
required a minimum concentration of 2 μM of SU-11274 to inhibit Met 
phosphorylation in a Western blot experiment231,261 as compared with the 
0.1 μM and 0.01 μM concentrations for PHA-665752233,262 and PF-
2341066166,240 respectively. These previously reported data helped me, in 
my cell system, initially to establish the range of concentrations likely to be 
required to evaluate, in dose response assays, the potency of these three 
different TKIs.  
First, consistent with the literature, I observed that PF-2341066 blocked 
the induced HGF Wt Met phosphorylation efficiently240. 
Second, in cells expressing the M1268T mutant, the basal level of 
phosphorylation of the tyrosines 1234-35 and 1349, located within the 
kinase domain and the docking site of the receptor respectively, was 
diminished strongly by all the TKIs tested (Fig. 2A-C). Among the three 
drugs, PHA-665752 and PF-2341066 seemed to be the more powerful, 
given that a concentration of 0.025 μM was shown to affect the 
phosphorylation of the receptor on these tyrosines significantly and that a 
concentration of 0.1-0.2 μM fully blocked their activity (p<0.01, p<0.001) 
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(Fig. 2A-B). In contrast, SU-11274 was at least 10 times less efficient as a 
significant degree of inhibition was only observed at concentrations equal 
to or greater than 1 μM (p<0.01) (Fig 2C).  
Third, SU-11274 and PHA-665752 had no impact on the phosphorylation 
status of the D1246N mutant, even at high concentrations (5 μM) (Fig. 2B-
C). PF-2341066 decreased phosphorylation levels at concentrations 
above 0.1μM. These reductions did not achieve significance levels. 
This dose/response assay thus allowed me to demonstrate that the 
M1268T Met mutant was highly sensitive to the drugs while the D1246N 
mutant appeared resistant or, at least, very poorly sensitive. Thanks to this 
approach I also determined, for the different inhibitors, the optimal 
concentrations to use in the rest of the study: these were determined to be 
0.1 μM, 2 μM and 0.2 μM for PHA-665752, SU-11274 and PF-2341066 
respectively.  
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Fig.2. The three Met inhibitors tested inhibit the basal activation of 
the M1268T mutant efficiently but have little or no effect on D1246N. 
(A) Western blots for Met, phosphorylated Met (Y1234-35), (Y1349) and 
tubulin were performed on Wt ± HGF (15 min, 50 ng/ml), D1246N and 
M1268T Met expressing cells treated with DMSO (-) or with increasing 
concentrations (0.025, 0.05, 0.1 and 0.2 μM) of PF-2341066 (PF). The 
graphs represent phosphorylated Met (Y1234-35) / tubulin ratios obtained 
by densitometric analysis from three independent experiments. 
*p<0.01, **p<0.01, ***p<0.001. 
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Fig.2. The three Met inhibitors tested inhibit the basal activation of 
the M1268T mutant efficiently but have little or no effect on D1246N. 
(B) Western blots for Met, phosphorylated Met (Y1234-35), (Y1349) and 
tubulin were performed on D1246N and M1268T Met expressing cells 
treated with DMSO (-) or with increasing concentrations (0.025, 0.01, 1, 2 
and 5 μM) with PHA-665752 (PHA). The graphs represent phosphorylated 
Met (Y1234-35) / tubulin ratios obtained by densitometric analysis from 
three independent experiments.  
*p<0.01, **p<0.01, ***p<0.001. 
 
 115 
 
 
 
Fig.2. The three Met inhibitors tested inhibit the basal activation of 
the M1268T mutant efficiently but have little or no effect on D1246N. 
(C) Western blots for Met, phosphorylated Met (Y1234-35), (Y1349) and 
tubulin were performed on D1246N and M1268T Met expressing cells 
treated with DMSO (-) or with increasing concentrations (0.025, 0.01, 1, 2 
and 5 μM) of SU-11274 (SU). The graphs represent phosphorylated Met 
(Y1234-35) / tubulin ratios obtained by densitometric analysis from three 
independent experiments.  
*p<0.01, **p<0.01, ***p<0.001. 
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3. The three Met inhibitors revert transformed morphology, migration 
and survival of cells expressing the M1268T Met mutant, but not the 
D1246N Met mutant 
Met mutants conferred upon the expressing cells a high transforming 
potential156,174 which translated into evident morphological changes. This 
observation was confirmed in our system. NIH3T3 cells expressing Wt Met 
were flattened, with tight interactions, while cells expressing D1246N or 
M1268T mutants were loosely adherent, rounded in shape and exhibited a 
less differentiated shape (Fig. 3A).  To further characterise the effect of 
the drugs on the different mutants, I next studied if exposure of the cells to 
Met-specific TKIs could affect this transformed morphology. After 16h of 
treatment, cells expressing the M1268T Met mutant reverted their 
phenotype and acquired a more flattened morphology, closer to that of the 
cells expressing Wt Met. In contrast, the shape of the cells expressing the 
D1246N Met mutant or the Wt form of the receptor appeared almost 
completely unchanged by these inhibitors (Fig. 3A). These results 
confirmed that the M1268T Met mutant was sensitive to the drugs 
whereas the D1246N mutant was resistant and, together with the data on 
the inhibition of the phosphorylation, suggested strongly that the 
transformed morphology of cells expressing the M1268T Met mutant was 
due to the constitutive activation of the receptor. 
It previously has been shown that expression of Met mutants in Madin-
Darby canine kidney cells strongly increased their motility174. To test the 
impact of the different mutants on the migratory properties of the NIH3T3 
cells, we set-up a Transwell migration assay. Cells, previously cultured in 
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1% serum, were plated in serum-free medium into the upper part of the 
well in the presence of the indicated drugs or the DMSO diluent as a 
control. To create a gradient of chemoattractants, the lower part of the well 
was filled in with cell culture medium containing 10% serum 
supplemented, or not, with HGF. After 2 h of incubation, only very few Wt 
Met expressing cells had migrated through the membrane under basal 
conditions. HGF significantly increased the number of cells found on the 
lower side of the membrane, demonstrating the ability of Met to promote 
cell migration (p<0.05). Moreover, cells expressing the M1268T or 
D1246N mutants had a significant higher migratory potential than the Wt 
cells (p<0.05) (Fig. 3B). As expected, when the cells were treated with the 
PHA-665752 or PF-2341066, the migration of the M1268T cells was 
inhibited significantly (p<0.05). Conversely, the migration of the cells 
expressing the D1246N mutant was not prevented significantly even 
though PF-2341066 at the same dose reduced D1246N phosphorylation 
slightly; a reduction that did not achieve significance (see Fig. 2A) (Fig. 
3C). These results confirmed that the high migratory potential of the 
M1268T expressing cells was due to Met activity and that the D1246N 
mutant was resistant to these drugs. Interestingly, PHA-665752 seemed a 
more potent inhibitor than PF-2341066 in this assay. Indeed, the 
percentage of inhibition of migration of the M1268T expressing cells 
obtained with PHA-665752 was greater (76%) than that achieved with PF-
2341066 (52%) (p<0.05). 
As an increase in survival capacity could be another factor in favour of cell 
transformation and resultant tumorigenesis, I next analysed whether these 
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cells also exhibited an advantage in terms of survival. I first tested this 
hypothesis by evaluating the capacity of cells expressing each of the Met 
forms to survive the phenomenon known as anoikis; i.e. the induction of 
apoptosis by loss of adherence to a substrate. Cells were cultured in 
serum free medium and were maintained in non-adherent conditions for a 
period of 16 h. Both of the cell lines expressing the Met mutants exhibited 
an increase in survival (from 22% to 33%) relative to survival of Wt Met 
cells (p<0.05) (Fig. 3D). This protection from anoikis could be due to a 
decreased apoptosis since the cleaved PARP enzyme (Poly(ADP-ribose) 
Polymerase), used as a marker of cells undergoing apoptosis, was 
detected in higher proportions in Wt Met than in D1246N and M1268T Met 
expressing cells (Fig. 3E). 
The Met inhibitor PHA-665752 dramatically reduced the increase in 
survival associated with the expression of the M1268T mutant by 85% 
(p<0.001), thus establishing a direct link between cell survival and Met 
activation. In contrast, PHA-665752 did not affect the survival potential of 
cells expressing the D1246N Met mutant, confirming the resistance of this 
mutant to these drugs. Moreover, correlating with the results already 
obtained and presented in Fig. 2, the level of phosphorylation of the 
M1268T Met mutant at the end of the survival assay was decreased 
considerably when cells were treated with PHA-665752 whereas this drug 
did not modify phosphorylation of the mutant D1246N (Fig. 3F).  
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Fig.3. The three Met inhibitors revert transformed morphology, 
migration and survival of cells expressing the M1268T Met mutant, 
but not the D1246N Met mutant  
(A) Wt, D1246N and M1268T Met expressing cells were treated overnight 
(16 h) with DMSO, or with one of the TKIs: 0.1 μM PHA-665752, 2 μM SU-
11274, 0.2 μM PF-2341066 and morphological changes were observed 
with an inverted microscope.  
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Fig.3. The three Met inhibitors revert transformed morphology, 
migration and survival of cells expressing the M1268T Met mutant, 
but not the D1246N Met mutant  
(B) The graph represents the average number of Wt, D1246N and 
M1268T Met expressing cells that have migrated through Transwells over 
2 hours of incubation with, as a chemoattractant, 10% serum (DCS) or 
HGF (50 ng/mL) from at least three independent experiments.  
(C) The graph represents the percentage of Wt, D1246N and M1268T Met 
expressing cells that have migrated through Transwells (serum gradient) 
when treated with DMSO or 0.1 μM PHA-665752, or 0.2 μM PF-2341066 
from three independent experiments.  
*p<0.01, **p<0.001. 
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Fig.3. The three Met inhibitors revert transformed morphology, 
migration and survival of cells expressing the M1268T Met mutant, 
but not the D1246N Met mutant 
(D) Wt, D1246N and M1268T Met expressing cells were incubated in 
suspension for 16 hours in serum-free medium supplemented with DMSO 
or with 0.1μM PHA-665752. Cells were stained with Propidium Iodide. The 
graph represents the % of increase in survival of mutant expressing cells 
versus Wt expressing cells in control condition (DMSO) or PHA-665752 
treatment from three independent experiments. 
(E-F) Cell aliquots from experiments (D) were lysed and analysed by 
Western blotting, with anti-cleaved PARP and an anti-tubulin (E) or with an 
anti-phosphorylated-Met (Y1234-35) and an anti-Met (F).  
*p<0.01, **p<0.001. 
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4. Topical application of PHA-665752 and PF-2341066 inhibited tumour  
growth of cells expressing the M1268T Met mutant, but not the 
D1246N Met mutant 
Inhibiting the activity of the M1268T mutant cells with Met-specific TKIs 
decreased cell migration and survival but had no effect on the D1246N 
mutant. The next question I chose to address was then to investigate the 
influence of the TKIs on in vivo tumour growth driven by these mutants. 
Cells expressing the Wt, or one of the two mutated forms of Met were 
grafted subcutaneously into nude mice (as described in Fig. 1E). When 
the volume of the tumours reached a size comprised of between 30 and 
50mm3, daily treatment with the indicated drug was initiated. PHA-665752 
was not water-soluble and, as a consequence, could not be administered 
orally. Treatment by daily injection of the drug into the tail vein233 or into 
the tumour236 had been reported previously where the treatment had some 
success against tumour growth. However, I was concerned that daily 
injection of DMSO, the solvent used, might be harmful so I thought about 
another approach. As DMSO increases the penetration of substances 
through the skin, and as PHA-665752 is DMSO-soluble, I decided to apply 
a solution of these TKIs by painting them daily over the skin surface above 
the growing tumours.  
The skin remained healthy after several days of treatment, showing that 
the DMSO by itself was not irritant or toxic. Strikingly, from day 5 post-
graft, the topical application of PHA-665752 rapidly induced a slow down 
in tumour growth in those grafts derived from M1268T mutant expressing 
cells. This led at the end of the assay, to a reduction of tumour size by 
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60% versus the size of the control DMSO treated tumours (p<0.05) (Fig. 
4A). Conversely, no significant change in tumour size was observed in 
similarly treated mice grafted with Wt Met expressing cells; again 
demonstrating that the growth of these tumours was not dependent on Met 
activity. Interestingly, and consistent with our in vitro data, PHA-665752 
had no effect on tumours derived from implanted D1246N Met mutant-
expressing cells (Fig. 4A). 
A comparable set of data was obtained when PF-2341066, also soluble in 
DMSO, was applied topically. Indeed this drug inhibited the growth of the 
M1268T tumour but had no effect on tumours derived from Wt Met or 
D1246N Met mutant-expressing cells. As observed in the migration assay, 
PF-2341066 also appeared to be somewhat less effective than PHA-
665752 in this model (Fig. 4B). While PHA-665752 slowed down tumour 
development after its first application PF-2341066 seemed to require 
several days of treatment to have a significant effect. Moreover, the 
percentage of tumour growth inhibition at the end of the experiment was 
slightly greater with PHA-665752 (62%) than it was with PF-2341066 
(57%) although this difference was not significant. 
This method of application appeared to have worked because the TKIs 
could penetrate into the tumours where they inhibited Met M1268T 
activation, and as a consequence slowed down the tumour expansion.  
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Fig.4. Topical application of PHA-665752 and PF-2341066 inhibited 
tumour growth of cells expressing the M1268T Met mutant, but not 
the D1246N Met mutant 
(A) Wt, D1246N and M1268T Met expressing cells were injected 
subcutaneously into nude mice. The graph plots tumour volumes against 
time post-injection. When tumours had reached 30-50 mm3, DMSO or 
PHA-665752 (0.1 μM) was applied topically over the surface of the tumour 
mass each day (from two independent experiments, except for experiment 
with Wt cells done one time).  
*p<0.05, **p<0.01. 
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Fig.4. Topical application of PHA-665752 and PF-2341066 inhibited 
tumour growth of cells expressing the M1268T Met mutant, but not 
the D1246N Met mutant 
(B) D1246N and M1268T Met expressing cells were injected 
subcutaneously into nude mice. The graphs plot tumour volumes against 
time post-injection. When tumours had reached 30-50 mm3, DMSO or PF-
23410066 (0.2 μM) were applied topically over the surface of the tumour 
mass each day (5 mice per group).  
*p<0.05, **p<0.01. 
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5. Oral administration of PF-2341066 inhibited growth of M1268T Met 
mutant tumours but not of D1246N Met mutant expressing cells 
In the clinic such tumour painting might seem attractive but it would have 
to be restricted to some types of tumours, such as melanoma in which Met 
recently has been identified as a new therapeutic target234, with treatment 
restricted to those which are located superficially. These are not likely to 
be numerous. Therefore, the most practical way to administer a drug is 
likely to be per os. PF-2341066 is water-soluble and designed for this 
purpose. In order to test the efficiency of this drug using this classic route 
of administration, a tumour growth assay was conducted. Thus PF-
2341066 was given daily by oral gavage at a dose of 50 mg/kg; a dose 
reported to be efficient in several tumour models in which tumour growth 
was dependent on Met activation238. As expected, tumour cells expressing 
the D1246N Met mutant were resistant to PF-2341066 treatment whereas 
tumours derived from the M1268T expressing cells were highly sensitive 
(Fig. 5).  
 
Taken together, these data suggest that the three Met-specific TKIs tested 
in this study can inhibit Met mutant M1268T-dependent tumour growth. 
However the D1246N Met mutant was resistant to the treatment. These 
observations suggested that, although distinct activating mutations 
occurring in the kinase domain can lead to similar cell behaviour (here 
M1268T and D1246N both modify cell morphology, increase migration and 
survival similarly), such mutations confer upon the receptor different 
sensitivities to different drugs. My results underline the importance of 
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developing new “types” of Met-specific drugs, especially when resistance 
occurs.  
My data also reinforce the importance of screening patients for the specific 
mutations driving their cancers in order that the most efficient treatment 
can be used, rather than applying a general inhibitor to a range of 
mutations.  
Finally, I have demonstrated here that TKIs administered topically are able 
to penetrate through the skin and agents delivered in this fashion slowed 
down subcutaneous tumour growth efficiently.  
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Fig.5. Oral administration of PF-2341066 inhibited growth of M1268T 
Met mutant tumours but not of D1246N Met mutant expressing cells 
D1246N and M1268T Met expressing cells were injected subcutaneously 
into nude mice. The graph plots tumour volumes against time post-
injection. Mice bearing tumours of 30-50 mm3 received vehicle alone or 
PF-2341066 (50 mg/kg) administered daily by oral gavage (from two 
independent experiments).  
*p<0.05, **p<0.01. 
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DISCUSSION - PART I 
 
 
In the first part of the present study, I have reported that two Met forms, 
mutated in the kinase domain with both leading to high Met 
phosphorylation, constitute an ideal model with which to study Met-driven 
tumorigenesis. Our data confirm Met plays a role in cell transformation and 
tumorigenesis and underline the possibilities that the use of Met-specific 
TKIs may represent a valuable strategy for cancer therapy. However, I 
also have been able to show that one of the mutants is resistant to various 
TKIs used, emphasising the importance of developing new TKIs or new 
“types” of drugs that are Met specific. In addition, I have demonstrated that 
topical application is a novel and potentially advantageous way, of 
administering drug. This at least is true for preclinical studies and it may 
be that such a screening system could be a useful way of evaluating 
efficacy against a broad range of Met mutations. Finally then another 
interesting aspect of my work is that I have identified and characterised a 
Met-driven tumorigenesis model that could be used to test the efficiency of 
any drugs on any Met mutant. 
 
Activation of Met mutants 
I showed that, in absence of the ligand, the Met mutants D1246N and 
M1268T are highly activated as compared to Wt Met and that HGF 
enhances their activation. These results are in accordance with the 
literature156,174. Thanks to the recent availability of antibodies specifically 
recognising the different Met phosphorylated tyrosines, I was able to 
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dissect out the Met mutants’ phosphorylation status, more precisely than 
previously reported in different studies relying on Met immunoprecipitation 
and blotting with a pan anti-phosphotyrosine antibody. I notably showed 
that D1246N and M1268T Met mutants are both significantly more 
phosphorylated on tyrosines located within the kinase domain and the 
docking site than is Wt Met. The NIH3T3 cells used in my studies produce 
a low amount of HGF156, which suggests that the Met phosphorylations 
that I have detected are constitutive. Consistent with this, Jeffers et al 
previously excluded the existence of an autocrine activation loop using a 
chimeric Met receptor composed of the extra-cellular domain of the Nerve 
Growth Factor (NGF) fused to the mutated intracellular domain of Met. By 
expressing this chimera in NIH3T3 cells (which do not secrete any NGF), 
they showed that the cells were highly tumorigenic in vitro and in vivo, 
more than those expressing a chimera made with the intracellular domain 
from the Wt form of the receptor174. This demonstrated that the 
transforming potential of Met mutants is due to the intrinsic properties of 
the mutated receptors.  
 
No requirement for HGF binding for alteration of various cell 
functions 
Although it has been claimed that the transformation mediated by Met 
mutants is ligand-dependent190,269, most studies agree on there being a 
ligand independency for this characteristic156,174,191. We found in our model 
that, in the absence of exogenous HGF, cells expressing the Met mutants 
exhibited a transformed morphology, with a dedifferentiated shape, 
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exhibited a higher migratory capacity and had an enhanced survival 
potential compared with cells expressing Wt Met. Consistent with our data, 
the introduction of the M1268T and D1246N mutations in RON, another 
member of the Met subfamily, confers on the mutated receptor a 
transforming potential. Notably it became highly phosphorylated and highly 
tumorigenic in vitro in the absence of its ligand, the Macrophage 
Stimulating Protein (MSP), thus confirming that the ligand is not necessary 
for cell transformation270,271. An unresolved question is whether Met 
mutations alone can promote tumorigenesis in vivo in “HGF free” 
conditions. Our lab may investigate this in the future. Murine HGF cannot 
stimulate Human Met219,224,272. Thus, human cells expressing a Human 
Met (either Wt or mutated) could be grafted subcutaneously into 
immunoincompetent mice. In such a situation the murine HGF secreted by 
the tumoral environment would not be able to influence tumour 
development. We would then be able to determine the role played by 
activated Met mutants alone in tumorigenesis without the confounding 
influence of concurrent HGF stimulation. 
 
Different mutants, different TKIs, and the importance of 
characterising the sensitivity of each mutation: typing cancer 
patients to optimise therapies 
According to the literature, aberrant activation of Met, through activating 
mutations, can positively influence tumorigenesis. More generally, primary 
or secondary mutations in RTK frequently constitute a key event in cancer 
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progression and are one of the most important causes of failure in tumour 
responses to TKI237,248.  
 
Distinct Met mutations sensitivity to the same TKIs 
We have evaluated the sensitivity of two oncogenic Met mutations, 
D1246N and M1268T, to three specific Met inhibitors, PHA-665752, SU-
11274 and PF-2341066. These two mutations were first identified in 
PRC168 but the M1268T mutation was also detected in Head and Neck 
Squamous Cell Carcinomas176 and in Childhood Hepatocellular 
Carcinomas 175. We found that the M1268T Met mutant is sensitive to all 
three of the compounds tested. PF-2341066 was previously described as 
being efficient in inhibiting the activity of the M1268T Met mutant238. 
However, this conclusion was drawn based only on in vitro kinase assays 
on a recombinant or immunoprecipitated Met in a test tube and no data on 
the potency of PHA-665752 have been described. Moreover, I have 
established that the D1246N mutant is resistant to three of the TKIs that 
we tested and this had never been reported before. 
Interestingly, these mutations both are activating mutations located in the 
kinase domain of the receptor though their location within this region is 
different. While M1268T is located in the P+1 loop, the D1246N mutation 
affects the activation loop (A loop)186. This suggests that the efficiency of 
TKIs could depend on the location of the mutation within the kinase 
domain. This hypothesis is reinforced by a study demonstrating that 
distinct single-points mutations within the kinase domain lead to different 
conformational changes of the receptor167,186. Indeed, analyses of these 
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structures showed that the D1246N mutation contributes to the 
stabilisation of the active conformation of the enzyme while the M1268T 
mutation favours its active form by destabilising the inhibitory position of 
the A loop186. These structural modifications could affect differentially the 
accessibility of the drug to Met, thus explaining the difference in the 
sensitivity of the different mutants. In accord with this hypothesis, the three 
TKIs tested in our study, all of which are ATP-competitive molecules, 
should bind to Met in a similar manner. This similarity in mode of action 
could explain why none of them is efficient against the D1246N mutation 
and why all of them affect the M1268T mutant. Interestingly, the 
analogous D1246N mutation in the Kit receptor, D816Y/V, confers 
resistance to the TKI, imatinib252. This suggests that the same mutation at 
the corresponding-amino-acid position in other RTKs may predict TKI 
sensitivity or resistance. Had I had more time available I might have tested 
this possibility using a larger panel of cell lines. 
This variability, in terms of sensitivity to a given drug of the different Met 
mutants and the resistance to Met TKIs that could be encountered in 
tumours harbouring Met mutations, leads to at least three important 
conclusions. First, new compounds have to be developed to overcome the 
different mechanisms of resistance. Second, all the drugs should be tested 
systematically both in vitro and in vivo against all the different mutants 
identified in human cancer prior to entrance into any clinical trial. Third, 
patients should be screened before starting any treatment in order to 
match a certain mutation to its most effective inhibitor (when ever 
possible). This systematic approach would help to avoid sub-optimal 
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clinical trials in which patients are treated with a drug which is inefficient 
against the mutated receptors expressed by their autochthonous tumour 
cells.  
 
Drug dose efficiency 
Difference in sensitivity to TKIs between Wt and mutated Met  
I have tested, for the first time, the ability of both PHA-665752 and PF-
2341066 to inhibit in vivo tumorigenesis of cells expressing these two 
mutations. 
I showed that a dose of 50mg/kg of PF-2341066, administered per os, 
induced a significant reduction of 60% (P<0.05) in the size of tumours 
derived from M1268T-expressing cells as compared to diluent controls. In 
previous studies, this dose resulted in a total blockade of Met dependent 
tumour growth238, and 50% of inhibition was obtained with a dose of only 
12.5 mg/kg240. Models used in these studies were different from ours. 
They used cell systems in which Met is not mutated, for example the UM-
22B HNSCC cell line240 or cells with constitutively activated, although not 
mutated, Met. For instance, GTL-16 gastric carcinoma cells express 
constitutively activated Met as a consequence of Met amplification238. 
U87MG glioblastoma cells are also expressing the activated form since 
Met in these cells is activated via an autocrine secretion of HGF238.  
The origin of the discrepancy in the efficiency of the drugs between these 
different models is difficult to explain. It might simply be due to the fact that 
the mutated receptor is more difficult to inhibit than the activated Met, due 
to conformational changes for example. Nevertheless, these observations 
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highlight the importance of testing the potency of each TKI against all the 
different Met mutants, and determining the efficiency of these drugs in in 
vivo models and not only in in vitro assays. 
 
Balance between drug potency and drug selectivity 
In our in vivo experiment of topical application, where the two molecules 
were given via the same route and with the same solvation vehicle, PHA-
665752 seemed more potent in its activity than PF-2341066, even though 
the dose used for PF-2341066 was higher (0.2 μM versus 0.1 μM) and its 
published IC50, evaluated on Wt Met, smaller (4 nM versus 9 nM)233,239. 
Thus, although PF-2341006 was reported to be more Met specific than 
PHA-665752239, it seems less potent to inhibit M1268T Met mutant activity 
in our model.  
A similar observation has been made about PF-2341066 and PF-4217903 
in the literature 241; PF-4217903 is highly Met selective and is even more 
specific than PF-2341066. However, although these two compounds 
present the same potency against Wt Met, they display differences in their 
ability to inhibit the activity of diverse Met mutations. In fact, PF-4217903 
seems less potent and less able to hamper Met mutations as compared to 
the activity of PF-2341066.  
Together these results suggest that increasing the selectivity of the TKI 
might decrease its potency to inhibit activating mutations. If this is the 
case, then it may imply that a balance between selectivity and potency 
against mutations has to be taken into account for the generation of new 
TKIs241.  
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Met specific TKIs and angiogenesis   
We have demonstrated that the three TKIs tested abolish the constitutive 
phosphorylation of the M1268T Met mutant efficiently. This correlates with 
a decrease in cell survival, which probably accounts for most of the 
reduction in tumour growth observed in our in vivo model under TKI 
administration. However, a direct effect of the drugs on Met expressed by 
tumour cells does not exclude an indirect action on the local environment 
of the tumour, most notably the possibility that the inhibitors are working 
through an effect on angiogenesis.  
The HGF/Met axis promotes angiogenesis by modulating different 
processes. HGF can, for example, directly promote the migration and 
proliferation of endothelial cells147,273. HGF can also act indirectly, by 
promoting VEGF production by both endothelial and tumour cells274,275. 
The involvement of Met in the vascularisation process was reported also in 
different studies in which blocking Met activity with an HGF neutralising 
antibody220, decoy Met223 or specific inhibitors, such as PHA-665752 or 
PF-2341066, were found to inhibit angiogenesis166,236 predominately by 
affecting endothelial cell migration and tubulogenesis238. Moreover, in an 
in vivo matrigel xenograft tumour model, PHA-665752 and PF-2341066 
treatments resulted in a dramatic reduction in the number of intra-tumoral 
cells expressing CD31, a specific marker of endothelial cells. In this 
system, PHA-665752 treatment decreased the production of VEGF while 
increasing the production of the angiogenesis inhibitor              
Thrombospondin-1236.  
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All of these data, associated with the presence of an important network of 
blood vessels infiltrating the tumour in our model (data not shown) suggest 
that the anti-tumour effect of PHA-665752 and PF-2341066 could result, in 
part, from their action on angiogenesis. Should such an activity be a 
possible explanation for our in vivo results, we can at least exclude a 
major role for a direct inhibition of Met in endothelial cells. For example, if 
Met-dependent signalling in endothelial cells was necessary for tumour 
growth, the drug treatments used should also affect the growth of the 
tumour in mice grafted with the D1246N mutant-expressing cells. We 
obtained good inhibitions in vitro, where the tumour cells are cultured 
alone, suggesting that the prime activity was against these transformed 
cells.  
PHA-665752 and PF-2341066 nevertheless could block angiogenesis 
indirectly, by inhibiting Met-dependent VEGF production by tumour cells. It 
would be interesting to evaluate the contributions of angiogenesis in our 
tumour model and to determine if PHA-665752 or PF-2341066 treatments 
have an impact on the formation of new blood vessels by, for example, 
inhibiting the production of pro-angiogenic factors, or by enhancing the 
secretion of anti-angiogenic molecules. In line with the different ongoing 
clinical trials, it also would be of interest to compare the impact on tumour 
growth of blocking only Met or of neutralising both Met and the VEGFR. 
XL880, a new compound from Exelixis (Table 4), currently is being tested 
in clinical trials (Phase I and II) and is capable of antagonising the two 
receptors218 such that it would be a very good reagent with which to 
address this question in my model system .  
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New perspectives 
TKIs with a new binding mode  
To overcome the mechanisms of resistance, the design of new 
compounds with different binding modes is necessary and such an 
approach could bring major clinical benefits. Amgen already have started 
to engineer such a novel generation of Met small-molecule inhibitors276,277. 
In a recent study, Bellon et al compared the binding mode of AM7 
(Amgen), a new orally bioavailable Met-specific TKI, to SU-11274. When 
they superimposed the crystal structure of the two compounds interacting 
with the unphosphorylated form of the receptor, they observed only a 
partial overlap. Although the two molecules bind to the kinase linker, they 
occupy totally different areas of the kinase domain276. Interestingly, these 
differences in binding modes are translated into efficiency of inhibition. 
The new compound is effective against the D1246N mutant that we found 
resistant to the three different TKIs we tested. Interestingly this new Met 
specific inhibitor could inhibit tumour growth in both HGF-dependent and 
HGF- independent xenograft models276. 
 
Multitargeting drugs  
In addition to the apperance of secondary mutation(s), the activation of 
another oncogene upon specific RTK inhibition, “oncogene switching”, 
could be the reason for observed acquired resistance278,279 including that 
to Met TKI 256. In addition, recent evidence has indicated that cooperations 
between the different receptors are common in RTK-driven 
malignancies280.  
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Thus, in order to overcome drug resistance, in parallel with the pursuit of 
improving the specificity of the inhibitors, the clinical evaluation of specific 
molecules able to target several RTKs recently has begun (this approach 
is via combined therapies or via the use of broad spectrum TKIs).  
Trials (Phase I, II, III) with six broad spectrum TKIs (including inhibitions of 
Met, Ron, VEGFR1-3, Ret, Kit, Tie-2, PGFR and FLT-3) are ongoing 
(Table 4).  
TKIs that target both Met and VEGFR have emerged as a promising 
approach in term of combinations that notably inhibit tumour angiogenesis; 
a phenomenon known to contribute to and to be necessary, for cancer 
progression. Attempts to block tumour angiogenesis with VEGFR2 
inhibitors have led to disappointing results281. One of the explanations for 
these failures could be that the Met/HGF axis can also promote 
angiogenesis and seems to act synergistically with the VEGFR2273. 
Therefore inhibiting Met and VEGFR in combination is a promising option 
to prevent angiogenesis and, in consequence, to slow down tumour 
progression by preventing the supply of oxygen and nutrients to the 
developing cancer282. The compound XL880 (Exelixis), targeting more 
specifically both Met and VEGFR2, currently is being tested in the 
clinic283,284. 
 
HSP90 inhibitors 
A recent study reported an indirect way to inhibit Met-driven tumours285. 
Because Met is a client for the Heat Shock Protein 90 (HSP90), it has 
been proposed that interfering with the activity of this chaperone molecule 
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could induce the degradation of Met. Based on this hypothesis, the 
authors established a protocol inducing a durable inhibition of Met and 
downstream signals of Met using an HSP90 inhibitor, 17-AAG (17-
allylamino-17-demethoxygeldanamycin)285. This approach is a highly 
attractive theoretical option as the inhibition induced on downstream 
effectors with SU-11274 was not durable285. Indeed, upon SU-11274 
treatment, even if Met phosphorylation was still blocked efficiently, 
downstream pathways of Met became reactivated. In contrast, this 
reactivation was completely prevented with 17-AAG285. These results 
suggested that this type of inhibitor should be tested in Met driven 
tumours. 
 
A new way for drug administration 
Based on the cell migration assay, PHA-665752 seemed to have greater 
inhibitor activity than PF-2341066 on cells expressing the M1268T Met 
mutant. In order to compare side-by-side the efficiency of these two drugs 
in an in vivo tumour growth assay, because PHA-665752 is not water 
soluble and cannot be administrated per os, we developed an alternative 
strategy to deliver the two compounds. Drugs were first diluted in DMSO 
and then applied topically, with a paintbrush, onto the skin over the 
tumour. Fairly soon after PHA-665752 applications, I observed a 
significant slow down in growth rate that was evident when the vehicle was 
applied alone.  
This experiment demonstrated that these types of drugs can be delivered 
by topical application. This approach may be quite interesting as an assay 
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in preclinical studies and even possibly in the clinic for some tumours as it 
limits the whole body toxicity consequent to systemic application. Drug 
concentrations could be reduced using this approach. For example, PF-
2341066, used at 50 mg/kg for a mouse of 20 g, required 1mg of 
compound. In contrast 100 μl of PF-2341066 at 200 nM for topical 
application required only 9μg. Even though this method of delivery 
probably would be restricted to very specific types of cancers, most likely 
located in superficial areas of the body such as melanomas in which Met 
recently has been implicated as a major driver234 and probably would be 
restricted to palliative rather than curative intent, it seems to me that there 
might be indications for evaluating this approach. Certainly however in 
preclinical graft systems, still the basis of most drug evaluations, such a 
route of delivery could be built into a screening approach. 
 
Preventing endosomal signalling  
An emerging concept recently reported in the literature could generate 
new avenues for anti-cancer drug development. It has been proposed that 
signalling events are regulated according to time but also to space115,116. 
This means, for example, that many receptors continue to signal after 
internalisation, this activity modulating qualitatively and/or quantitatively 
the signals delivered initially from the plasma membrane111. These 
observations imply that endocytosis should not anymore be considered as 
only a way of desensitisation and drugs that disturb signal localisation, like 
the ones, which disturb signal intensity, potentially could become new 
therapeutic agents (see Fig. 9 in Introduction). This particularly could be 
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true for Met, which requires endocytosis for full activation and optimal 
downstream signalling70,71,132.  
 
 
In conclusion, the cell model I have used, NIH3T3 cells stably transfected 
with Met mutants in the kinase domain, is an ideal model with which to 
study Met dependent tumorigenesis. In addition to being a suitable model 
to evaluate the potency of different TKIs against Met mutations, it also 
could be used to elucidate the mechanisms of oncogenic Met which lead 
to cell transformation. The following part of my study has focused on this 
aspect. More precisely it has focused on the relevance of RTK endosomal 
signalling in cell transformation and examined whether the topical 
application, over the skin of the tumours, of agents which inhibit 
endocytosis, could represent a useful method for blocking tumour 
development. 
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RESULTS - PART II  
 
 
A Direct Role For Met Endocytosis In Tumorigenesis 
 
 
We showed (see Results -Part-I), that Met mutants are strongly activated 
under basal conditions and only the D1246N and M1268T Met mutants 
are highly tumorigenic in vivo. Indeed, tumours derived from cells 
expressing the Y1248C Met mutant, even if it was slightly more activated 
than the Wt Met, developed similarly to the Wt tumour derived cells. As 
recently reported in the literature, “spatio-temporal signalling” could 
modulate cellular responses41,132 and Met was shown to require 
endocytosis for full activation and downstream signalling70,71. We therefore 
investigated whether the D1246N and M1268T Met mutants’ endocytic 
trafficking could play a role in their transforming abilities.   
 
1. The active D1246N and M1268T Met mutants accumulate in 
intracellular compartments 
We first analysed Met localisation by immunofluorescence. In basal 
conditions, while Wt and mutated Met all were expressed at the plasma 
membrane (Fig. 1A), an intracellular punctate localisation of Met was 
observed in around 60% of the cells expressing D1246N and M1268T, 
whereas this pattern of distribution occurred in around only 35% of the 
cells expressing the Wt and the Y1248C Met (p<0.05 and p< 0.01) (Fig. 
1A, B).  Thus, the mutants D1246N and M1268T were localised both at 
the plasma membrane (as unstimulated Wt) and inside the cell (as HGF 
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stimulated Wt). Colocalisation with phospho-tyrosine suggested that the 
D1246N and M1268T mutants were activated in these intracellular pools 
as well as at the plasma membrane. In contrast, phospho-tyrosine staining 
was weak in cells expressing the Y1248C and Wt Met (Fig. 1A). The Met 
specific TKI PHA-665752 totally abolished the phospho-tyrosine staining 
of the M1268T mutant expressing cells, confirming the phospho-tyrosine 
staining resulted from Met activity (Fig. 1C).  
These data were confirmed using a biochemical “biotin surface removal 
assay”268 allowing separation of cell surface from intracellular proteins. 
The different fractions (total, intracellular [= unbound] and surface [= 
bound]) were analysed by Western blot for Met and phosphorylated Met. 
Around 50% of the D1246N and M1268T mutants were in the intracellular 
fraction, where they were activated, as compared to 15% of Wt Met (Fig. 
1D, E).  
Thus a significant proportion of the D1246N and M1268T Met mutants are 
present in intracellular compartments, in a high-activated state, without 
HGF stimulation.  
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Fig.1. The active D1246N and M1268T Met mutants accumulate in 
intracellular compartments. 
(A) Representative confocal sections of Wt (± HGF for 15 min), D1246N, 
M1268T and Y1248C Met expressing NIH3T3cells stained for Met (green),  
phospho-tyrosine clone 4G10 (red) and DAPI (blue). Arrows show Met at 
the plasma membrane.  
(B) Percentage (%) of indicated cells with observable Met intracellular 
pools obtained from three independent experiments. 
(C) Representative confocal sections of M1268T Met expressing cells 
treated or not with PHA-665752 (PHA) for 90 min and then stained for Met 
(green) and phospho-tyrosine clone 4G10 (red) and DAPI (blue).  
Scale bar: 10 μM. *p<0.05, **p<0.01. 
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Fig.1. The active D1246N and M1268T Met mutants accumulate in 
intracellular compartments. 
(D) Proportion of intracellular pools versus total cellular Met as determined 
from a biotin surface removal assay (see Materials and Methods). The 
indicated cells were surface-biotinylated and the surface protein fraction 
removed by streptavidin pull down. The total sample before pull down 
(Total), the supernatant corresponding to the intracellular fraction 
(Unbound) and the surface fractions (Bound) were analysed by Western 
blot for Met and phosphorylated Met (Y1234-35). 
(E) Quantitation of (D). The graph represents the percentage of 
intracellular Met calculated as a ratio to the total form and is the mean of 
three independent experiments.  
*p<0.05, **p<0.01. 
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2. The D1246N and M1268T Met mutants shuttle between the plasma 
membrane and endosomes  
We investigated whether the D1246N and M1268T Met mutants displayed 
modification in their trafficking compared to the Wt Met both under basal 
conditions and after stimulation with HGF. First, following incubation of 
cells with coupled-Cyanin3-transferrin (Cy3-transferrin), the D1246N and 
M1268T Met mutants, were found in transferrin positive vesicles to a 
greater extent (30% and 19% respectively) than non-stimulated Wt Met 
(8.6%) (p<0.05) (Fig. 2A). Next, after different times of cell incubation at 
37°C, the rate of surface biotinylated Met internalisation was measured by 
streptavidin-agarose pull-down followed by Met Western blot (Fig. 2B top 
panel). After fifteen minutes of incubation, around 20% of the M1268T Met 
mutant had internalised (Fig. 2B top panel); a level similar to that of the Wt 
Met stimulated with HGF (Fig. 2C) while 10% of non-stimulated Wt Met 
had internalised (p<0.05) (Fig. 2B bottom panel). After five minutes of 
incubation, 14% of the D1246N Met mutant had internalised whereas only 
3% of the Wt Met had internalised (Fig. 2D). These internalised Met 
molecules were phosphorylated (data not shown). Cy3-transferrin uptake 
was similar in all cells (Fig. 2E). Finally, the D1246N and M1268T mutants 
colocalised with EEA1 positive endosomes such as was seen with HGF-
stimulated Wt Met (Fig. 2F). A significantly higher colocalisation between 
EEA1 (Early Endosome Antigen 1) and the D1246N (23%) (data not 
shown) and M1268T (19%) Met mutants was detected than it was for the 
Met Wt (9%) (p< 0.05) (Fig. 2F). Taken together, these results indicated 
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that the activated D1246N and M1268T mutants internalise and are 
recruited to the EEA1 positive early endosome under basal conditions. 
Met mutant colocalisation with transferrin (Fig. 2A) as well as localisation 
on endosomes and at the plasma membrane, unlike HGF-stimulated Wt 
visualised only on endosomes (Fig. 1A, 2A, F, G and I), suggested that 
some internalised Met mutants might recycle back to the plasma 
membrane. This indeed was the case as found by co-staining for the small 
GTPase Rab11. D1246N (data not shown) and M1268T Met colocalisation 
with Rab11 was 26% and 37.5% respectively as compared to 15% for Wt 
Met (Fig. 2I). In a biotin recycling assay, where the pool of biotinylated 
protein that had internalised (after 15 minutes of incubation at 37°C) was 
allowed to recycle back during cell re-incubation at 37°C post-
internalisation (here 15 minutes), the proportion of the internalised 
M1268T Met mutant was reduced strongly compared with the Wt Met (Fig. 
2J) indicating that it had recycled back. Potential degradation was 
excluded (see Fig. 4B).  
Together, these data demonstrate that a proportion of the D1246N and 
M1268T Met mutants undergo a shuttling between the plasma membrane 
and the endosomes. These studies were conducted in the presence of 
cycloheximide, thus possible endosomal location of a neo-synthesised Met 
precursor or a mature form of Met in the endosomal secretory pathway 
were excluded as major alternative mechanisms.  
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Fig.2. The D1246N and M1268T Met mutants shuttle between the 
plasma membrane and endosomes  
(A) Confocal sections of Wt and M1268T Met expressing cells stained for 
Met (green), transferrin (red) and DAPI (blue). Indicated cells, pre-treated 
with cycloheximide for 4 hours (50 ?g/ml), were incubated with Cy3-
transferrin for 30 min before fixation. The graph represents the percentage 
of colocalisation in three independent experiments. Scale bar: 10 μM. 
(B-C) Biotin internalisation assay. Surface biotinylated Wt and M1268T 
Met expressing cells were incubated for 15 min at 37ºC (B) or for 5 and 15 
min with HGF (C). The biotin was cleaved and the remaining biotinylated 
Met (internalised) detected by Western blotting for Met (see Materials and 
Methods). (B, bottom panel) The graph is the quantitation of basal Met 
internalisation for Wt and M1268T from four independent experiments.  
*p<0.05.  
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Fig.2. The D1246N and M1268T Met mutants shuttle between the 
plasma membrane and endosomes  
(D) The graph represents the quantitation of Met internalisation for Wt and 
D1246N from two independent biotin internalisation assays. Surface 
biotinylated Wt and D1246N Met expressing cells were incubated for 15 
min at 37ºC.  
(E) The graph represents the rate of Cy-3 transferrin uptake in the 
indicated cells, expressed in arbitrary units in 3 independent experiments. 
(F) Confocal sections of Wt and M1268T Met expressing cells pre-treated 
with cycloheximide for 4 hours, stimulated or not with HGF and then 
stained for Met (green), EEA1 (red) and DAPI (blue). Numbers are the 
percentage of colocalisation obtained from three independent 
experiments. Scale bar: 10 μM. 
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Fig.2. The D1246N and M1268T Met mutants shuttle between the 
plasma membrane and endosomes  
(G) Confocal sections of Wt and M1268T expressing cells, stimulated with 
HGF for 0, 15 and 120 min and stained for Met (green), EEA1 (red) and 
DAPI (blue). Colocalisations appear in yellow. Scale bar: 10 μM. 
(H) Wt, D1246N and M1268T Met expressing cells were stimulated with 
HGF-Alexa-555 for, 0, 5 and 15 min then stained for EEA1 (image not 
shown). The graph represents the percentage of colocalisation between 
EEA1 and HGF-Alexa 555 at 5 and 15 min, determined using Metamorph 
software, from two independent experiments.  
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Fig.2. The D1246N and M1268T Met mutants shuttle between the 
plasma membrane and endosomes  
(I) Confocal sections of indicated cells stained for Met (green), Rab11 (red) 
and DAPI (blue). Numbers represent the percentage of colocalisation from 
two independent experiments. Scale bar: 10 μM. 
(J) In the indicated cells, the level of internalised Met recycling was 
measured with a recycling biotinylation assay over a 30 min time course 
(15 min internalisation, 15min recycling) (see Materials and Methods). 
Numbers indicate the percentage of internalised Met that has recycled 
back to the plasma membrane, from one experiment.   
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3. Endocytosis of the D1246N and M1268T Met mutants is clathrin, 
dynamin and Grb2 dependent but independent of high activation 
status 
Investigation into the internalisation of the Met mutants was then 
performed using the following endocytic blockers: a dominant negative of 
dynamin (dynamin 2 K44A-GFP), the dynamin pharmacological inhibitors 
dynasore286 and dynole 34-2287 and Clathrin Heavy Chain (CHC) transient 
and stable knock down by RNAi and shRNA (Fig. 3B). All blockers 
inhibited HGF-Alexa 555 cellular uptake in all cells (Fig. 3C-G) and 
therefore, Met endocytosis71 (Fig. 3J). Secondly all blockers inhibited the 
constitutive internalisation of the M1268T Met mutant. This is illustrated in 
Fig. 3A showing the blocking of the M1268T Met mutant internalisation by 
dynasore as measured by the biotinylation internalisation assay; Fig. 3D 
and 3I show the increase of the M1268T Met mutant at the plasma 
membrane and its decrease in intracellular pools in cells knocked down for 
CHC. These results confirmed that the intracellular accumulation of the 
Met mutants results from an increased endocytosis, which is dynamin- and 
clathrin-dependent.  
It recently was reported that adaptor protein Grb-2-mediated interactions 
regulate clathrin-dependent endocytosis of Wt Met simulated by HGF122. 
Additionally, previous studies had reported a constitutive association of the 
D1246N and M1268T mutants with the adaptor Grb2191,193. We 
hypothesised therefore that Grb2 could be responsible for the enhanced 
endocytosis of the D1246N and M1268T Met mutants. Knocking down 
Grb2 (Fig. 3K) significantly reduced, by three fold, the constitutive 
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endocytosis of the M1268T Met mutant (P<0.05) (Fig. 3L). Co-
immunoprecipitation studies confirmed that the M1268T Met mutant was 
associated constitutively with Grb2 (Fig. 3M and 3N). Thus Met mutants’ 
clathrin endocytosis is mediated by the adaptor Grb2. 
To investigate whether the Met mutants’ constitutive endocytosis was the 
results of their increased level of activation, the rate of internalisation of 
the M1268T Met mutant was measured by biotin internalisation assay in 
cells treated with DMSO or PHA-665752. Surprisingly, reducing activation 
(assessed by phosphorylated Met Western blot) did not modify the level of 
endocytosis of the M1268 Met mutant, which remained at 20% (Fig. 3O). 
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Fig.3. Endocytosis of the D1246N and M1268T Met mutants is 
clathrin, dynamin and Grb2 dependent but independent of high 
activation status 
(A) Biotin internalisation assay (as in Fig. 2B) with M1268T Met 
expressing cells pre-treated with DMSO (-) or dynasore (+) (80 ?M) for 30 
min. 
(B) M1268T Met expressing cells were transfected with control or Clathrin 
Heavy Chain (CHC) siRNA or transduced with a control shRNA or CHC 
shRNA. CHC and tubulin or HSC70 Western blots are shown. 
(C-D) Confocal section of M1268T Met expressing cells incubated with 
HGF-Alexa-555 (red) for 15 min then stained for Met (green) and DAPI 
(blue). (C) Cells were treated with DMSO, dynasore or dynole 34-2 prior to 
HGF stimulation. Pictures of DMSO and dynasore treated cells are shown. 
Dynole 34-2 gave the same results as dynasore (picture not shown). (D) 
Confocal section of M1268T Met expressing cells transfected for 3 days 
with control or CHC siRNA, incubated with HGF-Alexa-555 (red) for 15 
min. Scale bar: 10 μM. 
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Fig.3. Endocytosis of the D1246N and M1268T Met mutants is 
clathrin, dynamin and Grb2 dependent but independent of high 
activation status 
(E) Confocal section of M1268T Met expressing cells transfected for 24 
hours with dynamin 2 K44-GFP (dyn-K44A-GFP), incubated with HGF-
Alexa-555 (red) for 15 min. 
(F) The graph represents the percentage of uptake of HGF-Alexa-555 in 
non transfected cells (NT), transfected with a GFP vector (GFP) or with a 
dynamin 2 K44-GFP (dyn-K44A-GFP) from three independent 
experiments. Scale bar: 10 μM. 
*p<0.05, **p<0.01.  
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Fig.3. Endocytosis of the D1246N and M1268T Met mutants is 
clathrin, dynamin and Grb2 dependent but independent of high 
activation status 
(G-H) M1268T Met expressing cells were transduced with control or CHC 
shRNAs. (G) Confocal sections of cells incubated with HGF-Alexa-555 
(red) for 15 min. (H) Confocal sections of cells stained for Met (green) and 
DAPI (blue). 
(I) Representative confocal sections of M1268T Met expressing cells 
transduced with control or CHC RNAis, stained for Met (green) and DAPI 
(blue). Scale bar: 10 μM. 
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Fig.3. Endocytosis of the D1246N and M1268T Met mutants is 
clathrin, dynamin and Grb2 dependent but independent of high 
activation status 
(J) Confocal sections of Wt Met expressing cells incubated with HGF-
Alexa-555 for 15 min (red) stained for Met (green) and DAPI (blue). Scale 
bar: 10 μM. 
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Fig.3. Endocytosis of the D1246N and M1268T Met mutants is 
clathrin, dynamin and Grb2 dependent but independent of high 
activation status 
*p<0.05 
(K-L) M1268T Met expressing cells were transfected with control or Grb2 
RNAis. Grb2 and tubulin Western blot are shown. (L) Biotin internalisation 
assay as in (Fig. 2B). The graph represents the quantitation of Met 
internalisation obtained from three experiments.  
(M) Grb2 immunoprecipitation (IP) from cells expressing Wt and M1268T 
Met expressing cells. Met and Grb2 Western blots are shown. 
(N) Met immunoprecipition (IP) from M1268T Met expressing cells. Met 
and Grb2 Western blots are shown.  
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Fig.3. Endocytosis of the D1246N and M1268T Met mutants is 
clathrin, dynamin and Grb2 dependent but independent of high 
activation status 
NS: non significant. 
(O) Biotin Internalisation Assay. M1268T Met expressing cells were 
pretreated for 45 min (+), or not (-), with PHA-665752 (PHA), surface 
biotinylated and then incubated at 37°C for 15 min with (+) or without (-) 
PHA. The biotin was then cleaved, and the remaining biotinylated Met was 
analysed by Western blotting with an anti-Met or with an anti-
phosphorylated Met (Y1234-35) antibody. The graph represents the 
percentage of Met internalisation from three independent experiments.  
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4. The D1246N and M1268T Met Mutants present an impaired 
degradation due to HSP90 activity 
The recycling of the internalised M1268T Met mutant prompted us to 
analyse whether its degradation behaviour was modified. The expression 
levels of Wt Met and M1268T Met mutant initially present at the cell 
surface were analysed over time using a “biotin degradation assay”. The 
M1268T mutant degraded less than the Wt (Fig. 4A), indicating that its 
increased constitutive internalisation does not lead to an increased 
degradation but rather to a delay, consistent with its recycling back to the 
cell surface. As HGF stimulation normally induces a substantial 
degradation of endogenous Wt Met119, we speculated that differences in 
degradation rates between the Met forms would be more pronounced 
following HGF stimulation. First, Met protein levels were analysed by 
Western blot in lysates from cells pre-treated with cycloheximide allowing 
us to follow stability of the mature form of Met. Endogenous Met, in HeLa 
cells, is progressively degraded with only 20% of the initial Met expression 
after 8 hours of HGF stimulation 119. We reproduced these results with Wt 
Met (Fig. 4B) indicating that our Wt Met behaves like endogenous Met in 
another cell system. In marked contrast, degradation of the D1246N and 
M1268T mutants was reduced dramatically, with a level of Met expression 
non significantly different between 0 and 8 hours of HGF stimulation. The 
Y1248C Met mutant had a degradation level statistically similar to that of 
the Wt Met (Fig. 4B). Analysis of HGF stimulated degradation of plasma 
membrane biotinylated Met revealed that, after 8 hours of HGF 
 163 
stimulation, a substantial quantity of the M1268T Met mutant still was 
observed whereas Wt Met was undetectable (Fig. 4C).  
These results indicate that the Met D1246N and M1268T Met mutants 
present an impaired degradation, thus contributing to their endosomal 
accumulation. Indeed, the M1268T mutant remained in EEA1 positive 
endosomes even after 120 minutes of HGF stimulation (Fig. 2G). 
The defect in degradation does not result from an impaired endocytosis 
upon HGF stimulation (Fig. 2C, G and H) or from a defect in ubiquitination 
(Fig. 4D-F). In fact, if anything an increased ubiquitination level of the 
mutant over Wt Met was observed.  
The molecular chaperone heat-shock protein 90 (HSP90) plays a key role 
in ensuring the correct conformation, stability, and activity of many 
oncogenic client proteins. Thus recent studies have reported that inhibiting 
HSP90 activity triggers the degradation of oncogenic RTKs, such as 
mutated RON288, mutated EGFR205,289 and mutated Kit290. We 
hypothesised therefore that HSP90 activity might protect the Met mutants 
against degradation. Inhibiting HSP90 activity with the pharmacological 
compound 17-AAG (17-(Allylamino)-17 demethoxygeldana-mycin), or 
knocking down HSP90 isoforms ? and ? (Fig. 4G), restored the Met 
mutant degradation to a similar level to that of Wt Met (Fig. 4H). 
Consistent with these results, co-immunoprecipitation studies detected 
HSP90 association with the M1268T mutant (Fig. 4I). These results 
indicate that the defect in degradation of Met mutants is not a 
consequence of defective ubiquitination but rather is dependent on HSP90 
activity.  
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Fig.4. The D1246N and M1268T Met Mutants present an impaired 
degradation due to HSP90 activity 
 (A) Biotinylation degradation assay. Wt and M1268T Met expressing cells 
were surface biotinylated and then incubated at 37°C. At the indicated 
times, cells were lysed and the remaining biotinylated Met, after 
streptavidin pull-down, was analysed by Western blotting with an anti-Met 
antibody.  
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Fig.4. The D1246N and M1268T Met Mutants present an impaired 
degradation due to HSP90 activity 
(B) Met / HSC-70 ratios obtained by densitometric analyses of Western 
blots from three independent experiments and plotted as the percentage 
of the initial content. Wt, D1246N, M1268T and Y1248C Met expressing 
cells and HeLa cells were pre-treated with cycloheximide (50 ?g/ml) for 15 
min and stimulated with HGF for the indicated times.   
(C) Biotin degradation assay. Indicated cells were surface biotinylated and 
incubated with HGF. At the indicated times, cells were lysed and the 
remaining biotinylated Met, after streptavidin pull-down, was analysed by 
Western blotting for Met.  
*p<0.05, **p<0.01, NS: non significant, compared to t=0. 
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Fig.4. The D1246N and M1268T Met Mutants present an impaired 
degradation due to HSP90 activity 
(D) The indicated cells were stimulated, or not, with HGF for 5 min, then 
lysed in SDS-boiling lysis buffer and subjected to Met immunoprecipitation 
(IP). Ubiquitin (upper panel) and Met (middle panel) Western blots from 
the immunoprecipitates and an Ubiquitin Western blot from the lysates 
(lower panel) are shown. The numbers represent the fold increase in Met 
ubiquitination upon HGF stimulation over no stimulation (Met ubiquitination 
was calculated as the ratio of the intensity of ubiquitin co-IP over the 
intensity of Met IP, obtained by densitometry).  
(E-F) M1268T Met expressing cells were transfected with His-tagged 
Ubiquitin (+) or with empty vector (-), stimulated with HGF for 0, 3 and 30 
min and subjected to His pull-down with Nickel-NTA-Agarose beads 
Western blot for Met from pull downs and from total lysate are shown. (F) 
Western blot for ubiquitin from lysates is shown.  
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Fig.4. The D1246N and M1268T Met Mutants present an impaired 
degradation due to HSP90 activity 
(G) Western blots for HSP90 ?, ? and tubulin from M1268T Met 
expressing cells transfected with control or HSP90 ? and ? RNAis. 
(H) Met / HSC-70 ratios obtained by densitometric analysis of Western 
blots and plotted as the percentage of the initial content. M1268T Met 
expressing cells treated with DMSO or 17-AAG (100 nM) or subjected to 
HSP90 ? and ? siRNA were pre-treated with cycloheximide (50 ?g/ml) and 
stimulated with HGF for the indicated times (three independent experiment 
were done with 17-AAG and one with HSP90 RNAi, each experiment was 
done in triplicate).    
(I) Lysates from M1268T Met expressing cells were subjected to HSP90 
alpha IP (left panel) or Met IP (right panel). Met, HSP90 ? and pan HSP90 
Western blot from IP or from total lysates are shown.  
*p<0.05, NS: non significant. 
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5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
Endosomal accumulation of the active D1246N and M1268T Met mutants 
could be responsible for cellular outcomes. According to the change in 
morphology, such as reduced adhesion and rounded shape, described in 
Results-Part I, Fig. 3A, staining for paxillin revealed that the number of 
focal adhesions was reduced significantly in cells expressing the D1246N 
and M1268T Met mutants (Fig. 5A). The organisation of F-actin 
(visualised by phalloidin-Cy3 staining) was perturbed dramatically under 
basal conditions in cells expressing the D1246N and M1268T Met mutants 
(Fig. 5C), similarly to Wt cells upon HGF treatment (Fig. 5D). 60 to 78% of 
the D1246N and M1268T mutant expressing cells presented a 
disorganised actin pattern with no detectable stress fibres, while only 10 to 
25% of the Wt and Y1248C mutant expressing cells presented a similar 
phenotype (Fig. 5B). In the M1268T mutant expressing cells, PHA-665752 
significantly restored paxillin patches (Fig. 5A) and stress fibres (Fig. 5B), 
thus leading to a decrease in cells with actin disorganisation (Fig. 5C), 
confirming these phenotypes are due to Met activity. The D1246N mutant 
expressing cells did not respond to this treatment (Fig. 5B, C), consistent 
with no reduction of Met phosphorylation (Results-Part I, Fig. 2B).  
Interestingly, decreasing Met mutant accumulation on endosomes, using 
endocytic blockers such as dynasore, expression of dynamin 2 K44A-GFP 
and CHC stable knock down (Fig. 5E-H) or impairing Grb2 function 
through knock-down or through expression of mutants in SH2 or SH3 
domains (Fig. 5I-J) or inhibiting HS90 activity with 17AAG (Fig. 5K) led to 
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restoration of the stress fibres in cells expressing the D1246N and 
M1268T mutants.  
Together, these results indicate that Met activation, increased 
internalisation and a defect in degradation, participated in the loss of actin 
stress fibres and that blocking endocytosis could overcome the resistance 
to inhibition by Met specific TKI (PHA-665752) of the D1246N mutant.  
Decreased focal contacts, together with disorganised actin, likely 
participate in the high motility of the cells expressing the D1246N and 
M1268T mutants (Fig. 5L and see Results-Part I, Fig. 3B).  
After 2 hours of incubation, at least three fold more D1246N and M1268T 
mutant expressing cells had migrated through the pores than had Wt cells 
or Y1248C mutant expressing cells (Fig. 5L and 5M). HGF stimulation 
further increased the migration of the D1246N and M1268T Met mutant 
expressing cells (Fig. 5N). Interestingly, all endocytic blockers (dynamin 2 
K44A-GFP, dynasore, CHC RNAi and shRNA) significantly reduced the 
increased migratory capacity of the D1246N and M1268T mutant 
expressing cells (Fig. 5L, O). The same blockers (PHA-665752, dynamin2 
K44A-GFP, CHC RNAi) did not reduce the migration of Wt or Y1248C 
cells (Fig. 5L and 5P). Interestingly, Grb2 knock down and HSP90 
inhibition by 17AAG also reduced the migration of the M1268T and 
D1246N mutant expressing cells (Fig. 5O and 5Q, R). Clearly the D1246N 
and M1268T Met mutants regulate cell migration both through activation 
and accumulation on endosomes; and thus blocking endocytosis, unlike 
PHA-665752 (Results-Part I, Fig. 3C), efficiently blocked the migration of 
the D1246N Met mutant expressing cells.  
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(A) The graph represents the number of indicated cells showing marked 
patches of paxillin, determined on confocal pictures (not shown), counted 
in indicated cells treated with DMSO or PHA-665752 (PHA) for 30 min and 
presented as percentages from three independent experiments.  
#, * p<0.05, **p<0.01, ***p<0.001. 
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(B-D) Indicated cells were stained with Cy3-phalloidin (red) and DAPI 
(blue). (B-C) Cells were treated with DMSO or PHA for 90 mins. (B) 
Representative Confocal sections. (C) The graph represents the 
percentage of cells with no stress fibres obtained from three independent 
experiments. (D) The graph represents the percentage of Wt Met 
expressing cells with no stress fibres upon HGF stimulation for 15 and 60 
min. One experiment was performed. Scale bar: 10 μM. 
#, * p<0.05, **p<0.01, ***p<0.001. 
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(E-I) Indicated cells were stained with Cy3-phalloidin (red) and DAPI 
(blue). (E) Confocal sections of cells treated with dynasore for 90 mins. (F-
G) Indicated cells were transfected, or not (NT), for 24 hours with GFP or 
GFP- dynamin 2 K44A dominant-negative mutant. (F) Representative 
confocal section. ? = transfected cell. (G) The graph represents the 
percentage of cells with no stress fibres in treatment groups as indicated 
from three independent experiments. (H-I) Confocal sections of M1268T 
Met expressing cells transduced with control or CHC shRNA (H) or 
transfected with control or Grb2 siRNA (I). Scale bar: 10 μM. 
* p<0.05, NS: non significant. 
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(J-K) Indicated cells were stained with Cy3-phalloidin (red) and DAPI 
(blue). (J) Confocal sections of cells transfected with myc-tagged Grb2 
constructs (Wt, dominant negative mutants 89A and 49L/303R). (K) 
Confocal sections of M1268T Met expressing cells treated with DMSO or 
17-AAG (100 nM). Scale bar: 10 μM. 
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(L) Mean numbers of the indicated cells that have migrated through 
Transwell pores over 2 hours of incubation in the presence of DMSO or 
dynasore, obtained from three independent experiments performed in 
triplicate or from two independent experiments performed in triplicate for 
dynasore treatments on D1246N and Y1248C expressing cells.  
(M) Representative field of migratory cells that went through the 
membrane after the Transwell assay.  
#, * p<0.05, # #, **p<0.01. 
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(N) Mean numbers of the indicated cells that went through the membrane 
over 2 hours of incubation ± HGF gradient. One experiment done in 
triplicate.  
(O) The graph represents the percentage of M1268T Met expressing cells 
that have migrated through Transwell pores when treated with PHA-
665752 (PHA) (from two independent experiments), transfected with 
dynamin 2 K44A-GFP, CHC siRNA (from three independent experiments) 
or Grb2 siRNA (from three independent experiments) or transduced with 
shRNA CHC (from two independent experiments). Data are normalised to 
appropriate controls (DMSO, GFP, siRNA control and shRNA control 
respectively). All experiments were performed in triplicate.  
* p<0.05, **p<0.01. 
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Fig.5. The D1246N and M1268T Met mutants require the endocytosis 
machinery to stimulate cell migration 
(P) The graph represents the percentage of Wt Met expressing cells that 
have migrated through Transwell pores when treated with PHA-665752 
(PHA), transfected with dynamin-K44A-GFP dominant negative mutant or 
with CHC siRNA over appropriate controls (DMSO, GFP vector and siRNA 
control respectively). Three experiments were performed in triplicate 
except experiments with PHA, which were done twice in triplicate. 
(Q-R) The graph represents the percentage of D1246N Met expressing 
cells transfected with Grb2 RNAI. (Q) or M1268T Met expressing cells 
treated with DMSO or 17-AAG (R) that have migrated through Transwell 
pores. One experiment was performed in triplicate.  
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6. The D1246N and M1268T Met Mutants induce Rac1 activation, 
which is dependent on endocytosis  
Since Rac1 has been shown to induce actin stress fibre loss47 we 
investigated this pathway. Rac1 activation was detected in D1246N and 
M1268T mutant expressing cells using GST pull-down assays (Fig. 6A). 
Inhibition by both a Rac inhibitor and Rac1 RNAi mediated knock down led 
to a restoration of stress fibres and thus to a significant reduction in the 
percentage of cells with disorganised actin (Fig. 6B and 6C) as well as an 
inhibition of cell migration (Fig. 6D) in D1246N and M1268T expressing 
cells but not Y1248C or Wt cells (Fig. 6B and 6E). Rac1 was knocked 
down efficiently (Fig. 6F).  
These results indicate that the D1246N and M1268T mutants trigger actin 
remodelling as well as cell migration through activating Rac1.  
Interestingly, Rac1 activation appeared to be endocytosis dependent in 
M1268T expressing cells since it was undetectable upon CHC knock down 
(Fig. 6G) suggesting the D1246N and M1268T mutants require 
endocytosis to activate Rac1. 
In Wt and Y1248C expressing cells Rac1 staining was diffuse whereas in 
cells expressing D1246N and M1268T Met, Rac1 was observed at 
membrane protrusions (Fig. 6H, I), resembling HGF-stimulated Wt cells 
(Fig. 6J), and in punctate cytoplasmic structures, partially colocalising with 
EEA1 (Fig. 6H). When treated with PHA-665752 (Fig. 6I, H) or the 
recycling inhibitor primaquine (data not shown), the percentage of M1268T 
expressing cells displaying Rac1 staining at membrane protrusions was 
reduced down to that of Wt expressing cells. These results suggested 
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further that D1246N and M1268T Met mutants could lead to Rac1 
activation on endosomes with subsequent recycling back to the plasma 
membrane, as recently described in HeLa cells stimulated by HGF 
stimulation or transfected by Rab5108. Consistent with this hypothesis, 
expression of dynamin 2 K44A-GFP decreased Rac1 localisation to 
endosomes and membrane protrusions significantly (Fig. 6K), reducing 
this to a level similar to that exhibited by Wt expressing cells (data not 
shown). Taken together, these results strongly suggest that the D1246N 
and M1268T mutants require endocytosis to activate Rac1. 
Pharmacological inhibition of PI3-K by LY294002 (LY) reduced Rac1 
localisation significantly in the membrane protrusions in M1268T cells 
(Fig. 6L) but not in Wt Met expressing cells (Fig. 6M), suggesting that, 
Met mutants activate Rac1 through PI3-K activation, which previously has 
been shown to promote Rac activation through the generation of the 
second messenger PIP3, which can in turn elicit activation of some 
GEFs62. PIP3 staining was detected in the D1246N and M1268T 
expressing cells only, where it was located in punctate cytoplasmic 
structures partially colocalising with Met (Fig. 6N). These data suggested 
a possible stimulation of PI3-K by Met on the endosome leading to local 
generation of PIP3. LY and PHA-665752 treatment abolished PIP3 
staining in the M1268T mutant expressing cells, confirming the specificity 
of the staining and that generation of PIP3 is dependent on Met activity in 
these cells (data not shown). Following LY treatment stress fibres were 
restored (Fig. 6O) and cell migration impaired (Fig. 6P) in the M1268T 
cells but not in the Wt cells (Fig. 6Q). 
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Together these results indicate that the D1246N and M1268T Met mutants 
activate PI3-K, which is responsible for endocytosis dependent Rac1 
activation, causing loss of stress fibres and enhanced cell migration. In 
addition, they strongly suggest that Rac1 is activated on endosomes.  
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Fig.6. The D1246N and M1268T Met mutants induce Rac1 activation, 
which is dependent on endocytosis  
(A) Levels of Rac1-GTP measured by GST-CRIB pull down and of total 
Rac1 in (see Materials and Methods) in the indicated cells. 
(B) The graph presents the percentage, from three independent 
experiments, of indicated cells with no stress fibres after treatment for 60 
min with PBS or with a Rac inhibitor (NSC23766).   
(C) The graph represents the percentage, from three independent 
experiments, of indicated cells with disorganised actin when the indicated 
cells were transfected with control or Rac1 siRNA.  
* p<0.05, **p<0.01. 
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Fig.6. The D1246N and M1268T Met mutants induce Rac1 activation, 
which is dependent on endocytosis  
(D-E) The graphs represent the percentage of M1268T Met expressing 
cells from three independent experiments (D) or Wt Met expressing cells 
from two independent experiments (E) that have migrated through 
Transwells when treated with the Rac inhibitor (NSC23766) or transfected 
with Rac1 siRNA, over the appropriate controls (PBS and control siRNA, 
respectively).  
(F) Western blots for Rac1 and tubulin from indicated transfected cells with 
control or Rac1 RNAis.  
(G) Levels of CHC, Rac1-GTP, total Rac1 and HSC70 in M1268T Met 
expressing cells transfected with control or CHC siRNA.  
* p<0.05, **p<0.01, ***p<0.001. 
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Fig.6. The D1246N and M1268T Met mutants induce Rac1 activation, 
which is dependent on endocytosis  
(H-I) Indicated cells were treated with DMSO or PHA-665752 (PHA) for 60 
min and stained for Rac1 (red), EEA1 (green) and DAPI (blue). (H) 
Confocal sections. (I) The graph represents the percentage of indicated 
cells with marked Rac1 staining present at membrane protrusions from 
three independent experiments, except for Y1248C Met expressing cells 
done 2 times. Scale bar: 10 μM. 
* p<0.05, **p<0.01. 
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Fig.6. The D1246N and M1268T Met mutants induce Rac1 activation, 
which is dependent on endocytosis  
(J) Confocal sections of Wt Met expressing cells after 30 min of HGF 
stimulation, stained for Rac1 (red) and DAPI (blue). Arrows indicates 
membrane protusions. Scale bar: 10 μM. 
(K) The graph represents the percentage of M1268T Met expressing cells, 
transfected with GFP vector (GFP) or with dynamin 2-K44A-GFP (dyn-
K44A-GFP), with Rac1 at membrane protrusions, from three independent 
experiments.   
* p<0.05, **p<0.01. 
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Fig.6. The D1246N and M1268T Met mutants induce Rac1 activation, 
which is dependent on endocytosis  
(L-M) The graph represents the percentage of cells with Rac1 at 
membrane protrusions when M1268T (L) or Wt Met expressing cells (M) 
were treated for 60 min with DMSO or LY-294002 (LY). Data obtained 
from three and two independent experiments with M1268T and Wt Met 
expressing cells respectively. 
(N) Confocal sections of indicated cells stained for PIP3 (red), Met (green) 
and DAPI (blue). Scale bar: 10 μM. 
* p<0.05. 
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Fig.6. The D1246N and M1268T Met mutants induce Rac1 activation, 
which is dependent on endocytosis  
(O) The graph represents the percentage of indicated cells with 
disorganised actin when treated with DMSO or LY-294002 for 90 min from 
three independent experiments. 
(P-Q) The graph represents the percentage of the M1268T Met expressing 
cells (P) or Wt Met expressing cells (Q) that have migrated through 
Transwell pores when treated with LY-294002.  
* p<0.05, **p<0.01, ***p<0.001. 
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7. Blocking endocytosis reduces tumour transformation, stimulated 
by the D1246N and M1268T Met Mutants, both in vitro and in vivo 
To assess growth in anchorage independent conditions, as a measure of 
cell transformation, the various lines were embedded and grown in three-
dimensional soft agar gels to measure their colony formation. After 9 days 
of culture, colony number (Fig. 7A) and area (Fig. 7B) were increased 
significantly in the D1246N and M1268T mutant expressing cells versus 
Wt and Y1248C expressing cells. Interestingly, dynasore treatment from 
day five reduced the colony area of the D1246N and M1268T mutant 
expressing cells significantly (Fig. 7B) while stable CHC knock down (Fig. 
7C) almost prevented the growth of the M1268T mutant expressing cells, 
indicating that endosomal signalling contributes to their transformed 
phenotype.  
 
To investigate the requirement of endocytosis for in vivo tumorigenesis 
driven by Met mutants, dynasore, or control DMSO diluents, were applied 
topically (by paint-brush) to animals on the skin surface over tumours once 
they had achieved 50 mm3 size (Fig. 7D) or on the day following cell 
injection (Fig. 7E). Tumour volumes were measured daily. Strikingly, the 
tumour growth slowed dramatically and significantly in grafts derived from 
D1246N and M1268T mutant expressing cells treated with dynasore 
versus DMSO. Thus, tumour sizes were approximately 50% after 5 days 
of treatment with dynasore relative to controls (Fig. 7D). Significant 
inhibition of M1268T tumour growth also was obtained with the novel 
dynamin inhibitor dynole 34.2 (Fig. 7F). Moreover, stable clathrin (CHC) 
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knock down, by lentivirus technology, also led to a significant reduction of 
tumour size by 50%, indicating that non-specific effects outside of 
endocytosis inhibition were not involved (Fig. 7G). Importantly, no 
significant change in tumour growth was observed in grafts of Wt and 
Y1248C expressing cells (Fig. 7D-F), indicating that the growth of these 
tumours, which is unrelated to Met activity, is unrelated to endocytosis.  
Importantly, dynasore led to the same inhibition of M1268T tumour growth 
as the Met TKI PHA-665752 while the D1246N tumours were resistant to 
PHA-665752 (as already demonstrated in Results-Part I, Fig. 4A) but 
sensitive to dynasore. Thus, blocking endocytosis overcomes the 
resistance of D1246N to TKI in in vivo tumorigenesis.  
Interestingly, the HSP90 inhibitor 17AAG also inhibited M1268T tumour 
growth by 50% (Fig. 7H); a result consistent with the restoration of Met 
mutant degradation (Fig. 4H).  
Finally, the M1268T mutant cells knocked down for CHC displayed a 
drastic reduction in lung colonisation capacity following injection in the tail 
vein of nude mice as compared to the cells knocked down with control 
shRNA (Fig. 7I-J). Lungs from mice grafted with cells expressing the 
M1268T shRNA control displayed a significant increase in size and weight 
compared with the lungs from mice grafted with cells expressing the 
M1268T shRNA CHC cells (Fig. 7I). Haematoxylin / eosin staining on 
paraffin sections of the tumours showed that the lungs of mice grafted with 
M1268T shRNA control expressing cells were infiltrated with tumour cells 
and almost no healthy area could be observed. Conversely, lungs from 
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mice grafted with M1268T control shRNA or Wt Met expressing cells, 
looked similar with no or few tumour infiltrated cells (Fig. 7J).  
This result indicates that Met mutant endocytosis promotes experimental 
metastasis, consistent with its role on the actin cytoskeleton and in cell 
migration (Fig. 5).   
The localisation of Met was analysed by performing immunofluorescence 
on fixed DMSO- or dynasore- treated tumours (from Fig. 7D). Wt and 
Y1248C Met were expressed at the plasma membrane in a high 
proportion of cells within tumors while D1246N and M1268T Met were 
expressed in EEA1 positive endosomes rather than at the plasma 
membrane (Fig. 7K). Dynasore increased D1246N (data not shown) and 
M1268T mutants (Fig. 7K) at the plasma membrane. We conclude that 
activated D1246N and M1268T Met mutants are tumorigenic in vivo due to 
their enhanced endosomal trafficking, leading to their accumulation and 
signalling on endosomes (Fig. 8, model). Interestingly, dynasore did not 
reduce the level of phosphorylation of the different Met forms (or indeed 
the level of expression) in the tumours (Fig. 7L). Consistent with this, in 
vitro CHC or Grb2 knock down also did not reduce the level of the M1268T 
Met phosphorylation (Fig. 7M-N). Moreover, tumours derived from cells 
stably knocked down for CHC did not present any change in Met 
phosphorylation level as compared to control cells (Fig. 7O). 
All together, these data strongly suggest that the high tumorigenicity of the 
D1246N and M1268T mutants is linked directly to their enhanced 
endosomal trafficking. These results suggest that it is localisation, rather 
than activation per se, which determines transformation capacity.  
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Fig.7. Blocking endocytosis reduces tumour transformation, 
stimulated by the D1246N and M1268T Met mutants, both in vitro and 
in vivo. 
(A-C) Indicated cells were cultured in soft agar.  (A-B) After day 5, DMSO 
or dynasore were added daily to the medium. (A) Pictures at day 9. 
Numbers are the mean total number of colonies per plate obtained from 
three independent experiments. (B) Average colony areas obtained from 
three independent experiments. A.U: Arbitrary Units (C) M1268T Met 
expressing cells transduced with control or CHC shRNA. Pictures at day 9.   
* or # p<0.05.  
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Fig.7. Blocking endocytosis reduces tumour transformation, 
stimulated by the D1246N and M1268T Met mutants, both in vitro and 
in vivo. 
(D-E) The indicated cells (500,000) were injected subcutaneously into 
nude mice (minimum 5 mice per group). The graphs represent the tumour 
growth curves of the different cell lines over treatment time. When tumours 
had reached around 50 mm3 (D) or the day after the graft (E), DMSO or 
dynasore (80 μM) were applied topically over the surface of the tumour 
mass each day for five days (from two independent experiments for D and 
one for E).  
* or # p<0.05, **p<0.01, ***p<0.001.  
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Fig.7. Blocking endocytosis reduces tumour transformation, 
stimulated by the D1246N and M1268T Met mutants, both in vitro and 
in vivo. 
(F) The indicated cells were injected subcutaneously into nude mice 
(minimum 5 mice per group). When tumours had reached around 50 mm3 
DMSO or dynole 34-2 (30 μM) were applied topically over the surface of 
the tumour mass each day for five days. The results are represented as 
box and whisker plots, a histogram like method for displaying upper and 
lower quartiles and maximum and minimum values in addition to median. 
They represent the tumour volume after 7 days of treatment. 
(G) M1268T Met expressing cells transduced with control or CHC shRNAs 
were injected subcutaneously into nude mice (minimum 5 mice per group). 
The graphs represent the tumour growth curves of the different cell lines 
over treatment time. 
(H) M1268T Met expressing cells were injected subcutaneously into nude 
mice (minimum 5 mice per group). The graphs represent the tumour 
growth curves of the different cell lines over treatment time. When tumours 
had reached around 50 mm3, DMSO or 17-AAG (100 μM) were applied 
topically over the surface of the tumour mass each day for 5 days.  
* or # p<0.05, **p<0.01.  
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Fig.7. Blocking endocytosis reduces tumour transformation, 
stimulated by the D1246N and M1268T Met mutants, both in vitro and 
in vivo. 
(I-J) M1268T Met expressing cells (500,000) transduced with control or 
CHC shRNA were injected intravenously and, after 10 days, lungs were 
photographed and weighed (I). Haematoxylin/eosin staining of the paraffin 
embedded lung sections from the mice grafted with the indicated cells (J).  
Scale bar: 100 μM. *p<0.05.  
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Fig.7. Blocking endocytosis reduces tumour transformation, 
stimulated by the D1246N and M1268T Met mutants, both in vitro and 
in vivo. 
 (K) Confocal sections of tumour sections from Wt and M1268T Met 
expressing cells (from D) stained for c-Met (green), EEA1 (red) and DAPI 
(blue). Arrows show plasma membrane Met.  
(L) Western blots for phosphorylated Met (Y1234-35), total Met and HSC-
70 performed on tumour samples from three different mice for each 
condition from D. The numbers are the fold increases of the 
phosphorylated Met (P-Met / Met) for dynasore treatment versus DMSO. 
Scale bar: 10 μM. 
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Fig.7. Blocking endocytosis reduces tumour transformation, 
stimulated by the D1246N and M1268T Met mutants, both in vitro and 
in vivo. 
(M-N) M1268T Met expressing cells were transfected with control, CHC or 
Grb2 siRNA. Western blots for CHC (M), Grb2 (N), phosphorylated Met 
(Y1234-25), Met and tubulin are shown. 
(O) Western blots for phosphorylated Met (Y1234-35), total Met and 
tubulin were performed on tumour samples from three different mice for 
each condition from G. The numbers are the fold increases of 
phosphorylated Met (Y1234-35) for shRNA control versus shRNA CHC 
cells.  
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Fig. 8. Signalling model of the Wt Met and of the D1246N and M1268T 
oncogenic Met mutants  
PM, plasma membrane. Signal specificity (generated through endosomal 
signalling) and signal persistence (due to the mutants’ constitutive 
activation, shuttling between plasma membrane and endosomes and 
impaired degradation) constitute the “transforming signals”. 
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DISCUSSION - PART II 
 
 
I have reported here that two Met activating mutations, found in human 
cancer, displayed constitutive endocytosis and recycling, coupled to an 
impaired down-regulation. These modifications in trafficking had important 
consequences for associated biological functions. Indeed, specific 
blocking of endocytosis resulted in the significant reduction of various 
parameters of in vitro transformation and in a striking slow down in tumour 
progression and experimental lung metastasis in immunoincompetent 
mice. Thus, in this study, I demonstrate a direct link between endocytosis 
and tumorigenicity. 
 
Enhanced intracellular localisation of the M1268T and D1246N Met 
mutants  
Intracellular and plasma membrane localisation 
I reported that, in addition to their plasma membrane location, the 
activated mature forms of the D1246N and M1268T Met mutants are 
localised in an intracellular pool corresponding to endosomes. In 
unstimulated cells, RTKs are not found commonly on endosomes. An 
exception to this general statement however, is VEGFR which has been 
detected in an endosomal pool corresponding to what has been thought to 
be acting as a storage compartment268. Because Wt Met is located 
predominantly at the plasma membrane, I conclude that this internal 
location of the two mutants is due to the mutation itself.  
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Several mutated RTKs have been reported to accumulate, in their 
immature state, in intracellular compartments which are distinct from 
endosomes. Thus, immature Kit mutants accumulate in the Golgi208 while 
immature Ret, FLT-3 and FGFR3 mutants accumulate in the endoplasmic 
reticulum (ER)201,209,211. These mutants present with a defect in sorting 
and, thus their mature forms are not expressed, or are expressed at very 
low levels, at the plasma membrane.  
All the Met forms which I have examined are well expressed at the plasma 
membrane, as I demonstrated by immunofluorescence and biochemical 
analysis. From these data I conclude that the Met mutants are matured 
correctly and can be addressed to the plasma membrane. My results 
indicate that, for Met mutants, it is only the mature form (p-145), which is 
phosphorylated, confirming further that the observed intracellular 
accumulation of the activated Met mutants corresponds to correctly 
processed Met forms that accumulate intracellularly on endosomes.   
When I started my thesis, no mutated RTKs had been reported in their 
mature form on endosomal compartments. However, a new study at the 
end of my thesis, in November 2009, reported that this indeed is the case 
for three constitutively activated EGFR mutants identified in NSCLC; 
EGFR ?746-750, ?747-749/A750P and L858R/T90M291. Although these 
EGFR mutants were investigated previously in several studies, none of 
them had investigated their subcellular localisation205,292.   
 
The endosomal localisation of D1246N and M1268T Met mutants 
suggested that they could induce important modifications in receptor 
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trafficking. Consistent with this hypothesis, I have shown that these two 
distinct Met mutants displayed a constitutive endocytosis / recycling 
behaviour and a reduced degradation, which could account for their 
transforming activity. 
 
Increased endocytosis 
Using immunofluorescence and biochemical assays, I have demonstrated 
that the accumulation of the two oncogenic Met mutants on endosomes 
results from their significantly enhanced rate of basal internalisation as 
compared to Wt Met.  
I further demonstrated that the constitutive endocytosis of the two Met 
mutants is dynamin- and clathrin- dependent, as previously reported for 
Wt Met71,119. This indicates that endocytosis of the Met oncogenic mutants 
probably is controlled by the same pathways as are involved in the 
endocytosis of Wt Met. 
Consistent with the emerging role of the adaptor Grb2 in clathrin-
dependent endocytosis of RTKs111,122, and its previously described 
constitutive association with the M1268T mutant191,193 (that I reproduced in 
our system), I found that Grb2 is required for internalisation of the Met 
mutants.  
The adaptor and ubiquitin ligase c-Cbl directly and indirectly interacts with 
Wt Met121,122. The indirect interaction between Wt Met and c-Cbl has been 
reported to occur through Grb2 and was shown to be required for HGF-
dependent Wt Met internalisation122. In addition, the ubiquitin ligase 
activity of c-Cbl would appear to be essential to mediate HGF-dependent 
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Met internalisation122. Thus, one possibility would be that c-Cbl 
constitutively interacts with the activated Met mutants indirectly via Grb2 to 
promote their internalisation.  
Importantly, I reported that Met M1268T internalises to the same extent 
when its activity is inhibited (or at least strongly reduced) by a Met specific 
TKI. Accordingly, previous studies have shown that an EGFR kinase dead 
(K721A) is able to internalise293,294 and that if EGFR kinase activity is 
partially inhibited, ubiquitination of the receptor can mediate its 
internalisation80. Dimerisation has also been proposed to be required for 
RTK internalisation over activation status294. As a potential residual 
phosphorylation of Met may remain following TKI treatment, generation of 
mutations in the kinase domain of the Met mutants would determine for 
sure whether or not the mutants require activation for their internalisation. 
Nevertheless, our results with the TKI demonstrate that the increased 
endocytosis rate of the mutants is not simply a consequence of their 
increased activation state. 
 
Decreased degradation 
I demonstrated that, although the rate at which mutants D1246N and 
M1268T undergo internalisation is increased, their basal degradation is no 
higher than that of the Wt Met; in fact, if anything, their degradation is 
somewhat delayed. Furthermore, upon HGF treatment, these two mutants, 
in striking contrast with Wt and Y1248C Met, were unable to undergo 
efficient degradation. This impaired degradation was not due to an 
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impaired internalisation since, upon HGF treatment, Met mutants 
displayed enhanced endocytosis.  
 
There is growing evidence that impaired RTK downregulation is 
associated with human cancer295,296. Interestingly, defective degradation 
recently was reported to occur with several EGFR forms mutated in the 
extracellular domain (the EGFRvIII mutant)206,207 or in the kinase domain 
(L858R, L858R/T790M and L861R)205,292; however to our knowledge, no 
association with increased endocytosis has been described for such 
mutants. Furthermore, the defective degradation of some of these EGFR 
mutants was associated with a reduced, or an impaired, endocytosis 
combined with a lack of effective ubiquitination207,292. Absence or reduced 
coupling with c-Cbl207,292, or a defect in its ubiquitin ligase activity205, were 
proposed as possible mechanisms to explain this absence in 
ubiquitination.  
Met degradation defects associated with a normal internalisation process 
have been reported previously. Because c-Cbl binds to Met on a 
phosphorylated tyrosine at the position 1003, the Met mutant Y1003F was 
generated and this, therefore, was unable to be ubiquitinated. While this 
mutant failed to degrade, it could be internalised with similar kinetics to 
those of the Wt Met124. Y1003 is located in the juxtamembrane domain, 
where a naturally occurring mutation was identified in lung cancer, leading 
to the generation of a deleted form of Met lacking the juxtamembrane 
domain185. This Met deletion mutant also was targeted inefficiently for 
degradation, but no investigation was done on its internalisation. Similarly, 
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the oncogenic mutant TPR-Met123, which also lacks the tyrosine 1003, 
displayed inefficient degradation. 
 
Our data indicate that the mechanisms leading to the defects in 
degradation of the D1246N and M1268T mutants are different from a 
simple defect in ubiquitination. In fact, if anything an increased 
ubiquitination level of the mutant M1268T over Wt Met was observed upon 
HGF stimulation. This might suggest a possible defect in de-ubiquitination 
of the Met mutants. 
Deubiquitination is operated by endosomal DeUBiquitinating enzymes 
(DUBs). To date, it is unknown which DUB, among 79 members, affect(s) 
Met degradation. Recently, 12 DUBs have been identified and 
characterised to be involved in the HGF dependent scattering response 
but they had no influence on Met expression levels297. Two DUBs, UBPY 
(UB-specific Protease Y) and AMSH (Associated Molecule with the SH3 
domain of STAM), both de-ubiquitinate the EGFR on endosomes but, 
depending on the studies, have been reported to promote 298,299 or 
prevent300,85,86 EGFR degradation.  
In fact, while ubiquitination promotes the sorting of cargos towards 
degradative compartments, a step of deubiquitination is required for their 
enclosure into the multivesicular body, a step considered necessary for 
the degradation
298
. In addition, in order to be delivered into internal 
vesicles of the MVBs, RTKs interact on endosomes with the protein Hrs 
that, in turn, recruits the ESCRT complex. Hrs binds only ubiquitinated 
RTKs. Thus, as suggested by McCullough et al86, it seems logical that 
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when DUBs act on RTKs before their interaction with Hrs, RTKs cannot be 
targeted to the degradation pathway anymore.  
Thus, deubiquitination is a complex process that can lead to opposite 
fates for the cargo depending on when and where the deubiquitinating 
enzymes act along the trafficking route.  
In the studies reporting that AMSH prevent EGFR degradation, its role in 
promoting EGFR recycling was also observed85,86. AMSH may, for 
example, be implicated in the high recycling rates that the Met mutants 
D1246N and M1268T display.  
 
Interestingly, I showed that the degradation of D1246N and M1268T Met 
mutants can be restored through inhibiting HSP90 activity. Because I 
found the M1268T mutant was complexed with HSP90, as previously 
described for constitutively activated EGFR mutants (L858R and 
L861Q)205, it is reasonable to propose that HSP90 inhibits Met mutant 
degradation directly rather than acting on a related protein. However, 
further studies would be needed to determine this. Moreover cell 
transformation and in vivo tumorigenesis induced by D1246N and M1268T 
Met mutants, are reduced significantly upon 17-AAG treatment. This 
suggests that such therapeutic approaches could be exploited to inhibit 
cancers driven by such oncogenic Met mutants. 
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Endosomal signalling: Specificity of pathways and of cellular 
outcome 
Since Met recruits almost all its downstream partners through only 2 
tyrosines (Y1349 and Y1356) in a unique docking site27,301, the basis of 
signalling selectivity has remained elusive. Endosomal signalling of Met, 
by spatially and temporally restricting signalling, may contribute to 
pathway specificity71,116,132.  
 
I identified Rac1 as the major regulatory molecule in the endosomal 
pathway which is responsible for the reduction in actin stress fibres and 
increased cell migration stimulated by the two transforming D1246N and 
M1268T Met mutants. In these cells, Rac1 activation requires intact 
clathrin- and dynamin-mediated endocytosis as well as PI-3K activity; 
findings consistent with recent data published on HeLa cells108. In this 
latter study, Palamidessi et al reported that HGF dependent Rac1 
activation occurs on endosomes108. Then Rac1 was targeted to the 
plasma membrane and induced the formation of actin-based migratory 
protrusions, including peripheral and circular ruffles. In my cell model, 
although circular ruffles were not observed, major actin remodelling 
occured including peripheral ruffles and loss of stress fibres. As was 
observed by Palamidessi et al, I see in my model that endocytosis is 
required for Rac1 activation. I suggest that Rac1 endosomal activation 
may occur on endosomes through the recruitment of a GEF to the 
D1246N and M1268T Met mutants. In this study of Palamidessi and 
colleagues, the GEF Tiam1 was observed on endosomes108. Further 
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experiments are required to identify which GEF activates Rac1 in my 
model.  
I also show that, in addition to Met activity, Rac1 activation and further 
translocation to the plasma membrane requires PI3-K activity. PIP3 
staining was observed only in cells expressing D1246N and M1268T Met 
mutants. The cytoplasmic punctate localisation of PIP3 suggests a 
possible activation of PI3-K by Met mutants on the endosome leading to 
this local production of PIP3. PIP3 could, in turn, activate the GEF leading 
to an increase in Rac1 GTP loading. Once activated on endosomes, 
Rac1-GTP would be targeted at the plasma membrane, eventually to 
induce actin reorganisation and promote cell motility. Thus, although 
further investigations are required to fully dissect out the mechanisms, I 
suggest that the D1246N and M1268T Met mutant generate the whole 
signalling cascade necessary to Rac1 recruitment and activation on 
endosomes.  
 
Endocytosis and cancer 
Since I started work on my thesis, there has been an increasing 
recognition of a mode of compartmental signalling of RTKs, the 
“endosomal signalling”66,111,302, which corresponds to the signalling of 
mature forms of RTKs on endosomes, post-internalisation from the plasma 
membrane.  
While initially, considered solely as being the way whereby RTK 
desensitisation was achieved, endocytosis recently has emerged as an 
important mechanism to also influence the signalling of the RTKs 
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positively. Signalling from a variety of receptors can be sustained, 
amplified or specifically generated along the endocytic 
pathway70,71,90,108,110,111,116,132. Interestingly, these pathways (ERK, STAT3, 
Rac) are known to play a role in tumour progression. Moreover, 
endocytosis very recently has emerged as an important regulator of cell 
functions such as cell cycle, cell polarity, mitosis and migration66. All these 
functions need to be tightly regulated and loss of their control is a major 
determinant in the development of cancers. Therefore, as proposed in two 
recent reviews112,303, the idea currently is emerging that deregulation of 
endocytic trafficking may be involved in cancer progression  
Indeed, some endocytic proteins have been found to display a 
modification in their expression in human cancers303,304. Thus, the clathrin-
associated protein HIP1 (Huntingtin Interacting Protein 1) was reported to 
be overexpressed in a wide variety of carcinomas, including prostate and 
colon cancers305. Moreover, experimentally overexpressed HIP1 
transformed, both in vitro and in vivo, NIH3T3 cells on the one hand, and 
induces in vitro overexpression of several RTKs, including EGFR, and 
increases their trafficking, on the other hand306. These results suggested a 
role for increased RTK trafficking in cell transformation.  
The endocytic protein NUMB, that interacts with Eps15 and AP2 on 
endosomes307, was found to be underexpressed in breast cancers308. A 
recent study demonstrated that NUMB, through inhibiting the E3 ubiquitin 
ligase of p53, led to the stability of this latter protein and therefore to the 
maintenance of its tumour suppressor activity308. However, the precise 
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role of the endocytosis process in this control of p53 function remains to 
be fully established112. 
A recent study reported that a mutant p53, through gain of function, drives 
cell invasion by promoting the enhancement of the integrin ?5?1 and 
EGFR recycling. This increased recycling was dependent on Rab-
Coupling Proteins, and resulted in a constitutive activation of the EGFR309.  
Thus, all these studies report on some molecular modifications in the cell 
(change of expression of endocytic regulators, p53 mutation), which 
impinge on trafficking of RTKs. However modification of RTK endocytic 
trafficking on its own has not, until now, been reported though oncogenic 
RTKs usually were shown to find ways to escape degradation207,292.  Thus, 
in the present work, I provide the first evidence of a direct link between 
RTK endocytosis and cancer development. 
 
Constitutive endocytosis / recycling and defects in degradation: 
signal specificity and persistence lead to transformation 
I propose that, at least in our model, continuous endocytosis associated 
with an impaired degradation contributes to the maintenance of the 
activated receptor on endosomes and therefore to the persistence of 
endosomal signals. Thus, signal specificity (generated through endosomal 
signalling) and signal persistence together may constitute the 
“transforming signals”.  
 
I have shown that the M1268T mutant recycles back to the plasma 
membrane post-endocytosis. The enhanced endocytosis / recycling of the 
 207 
transforming mutants, associated with their impaired degradation, 
suggests they undergo a persistent shuttling between the plasma 
membrane and the endosomes.  
Such shuttling of ligand-stimulated RTK, as well as the integrins, recently 
has been described as regulating spatial restriction of signalling necessary 
for directed migration109,310.  
Recent studies on RTKs, such as EGFR87 and TGF-? receptor97, suggest 
that degradation is associated with endocytosis but poor recycling, while 
enhanced signalling rather is associated with endocytosis but high 
recycling. Accordingly, upon ligand binding, Wt Met gets endocytosed, 
signals on endosomes and gets progressively degraded but is recycled 
poorly, allowing signal termination. In contrast the signal is maintained for 
the oncogenic Met mutants, which display an increased recycling and a 
poor level of degradation (see Results-part II, Fig. 8). 
I suggest that the generation of “transforming signals” by D1246N and 
M1268T Met mutants may require a substantial amount of recycling in 
addition to endocytosis. Hence, in the implanted subcutaneous tumours, 
the endocytic blocker dynasore, which strongly increased Met at the 
plasma membrane, did not totally deplete Met from endosomes (Fig. 7K) 
but it did reduce tumour size by two-fold relative to the control (Fig. 7D). 
While the cellular uptake of dynasore might be less than optimal, because 
of our novel route of topical application, these results suggest that 
dynamic shuttling between plasma membrane and endosome plays an 
important role in tumorigenesis, rather than the outcome being dependent 
on simple endosomal localisation only. 
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Signalling on the Endosome Positively influences Tumorigenesis  
RTKs are known to be oncogenic through their increased level of 
activation due to overexpression, autocrine signalling or activating 
mutations2,311. Generally, the global intensity of activation in the cell or 
tissue is the only parameter which has been taken into account, with little 
attention paid to the precise localisation of the signals. 
Interestingly however, recent studies, cited above, have reported the 
signalling of mutated activated RTKs, in an immature form, from 
intracellular compartments of the secretory pathway, such as the Golgi for 
Kit D814V208 and the endoplasmic reticulum for Ret R918T209, mutated 
FGFR3202,211 and FLT3-ITD 201,210.  
These mislocalised receptors generate different signals, in intensity, 
duration or nature, than they do when localised solely at the plasma 
membrane210. Kit D814V when localised in the Golgi was shown to 
enhance Stat3 and Stat5 activation as compared to plasma membrane 
location208. FLT3-ITD activated Stat5 preferentially when localised in the 
ER and only initiated ERK1/2 activation when it was located at the cell 
surface210. Moreover, intracellular localisation of Kit D814V, (Golgi or 
cytoplasm), was shown to promote fatal myeloproliferative disease in mice 
while the plasma membrane localisation of this mutant was not associated 
with this pathology208. 
Thus, these studies favour the general concept of “compartmental 
signalling’ where receptor signalling can be altered by the localisation of 
the trafficking molecule.  
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In the present study, I have shown that another mode of compartmental 
signalling of RTKs, the “endosomal signalling”, which corresponds to the 
signalling of mature forms of RTKs on endosomes, plays a role in cell 
transformation in vitro and in vivo. 
Thus, it is shown here that D1246N and M1268T Met mutants display an 
increased endocytosis / recycling, leading to persistent signalling from the 
endosome and to cell transformation in vitro and in vivo. 
Construction of 3-dimensional models of Wt and mutated catalytic 
domains suggested that the mutations either prevent Met from adopting an 
inhibitory conformation or stabilise it in an active form186. Uncoupling 
signal transducers from Met mutants, through mutation of the two major 
docking tyrosines, abrogates cell transformation and inhibits invasive 
growth191. Thus it has been assumed that the D1246N and M1268T 
mutants are oncogenic simply because they are highly activated. A major 
finding in our study is that Met activation alone is not sufficient to confer 
oncogenicity but that there is an additional spatial requirement for the 
generation of transforming signals. Met mutants are oncogenic not only 
because they are activated but also because they signal on endosomes. 
Indeed upon endocytosis inhibition, the D1246N and M1268T Met mutants 
remain activated but are not oncogenic.  
Based on our data, the current model of tumorigenesis stimulated by 
oncogenic RTK might need to be refined to also take into account the 
potential contribution of endosomal signalling to the process.  
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Interfering with Endocytic Trafficking or Endosomal Signalling as an 
Anti-Tumour Strategy?  
I have shown that inhibition of the transforming capacity of the D1246N 
and M1268T Met mutants can be achieved through endocytosis inhibition. 
Most strikingly in vivo tumour growth and/or experimental metastasis 
dependent on these Met mutants is reduced significantly by topical 
administration of pharmacological blockers of endocytosis or by stable 
clathrin knock down. These studies represent proof of principle that, at 
least in our model, endocytosis plays a role in tumour transformation. 
Met is a promising target for cancer therapy, as evidenced by its 
association with resistance of non-small cell lung and breast cancer to 
gefitinib and trastuzumab (or herceptin), which target EGFR and 
HER2214,216 and by increasing efforts to design Met inhibitors in the 
pharmaceutical industry312. Although it is not yet well established as to 
whether Met mutations occur widely in human cancer, they contribute 
strongly to improving our understanding of how oncogenic Met is 
transforming and therefore point to how to intervene in the tumorigenesis 
pathway. 
Of high interest, this novel inhibition method appears to overcome the 
resistance of one mutant to a Met specific TKI, in vitro and in vivo. 
Therefore, the phosphorylation of the D1246N Met mutant, the phenotypic 
modifications it induces, such as actin disorganisation, Rac1 localisation at 
membrane protrusions or increased cell migration, as well as tumour 
growth, were not modified by the Met specific TKI. However these 
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behavioural traits were significantly impaired by inhibition of endocytosis 
(Fig. 5, 6 and 7).  
Thus, my study is consistent with the possibility that oncologists could 
exploit novel strategies to inhibit Met dependent tumorigenesis based on 
interference with Met localisation or, more specifically, by designing 
“endosome-specific targeting” strategies as recently suggested85 (see Fig. 
9 in Introduction). Since Met also is involved in several non tumorigenic 
functions and is responsible for homeostasis maintenance, modifying its 
localisation or inhibiting the endosomal signalling, but not its global 
activity, could lead to an inhibition of the “transforming signals” generated 
on endosomes while maintaining the non-transforming signals. 
More generally, for some RTKs / cancers, interfering with the endocytic 
pathway or the endosomal signals may overcome the currently elevated 
tumour resistance to RTK specific TKIs or antibodies. 
 
I have established a direct link between endocytosis and cancer. These 
results, representing proof of principle, suggest that new anti-tumour 
strategies might be based on manipulating endosomal signalling. 
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CONCLUDING REMARKS 
 
 
Since its discovery in 19846, and its identification as a member of the RTK 
family in 19869, scientific interest in Met has not stopped growing. This 
interest has increased rapidly over the years, particularly since the 
deregulation of Met activity has been established to play a crucial role in 
cancer development15,265. Thus Met recently has emerged as a target of 
choice for cancer therapy by cancer researchers and pharmaceutical 
companies14,169,218,245.  
The discovery of Met activating mutations in human cancers167,168,175 
contributed to establishing the link between Met and cancer and 
underlined the importance of understanding the signalling mechanisms of 
the different mutationally activated forms of Met for the development of 
successful cancer therapeutics. Importantly, as for other mutated RTKs, 
as an issue which will need to be addressed, the potential problem of drug 
resistance of mutated Met has been raised261. 
 
When I started my thesis in 2006, although it had been demonstrated that 
several RTKs89,92,94,95, including Met70,132, could signal from endosomal 
compartments, the concept of “endosomal signalling” was only just 
emerging.  
Four years later, the interest in the field has increased significantly and 
more studies have shown that endocytosis is not a desensitisation 
mechanism only. Endosomes have been proposed to play the role of 
essential platforms in signal transduction66,85,111 rather than just as 
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“vehicles” for the receptors. Endocytosis now has been proposed to 
control cellular functions such as cell cycle, cytokinesis, polarity and 
migration66,304.  
Since it controls pathways and functions involved in cancer, endocytosis 
recently was proposed to possibly play a role in cancer development and 
progression112,303,304. However so far, clear evidence for this possibility 
was lacking. The main aim of my project was to test this hypothesis, using 
Met oncogenic mutations as a model. Thus, my subject area was in a fast 
growing and competitive field. 
 
I first demonstrated that one of the Met mutants I analysed is resistant to 
three Met-specific TKIs in vitro and in vivo. This underlined the importance 
of knowing patient genetic alterations in order to make decisions on 
treatment and the importance of developing new TKIs or new “types” of 
Met specific drugs. 
  
Then, I showed that two activated Met mutants, unlike Met Wt, were 
constitutively internalised and recycled back to the plasma membrane. I 
further demonstrated that endocytosis is required for the Met mutants’ 
dependent ability to affect in vivo tumorigenesis and experimental 
metastasis. Thus, I have demonstrated for the first time, a direct link 
between RTK endocytosis and cancer.  
We, in our laboratory, propose that it is the permanent shuttling between 
the plasma membrane and endosomes, associated to a defect in 
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degradation, that leads to the persistent generation of specific signals, “the 
transforming signals”, leading to cell transformation. 
Interestingly, while blocking Met mutant endocytosis inhibited tumour 
growth, it did not reduce their activation state, suggesting that signal 
location rather than activation which dictated cellular outcomes. Moreover, 
the mutant I have shown to be resistant to the Met specific TKIs in the first 
part of my thesis, was sensitive to endocytosis inhibition. Thus, this novel 
way of inhibition may overcome resistance to TKIs in some cases. 
These results open the way for the consideration of new potential 
therapies, aimed at preventing endosomal signalling as a means of 
targeting against Met-driven cancers and this potentially could be applied 
to other RTKs.  
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